• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    An analytical test device useful for example in pregnancy testing, comprises a hollow casing (500) constructed of moisture-impervious solid material, such as plastics materials, containing a dry porous carrier (510) which communicates indirectly with the exterior of the casing via a bibulous sample receiving member (506) which protrudes from the casing such that a liquid test sample can be applied to the receiving member and permeate therefrom to the porous carrier, the carrier containing in a first zone a labelled specific binding reagent is freely mobile within the porous carrier when in the moist state, and in a second zone spatially distinct from the first zone unlabelled specific binding reagent for the same analyte which unlabelled reagent is permanently immobilised on the carrier material and is therefore not mobile in the moist state, the two zones being arranged such that liquid sample applied to the porous carrier can permeate via the first zone into the second zone, and the device incorporating means, such as an aperture (508) in the casing, enabling the extent (if any) to which the labelled reagent becomes bound in the second zone to be observed. Preferably the device includes a removable cap for the protruding bibulous member.
    公开号:US20010008774A1
    申请号:US09/780,351
    申请日:2001-02-12
    公开日:2001-07-19
    发明作者:Keith May；Michael Prior；Ian Richards
    申请人:Conopco Inc；
    IPC主号:G01N33-54366
    专利说明:
    [0001] The present invention relates to assays involving specific binding, especially immunoassays. [0001]
    [0002] In particular, the invention relates to analytical devices which are suitable for use in the home, clinic or doctor's surgery and which are intended to give an analytical result which is rapid and which requires the minimum degree of skill and involvement from the user. The use of test devices in the home to test for pregnancy and fertile period (ovulation) is now commonplace, and a wide variety of test devices and kits are available commercially. Without exception, the commercially-available devices all require the user to perform a sequence of operations before the test result is observable. These operations necessarily involve time, and introduce the possibility of error. [0002]
    [0003] It is an object of the present invention to provide a test device which is readily usable by an unskilled person and which preferably merely requires that some portion of the device is contacted with the sample (e.g. a urine stream in the case of a pregnancy or ovulation test) and thereafter no further actions are required by the user before an analytical result can be observed. Ideally the analytical result should be observable within a matter of minutes following sample application, e.g. ten minutes or less. [0003]
    [0004] The use of reagent-impregnated test strips in specific binding assays, such as immunoassays, has previously been proposed. In such procedures a sample is applied to one portion of the test strip and is allowed to permeate through the strip material, usually with the aid of an eluting solvent such as water. In so doing, the sample progresses into or through a detection zone in the test strip wherein a specific binding reagent for an analyte suspected of being in the sample is immobilised. Analyte present in the sample can therefore become bound within the detection zone. The extent to which the analyte becomes bound in that zone can be determined with the aid of labelled reagents which can also be incorporated in the test strip or applied thereto subsequently. Examples of prior proposals utilising these principles are given in Thyroid Diagnostics Inc GB 1589234, Boots-Celltech Diagnostics Limited EP 0225054, Syntex (USA) Inc EP 0183442, and Behringwerke AG EP 0186799. [0004]
    [0005] The present invention is concerned with adapting and improving the known techniques, such as those referred to in the above publications, to provide diagnostic test devices especially suitable for home use which are quick and convenient to use and which require the user to perform as few actions as possible. [0005]
    [0006] A typical embodiment of the invention is an analytical test device comprising a hollow casing constructed of moisture-impervious solid material containing a dry porous carrier which communicates directly or indirectly with the exterior of the casing such that a liquid test sample can be applied to the porous carrier, the device also containing a labelled specific binding reagent for an analyte which labelled specific binding reagent is freely mobile within the porous carrier when in the moist state, and unlabelled specific binding reagent for the same analyte which unlabelled reagent is permanently immobilised in a detection zone on the carrier material and is therefore not mobile in the moist state, the relative positioning of the labelled reagent and detection zone being such that liquid sample applied to the device can pick up labelled reagent and thereafter permeate into the detection zone, and the device incorporating means enabling the extent (if any) to which the labelled reagent becomes in the detection zone to be observed. [0006]
    [0007] Another embodiment of the invention is a device for use in an assay for an analyte, incorporating a porous solid phase material carrying in a first zone a labelled reagent which is retained in the first zone while the porous material is in the dry state but is free to migrate through the porous material when the porous material is moistened, for example by the application of an aqueous liquid sample suspected of containing the analyte, the porous material carrying in a second zone, which is spatially distinct from the first zone, an unlabelled specific binding reagent having specificity for the analyte, and which is capable of participating with the labelled reagent in either a “sandwich” or a “competition” reaction, the unlabelled specific binding reagent being firmly immobilised on the porous material such that it is not free to migrate when the porous material is in the moist state. [0007]
    [0008] The invention also provides an analytical method in which a device as set forth in the proceeding paragraph is contacted with an aqueous liquid sample suspected of containing the analyte, such that the sample permeates by capillary action through the porous solid phase material via the first zone into the second zone and the labelled reagent migrates therewith from the first zone to the second zone, the presence of analyte in the sample being determined by observing the extent (if any) to which the labelled reagent becomes bound in the second zone. [0008]
    [0009] In one embodiment of the invention, the labelled reagent is a specific binding partner for the analyte. The labelled reagent, the analyte (if present) and the immobilised unlabelled specific binding reagent cooperate together in a “sandwich” reaction. This results in the labelled reagent being bound in the second zone if analyte is present in the sample. The two binding reagents must have specificities for different epitopes on the analyte. [0009]
    [0010] In another embodiment of the invention, the labelled reagent is either the analyte itself which has been conjugated with a label, or is an analyte analogue, ie a chemical entity having the identical specific binding characteristics as the analyte, and which similarly has been conjugated with a label. In the latter case, it is preferable that the properties of the analyte analogue which influence its solubility or dispersibility in an aqueous liquid sample and its ability to migrate through the moist porous solid phase material should be identical to those of the analyte itself, or at least very closely similar. In this second embodiment, the labelled analyte or analyte analogue will migrate through the porous solid phase material into the second zone and bind with the immobolised reagent. Any analyte present in the sample will compete with the labelled reagent in this binding reaction. Such competition will result in a reduction in the amount of labelled reagent binding in the second zone, and a consequent decrease in the intensity of the signal observed in the second zone in comparison with the signal that is observed in the absence of analyte in the sample. [0010]
    [0011] An important preferred embodiment of the invention is the selection of nitrocellulose as the carrier material. This has considerable advantage over conventional strip materials, such as paper, because it has a natural ability to bind proteins without requiring prior sensitisation. Specific binding reagents, such as immunoglobulins, can be applied directly to nitrocellulose and immobilised thereon. No chemical treatment is required which might interfere with the essential specific binding activity of the reagent. Unused binding sites on the nitrocellulose can thereafter be blocked using simple materials, such as polyvinylalcohol. Moreover, nitrocellulose is readily available in a range of pore sizes and this facilitates the selection of a carrier material to suit particularly requirements such as sample flow rate. [0011]
    [0012] Another important preferred embodiment of the invention is the use of so called “direct labels”, attached to one of the specific binding reagents. Direct labels such as gold sols and dye sols, are already known per se. They can be used to produce an instant analytical result without the need to add further reagents in order to develop a detectable signal. They are robust and stable and can therefore be used readily in a analytical device which is stored in the dry state. Their release on contact with an aqueous sample can be modulated, for example by the use of soluble glazes. [0012]
    [0013] An important aspect of the invention is the selection of technical features which enable a direct labelled specific binding reagent to be used in a carrier-based analytical device, e.g. one based on a strip format, to give a quick and clear result. Ideally, the result of the assay should be discernable by eye and to facilitate this, it is necessary for the direct label to become concentrated in the detection zone. To achieve this, the direct labelled reagent should be transportable easily and rapidly by the developing liquid. Furthermore, it is preferable that the whole of the developing sample liquid is directed through a comparatively small detection zone in order that the probability of an observable result being obtained in increased. [0013]
    [0014] Another important aspect of the invention is the use of a directly labelled specific binding reagent on a carrier material comprising nitrocellulose. Preferably the nitrocellulose has a pore size of at least one micron. Preferably the nitrocellulose has a pore size not greater than about 20 microns. In a particularly preferred embodiment, the direct label is a coloured latex particle of spherical or near-spherical shape and having a maximum diameter of not greater than about 0.5 micron. An ideal size range for such particles is from about 0.05 to about 0.5 microns. [0014]
    [0015] In a further embodiment of the present invention, the porous solid phase material is linked to a porous receiving member to which the liquid sample can be applied and from which the sample can permeate into the porous solid phase material. Preferably, the porous solid phase material is contained within a moisture-impermeable casing or housing and the porous receiving member, with which the porous solid phase material is linked, extends out of the housing and can act as a means for permitting a liquid sample to enter the housing and permeate the porous solid phase material. The housing should be provided with means, e.g. appropriately placed apertures, which enable the second zone of the porous solid phase material (carrying the immobilised unlabelled specific binding reagent) to be observable from outside the housing so that the result of the assay can be observed. If desired, the housing may also be provided with further means which enable a further zone of the porous solid phase material to be observed from outside the housing and which further zone incorporates control reagents which enable an indication to be given as to whether the assay procedure has been completed. Preferably the housing is provided with a removable cap or shroud which can protect the protruding porous receiving member during storage before use. If desired, the cap or shroud can be replaced over the protruding porous receiving member, after sample application, while the assay procedure is being performed. Optionally, the labelled reagent can be incorporated elsewhere within the device, e.g. in the bibulous sample collection member, but his is not preferred. [0015]
    [0016] An important embodiment of the invention is a pregnancy testing device comprising a hollow elongated casing containing a dry porous nitrocellulose carrier which communicates indirectly with the exterior of the casing via a bibulous urine receiving member which protrudes from the casing and which can act as a reservoir from which urine is released into the porous carrier, the carrier containing in a first zone a highly-specific anti-hCG antibody bearing a coloured “direct” label, the labelled antibody being freely mobile within the porous carrier when in the moist state, and in a second zone spatially distinct from the first zone an highly-specific unlabelled anti-hCG antibody which is permanently immobilised on the carrier material and is therefore not mobile in the moist state, the labelled and unlabelled antibodies having specificities for different hCG epitopes, the two zones being arranged such that a urine sample applied to the porous carrier can permeate via the first zone into the second zone, and the casing being constructed of opaque or translucent material incorporating at least one aperture through which the analytical result may be observed, together with a removable and replaceable cover for the protruding bibulous urine receiving member. A fertile period prediction device, essentially as just defined except that the analyte is LH, is an important alternative. [0016]
    [0017] Such devices can be provided as kits suitable for home use, comprising a plurality (e.g. two) of devices individually wrapped in moisture impervious wrapping and packaged together with appropriate instructions to the user. [0017]
    [0018] The porous sample receiving member can be made from any bibulous, porous or fibrous material capable of absorbing liquid rapidly. The porosity of the material can be unidirectional (ie with pores or fibres running wholly or predominantly parallel to an axis of the member) or multidirectional (omnidirectional, so that the member has an amorphous sponge-like structure). Porous plastics material, such as polypropylene, polyethylene (preferably of very high molecular weight), polyvinylidene flouride, ethylene vinylacetate, acrylonitrile and polytetrafluoro-ethylene can be used. It can be advantageous to pre-treat the member with a surface-active agent during manufacture, as this can reduce any inherent hydrophobicity in the member and therefore enhance its ability to take up and deliver a moist sample rapidly and efficiently. Porous sample receiving members can also be made from paper or other cellulosic materials, such as nitro-cellulose. Materials that are now used in the nibs of so-called fibre tipped pens are particularly suitable and such materials can be shaped or extruded in a variety of lengths and cross-sections appropriate in the context of the invention. Preferably the material comprising the porous receiving member should be chosen such that the porous member can be saturated with aqueous liquid within a matter of seconds. Preferably the material remains robust when moist, and for this reason paper and similar materials are less preferred in any embodiment wherein the porous receiving member protrudes from a housing. The liquid must thereafter permeate freely from the porous sample receiving member into the porous solid phase material. [0018]
    [0019] If present, the “control” zone can be designed merely to convey an unrelated signal to the user that the device has worked. For example, the control zone can be loaded with an antibody that will bind to the labelled antibody from the first zone, e.g. an “anti-mouse” antibody if the labelled body is one that has been derived using a murine hybridoma, to confirm that the sample has permeated the test strip. Alternatively, the control zone can contain an anhydrous reagent that, when moistened, produces a colour change or colour formation, e.g. anhydrous copper sulphate which will turn blue when moistened by an aqueous sample. As a further alternative, a control zone could contain immobilised analyte which will react with excess labelled reagent from the first zone. As the purpose of the control zone is to indicate to the user that the test has been completed, the control zone should be located downstream from the second zone in which the desired test result is recorded. A positive control indicator therefore tells the user that the sample has permeated the required distance through the test device. [0019]
    [0020] The label can be any entity the presence of which can be readily detected. Preferably the label is a direct label, ie an entity which, in its natural state, is readily visible either to the naked eye, or with the aid of an optical filter and/or applied stimulation, e.g. UV light to promote fluorescence. For example, minute coloured particles, such as dye sols, metallic sols (e.g. gold), and coloured latex particles, are very suitable. Of these options, coloured latex particles are most preferred. Concentration of the label into a small zone or volume should give rise to a readily detectable signal, e.g. a strongly-coloured area. This can be evaluated by eye, or by instruments if desired. [0020]
    [0021] Indirect labels, such as enzymes, e.g. alkaline phosphatase and horse radish peroxidase, can be used but these usually require the addition of one or more developing reagents such as substrates before a visible signal can be detected. Hence these are less preferred. Such additional reagents can be incorporated in the porous solid phase material or in the sample receiving member, if present, such that they dissolve or disperse in the aqueous liquid sample. Alternatively, the developing reagents can be added to the sample before contact with the porous material or the porous material can be exposed to the developing reagents after the binding reaction has taken place. [0021]
    [0022] Coupling of the label to the specific binding reagent can be by covalent bonding, if desired, or by hydrophobic bonding. Such techniques are commonplace in the art, and form no part of the present invention. In the preferred embodiment, where the label is a direct label such as a coloured latex particle, hydrophobic bonding is preferred. [0022]
    [0023] In all embodiments of the invention, it is essential that the labelled reagent migrates with the liquid sample as this progresses to the detection zone. Preferably, the flow of sample continues beyond the detection zone and sufficient sample is applied to the porous material in order that this may occur and that any excess labelled reagent from the first zone which does not participate in any binding reaction in the second zone is flushed away from the detection zone by this continuing flow. If desired, an absorbant “sink” can be provided at the distal end of the carrier material. The absorbent sink may comprise of, for example, Whatman 3MM chromatography paper, and should provide sufficient absorptive capacity to allow any unbound conjugage to wash out of the detection zone. As an alternative to such a sink it can be sufficient to have a length of porous solid phase material which extends beyond the detection zone. [0023]
    [0024] The presence or intensity of the signal from the label which becomes bound in the second zone can provide a qualitative or quantitative measurement of analyte in the sample. A plurality of detection zones arranged in series on the porous solid phase material, through which the aqueous liquid sample can pass progressively, can also be used to provide a quantitative measurement of the analyte, or can be loaded individually with different specific binding agents to provide a multi-analyte test. [0024]
    [0025] The immobilised specific binding reagent in the second zone is preferably a highly specific antibody, and more preferably a monoclonal antibody. In the embodiment of the invention involving the sandwich reaction, the labelled reagent is also preferably a highly specific antibody, and more preferably a monoclonal antibody. [0025]
    [0026] Preferably the carrier material is in the form of a strip or sheet to which the reagents are applied in spacially distinct zones, and the liquid sample is allowed to permeate through the sheet or strip from one side or end to another. [0026]
    [0027] If desired, a device according to the invention can incorporate two or more discrete bodies of porous solid phase material, e.g. separate strips or sheets, each carrying mobile and immobilised reagents. These discrete bodies can be arranged in parallel, for example, such that a single application of liquid sample to the device initiates sample flow in the discrete bodies simultaneously. The separate analytical results that can be determined in this way can be used as control results, or if different reagents are used on the different carriers, the simultaneous determination of a plurality of analytes in a single sample can be made. Alternatively, multiple samples can be applied individually to an array of carriers and analysed simultaneously. [0027]
    [0028] The material comprising the porous solid phase is preferably nitrocellulose. This has the advantage that the antibody in the second zone can be immobilised firmly without prior chemical treatment. If the porous solid phase material comprises paper, for example, the immobilisation of the antibody in the second zone needs to be performed by chemical coupling using, for example, CNBr, carbonyldiimidazole, or tresyl chloride. [0028]
    [0029] Following the application of the antibody to the detection zone, the remainder of the porous solid phase material should be treated to block any remaining binding sites elsewhere. Blocking can be achieved by treatment with protein (e.g. bovine serum albumin or milk protein), or with polyvinylalcohol or ethanolamine, or any combination of these agents, for example. The labelled reagent for the first zone can then be dispensed onto the dry carrier and will become mobile in the carrier when in the moist state. Between each of these various process steps (sensitisation, application of unlabelled reagent, blocking and application of the labelled reagent), the porous solid phase material should be dried. [0029]
    [0030] To assist the free mobility of the labelled reagent when the porous carrier is moistened with the sample, it is preferable for the labelled reagent to be applied to the carrier as a surface layer, rather than being impregnated in the thickness of the carrier. This can minimise interaction between the carrier material and the labelled reagent. In a preferred embodiment of the invention, the carrier is pre-treated with a glazing material in the region to which the labelled reagent is to be applied. Glazing can be achieved, for example, by depositing an aqueous sugar or cellulose solution, e.g. of sucrose or lactose, on the carrier at the relevant portion, and drying. The labelled reagent can then be applied to the glazed portion. The remainder of the carrier material should not be glazed. [0030]
    [0031] Preferably the porous solid phase material is nitrocellulose sheet having a pore size of at least about 1 micron, even more preferably of greater than about 5 microns, and yet more preferably about 8-12 microns. Very suitable nitrocellulose sheet having a nominal pore size of up to approximately 12 microns, is available commercially from Schleicher and Schuell GmbH. [0031]
    [0032] Preferably, the nitrocellulose sheet is “backed”, e.g. with plastics sheet, to increase its handling strenth. This can be manufactured easily by forming a thin layer of nitrocellulose on a sheet of backing material. The actual pore size of the nitrocellulose when backed in this manner will tend to be, lower than that of the corresponding unbacked material. [0032]
    [0033] Alternatively, a pre-formed sheet of nitrocellulose can be tightly sandwiched between two supporting sheets of solid material, e.g. plastics sheets. [0033]
    [0034] It is preferable that the flow rate of an aqueous sample through the porous solid phase material should be such that in the untreated material, aqueous liquid migrates at a rate of 1 cm in not more than 2 minutes, but slower flow rates can be used if desired. [0034]
    [0035] The spatial separation between the zones, and the flow rate characteristics of the porous carrier material, can be selected to allow adequate reaction times during which the necessary specific binding can occur, and to allow the labelled reagent in the first zone to dissolve or disperse in the liquid sample and migrate through the carrier. Further control over these parameters can be achieved by the incorporation of viscosity modifiers (e.g. sugars and modified celluloses) in the sample to slow down the reagent migration. [0035]
    [0036] Preferably, the immobilised reagent in the second zone is impregnated throughout the thickness of the carrier in the second zone (e.g. throughout the thickness of the sheet or strip if the carrier is in this form). Such impregnation can enhance the extent to which the immobilised reagent can capture any analyte present in the migrating sample. [0036]
    [0037] The reagents can be applied to the carrier material in a variety of ways. Various “printing” techniques have previously been proposed for application of liquid reagents to carriers, e.g. micro-syringes, pens using metered pumps, direct printing and ink-jet printing, and any of these techniques can be used in the present context. To facilitate manufacture, the carrier (e.g. sheet) can be treated with the reagents and then subdivided into smaller portions (e.g. small narrow strips each embodying the required reagent-containing zones) to provide a plurality of identical carrier units. [0037]
    [0038] By way of example only, some preferred embodiments of the invention will now be described in detail with reference to the accompanying drawings. [0038]
    [0039] Embodiment 1 [0039]
    [0040] FIGS. 1 and 2 represent a typical strip of porous solid phase material for use in an assay test in accordance with the invention, and illustrate the underlying principle upon which the invention operates. [0040]
    [0041] Referring to FIG. 1, the assay test strip [0041] 10 is seen as a rectangular strip having (for the purpose of this description) its longitudinal axis in a vertical situation. Adjacent the lower end 11 of strip 10 is a narrow band or zone 12 extending across the entire width of the strip. A small region 13 of strip 10 lies vertically below zone 12. Above zone 12 is a second zone 14, lying a discrete distance up strip 10 and similarly extending the entire width of the strip. The region 15 of strip 10 between zones 12 and 14 can be of any height as long as the two zones are separate. A further region 16 of the strip extends above zone 14, and at the top 17 of the strip is a porous pad 18 firmly linked to strip 10 such that pad 18 can act as a “sink” for any liquid sample which may be rising by capillary action through strip 10.
    [0042] Zone [0042] 12 is loaded with a first antibody bearing a visible (“direct”) label (e.g. coloured latex particle, dye sol or gold sol). This reagent can freely migrate through the strip in the presence of a liquid sample. In zone 14, the strip is impregnated with a second antibody having specificity for a different epitope on the same analyte as the first antibody. The second antibody is firmly immobilised on the strip.
    [0043] FIG. 2 illustrates what happens when the assay strip is used in an analytical procedure. The lower end [0043] 11 of the dry strip is contacted with a liquid sample (not shown) which may contain the analyte to be determined. Capillary action causes the fluid to rise through the strip and eventually reach pad 18. In so doing, the sample traverses zone 12 and the labelled antibody will dissolve or disperse in the sample and migrate with it through the strip. While migrating towards zone 14, the labelled antibody can bind to any analyte present in the sample. On reaching zone 14, any analyte molecule should become bound to the second antibody, so immobilising the labelled “sandwich” so produced. If a significant concentration of the analyte to be determined is present in the liquid sample, in a short period of time a distinct accumulation of the visible label should occur in zone 14.
    [0044] As an example of an analysis to which this embodiment can be applied, the analyte can be hCG, the reagents in zones [0044] 12 and 14 can be monoclonal antibodies to hCG which can participate in a “sandwich” reaction with hCG, and the label can be a particulate dye, a gold sol or coloured latex particles.
    [0045] Although described above in relation to a “sandwich” reaction, it will be readily apparent to the skilled reader that this can be modified to a “competition” reaction format if desired, the labelled reagent in zone [0045] 12 being the analyte or an analogue of the analyte.
    [0046] An assay based on the above principles can be used to determine a wide variety of analytes by choice of appropriate specific binding reagents. The analytes can be, for example, proteins, haptens, immunoglobulins, hormones, polyneucleotides, steroids, drugs, infectious disease agents (e.g. of bacterial or viral origin) such as Streptoccus, Neisseria and Chlamydia. Sandwich assays, for example, may be performed for analytes such as hCG, LH, and infectious disease agents, whereas competition assays, for example, may be carried out for analytes such as E-3-G and P-3-G. [0046]
    [0047] The determination of the presence (if any) of more than one analyte in sample can have significant clinical utility. For example, the ratio of the levels of apolipoproteins A[0047] 1 and B can be indicative of susceptibility to coronary heart disease. Similarly, the ratio of the levels of glycated haemoglobin (HbA) to unglycated (HbAo) or total (Hb) haemoglobin can aid in the management of diabetes. Additionally it is possible to configure tests to measure two steroids simultaneously, e.g E-3-G and P-3-G. By way of example, a dual analyte test for apolipoproteins A1 and B may be prepared by depositing, as two spacially distinct zones, antibody specific for apolipoprotein A1 throughout a first zone and depositing a second antibody specific for apolipoprotein B, throughout the second zone of a porous carrier matrix. Following the application of both antibodies to each of their respective zones via a suitable application procedure (e.g. ink-jet printing, metered pump and pen, or airbrush), the remainder of the porous material should be treated with a reagent, e.g. bovine serum albumin, polyvinyl alcohol, or ethanolamine, to block any remaining binding sites elsewhere. A third and fourth reagent, bearing a label, may then be dispensed onto the dry carrier in one or more zones near to one end of the strip, the strip being allowed to dry between applications of the two reagents to the same zone. Reagent 3 and Reagent 4 may comprise conjugates of anti-apolipoprotein A1 antibody and anti-apolipoprotein B antibody respectively. Both of these conjugates will become mobile in and on the carrier when in the moist state. Reagents 3 and 4 can migrate with the solvent flow when an aqueous sample is applied to the first end of the carrier strip. While migrating towards the two zones further along the strip, reagent 3 may bind any apolipoprotein A1 present in the sample and reagent 4 may bind any apolipoprotein B present in the sample. On reaching the first second-antibody zone (anti-apolipoprotein A1 antibody zone) anti-apolipoprotein A1 molecules should become bound to the second antibody, immobilising the labelled ‘sandwich’ so produced. No labelled apoliprotein B molecules will bind to this first zone. On reaching the second second-antibody zone (anti-apolipoprotein B antibody zone) any apolipoprotein B molecules should become bound to the second antibody (solid-phase antibody), immobilising the labelled ‘sandwich’ so produced. No labelled apolipoprotein A1 molecules will bind to the second zone. An accumulation of each of the direct label may occur at both or either zones to a lesser or greater extent resulting in a visible signal at either or both of the solid phase antibody zones. Excess unbound conjugate (of both reagent 3 and reagent 4) can pass freely over the two antibody zones and will be washed into the distal end of the strip.
    [0048] The development of a quantifiable colour in both of the second-antibody zones may be assessed with an appropriate form of instrumentation, yielding a ratio of colour density between the two sites. [0048]
    [0049] The determination of the presence of more than two (ie multiple) analytes in any sample may have significant clinical utility. For example, the detection of the presence of various different serotypes of one bacterium, or the detection of the presence of soluble serological markers in humans may be useful. By way of example, a multiple analyte test for the detection of the presence of different serotypes of Streptococcus can be prepared for groups A, B, C and D. A cocktail of monoclonal antibodies, each specific for various pathologically important group serotypes, or a polyclonal antiserum raised against a particular Streptococcal group, can be dispensed onto a porous carrier strip as a line extending the width of the strip of approximately 1 mm zone length. Multiple lines be dispensed in spatially discrete zones, each zone containing immunochemically reactive component(s) capable of binding the analyte of interest. Following the application of the multiple zones, via a suitable application procedure (eg ink-jet printing, metered pump and pen, airbrush), the remainder of the porous material should be treated with a reagent (eg bovine serum albumin, polyvinylalcohol, ethanolamine) to block any remaining binding sites elsewhere. Conjugates of label, e.g. a dye sol, and each immunochemically-reactive component specific for each bacterial group may then be dispensed either onto a single zone at the bottom end of the strip, proximal to the sample application zone, or as a series of separate zones. [0049]
    [0050] FIGS. 3, 4 and [0050] 5 of the accompanying drawings depict a complete device utilising a porous strip as just described above. FIG. 3 represents the complete device viewed from the front, FIG. 4 shows the same device partially cut away to reveal the details of the strip inside, and FIG. 5 shows the underside of the device.
    [0051] Referring to FIG. 3, the device comprises a flat rectangular body [0051] 30 the front face 31 of which is perforated by a circular hole or window 32 which reveals the porous test strip 10 within the body. The region of the test strip 10 visible through the window 32 incorporates a narrow horizontal zone 14.
    [0052] Referring to FIG. 4, the device comprises a dry rectangular test strip [0052] 10 made from porous material which extends from the bottom end 33 of the body 30 within the body between the front 31 and back 34 of the body. Near the bottom end 11 of the strip 10 is a horizontal zone 12 bearing a labelled specific binding reagent for an analyte, the binding reagent being mobile in the test strip in the moist state. Further up the test strip is the narrow horizontal zone 14 which is visible through the window 32. At the top 17 of the test strip 10 is a porous ‘sink’ 18 which can absorb any liquid sample that has permeated upwards through the strip.
    [0053] Referring to FIG. 5, the bottom edge [0053] 35 of the body 30 incorporates a lateral aperture in which the bottom end 11 of the strip lies.
    [0054] In operation, the bottom end [0054] 33 of the body 30 is immersed in a liquid sample (eg urine) so that the liquid sample can be absorbed by the bottom end 11 of the test strip 20 and rise by capillary action to the top 17 of the test strip and into the sink 18. In so doing, the liquid sample progresses via zone 12 to zone 14. Specific binding reactions as described above occur, and the test result is visible to the user through the window 32.
    [0055] Embodiment 2 [0055]
    [0056] FIGS. 6 and 7 of the accompanying drawings illustrate another test device according to the invention. FIG. 6 illustrates the complete device viewed from the front, and FIG. 7 depicts the same device partially cut away to reveal details of a porous test strip contained within the body of the device. [0056]
    [0057] Referring to FIG. 6, the device comprises an elongate body [0057] 200 terminating at its lower end 201 in a small integral receptacle 202 which can hold a predetermined volume of a liquid sample, eg urine. The front face 203 of the body 200 incorporates two square small square apertures or windows 204 and 205 located one above the other.
    [0058] Referring to FIG. 7, the elongate portion of the body [0058] 200 is hollow and incorporates a test strip 206 running almost the full height of the body. This test strip is of similar construction to those described under Embodiment 1, and incorporates near its lower end 207 a horizontal zone 208 bearing a labelled specific binding reagent that can freely migrate in the strip in the moist state. There are two circular zones 209 and 210 adjacent to the windows 204 and 205 and visible therethrough. The strip terminates at its top end 211 in a porous sink 212. At the bottom end 201 of the device, the receptacle 202 communicates with the hollow body via a lateral aperture 213.
    [0059] In operation, a liquid sample is applied to the bottom end of the device and a predetermined volume of the sample fills the receptacle [0059] 202. From the receptacle 202 the liquid sample rises by capillary action through the test strip 206 and conveys the labelled reagent from zone 208 to the two circular zones 209 and 210. A series of specific binding reactions as described in relation to Embodiment 1 above occur. In this embodiment the second circular zone 210 can act as a control (giving rise, for example, to a coloured signal irrespective of whether or not the sample contains the analyte to be determined) and the determination of the analyte takes place in the first circular zone 209. The user can determine whether the analyte is present in the sample by comparing the signal produced in the two zones.
    [0060] For example, if the test is used to determine the presence of hCG in urine during the course of a pregnancy test, the circular control zone [0060] 210 can contain immobilised HCG which will bind a labelled antibody which is carried upwards from zone 208 by the migrating liquid sample. The same labelled antibody can engage in a ‘sandwich’ reaction with hCG in the sample and be bound in the first circular zone 209 by another specific anti-hCG antibody which has been immobilised therein. Alternatively, if desired, the “control” zone can be designed merely to convey an unrelated signal to the user that the device has worked. For example, the second circular zone can be loaded with an antibody that will bind to the labelled antibody from zone 208, e.g. an “anti-mouse” antibody if the labelled antibody is one that has been derived using a murine hybridoma, to confirm that the sample has permeated the test strip.
    [0061] Embodiment 3 [0061]
    [0062] FIG. 8 of the accompanying drawings represents an isometric view of an assay device in accordance with the invention, and FIG. 9 represents a cross-sectional side elevation of the device shown in FIG. 8. [0062]
    [0063] Referring to FIG. 8, the device comprises a housing or casing [0063] 500 of elongate rectangular form having at one end 501 a portion 502 of reduced cross-sectional area. A cap 503 can be fitted onto portion 502 and can abut against the shoulder 504 at end 501 of the housing. Cap 503 is shown separated from housing 500. Extending beyond end 505 of portion 502 is a porous member 506. When cap 503 is fitted onto portion 502 of the housing, it covers porous member 506. Upper face 507 of housing 500 incorporates two apertures 508 and 509.
    [0064] Referring to FIG. 9, it can be seen that housing [0064] 500 is of hollow construction. Porous member 506 extends into housing 500 and contacts a strip of porous carrier material 510. Porous member 506 and strip 510 overlap to ensure that there is adequate contact between these two materials and that a liquid sample applied to member 506 can permeate member 506 and progress into strip 510. Strip 510 extends further into housing 500. Strip 510 is “backed” by a supporting strip 511 formed of transparent moisture-impermeable plastics material. Strip 510 extends beyond apertures 508 and 509. Means are provided within housing 500 by webbs 512 and 513 to hold strip 510 firmly in place. In this respect, the internal constructional details of the housing are not a significant aspect of the invention as long as the strip is held firmly in place within the housing, and porous member 506 is firmly retained in the housing and adequate fluid permeable contact is maintained between member 506 and strip 510. The transparent backing strip 511 lies between strip 510 and apertures 508 and 509 and can act as a seal against ingress of moisture from outside the housing 500 via these apertures. If desired, the residual space 514 within the housing can contain moisture-absorbant material, such as silica gel, to help maintain the strip 510 in the dry state during storage. The reagent-containing zones in strip 510 are not depicted in FIG. 8, but the first zone containing the labelled reagent which is mobile when the strip is moistened will lie in the region between the porous member 506 and aperture 508. The second zone containing the immobilised unlabelled reagent will lie in the region exposed through aperture 508 in order that when the device has been used in an assay, the result can be observed through aperture 508. Aperture 509 provides means through which a control zone containing further reagents which may enable the adequate permeation of sample through the strip to be observed.
    [0065] In operation, the protective cap [0065] 503 is removed from the holder and member 506 is exposed to a liquid sample e.g. by being placed in a urine stream in the case of a pregnancy test. After exposing member 506 to the liquid sample for a time sufficient to ensure that member 506 is saturated with the sample, the cap 503 can be replaced and the device placed aside by the user for an appropriate period time (e.g. two or three minutes) while the sample permeates test strip 510 to provide the analytical result. After the appropriate time, the user can observe the test strip through apertures 508 and 509 and can ascertain whether the assay has been completed by observing the control zone through aperture 509, and can ascertain the result of the assay by observing the second zone through aperture 508.
    [0066] During manufacture, the device can be readily assembled from, for example, plastics material with the housing [0066] 500 being moulded in two parts (e.g. upper and lower halves 515 and 516) which can be securely fastened together (e.g. by ultrasonic welding) after the porous member and test strip have been placed within one of the halves and then sandwiched between the two halves. The act of forming this sandwich construction can be used to “crimp” the porous member and test strip together to ensure adequate contact between them. Cap 503 can be moulded as a separate complete item. If desired, apertures 508 and 509 can be provided with transparent inserts which may insure greater security against ingress of extraneous moisture from outside the housing. By providing a tight fit between the end 505 of housing 500 and the protruding porous member 506, the application of sample to the protruding member will not result in sample entering the device directly and by-passing member 506. Member 506 therefore provides the sole route of access for the sample to the strip within the housing, and can deliver sample to the strip in a controlled manner. The device as a whole therefore combines the functions of samples and analyser.
    [0067] By using the test strip materials and reagents as hereinafter described, a device in accordance with FIGS. 8 and 9 can be produced which is eminently suitable for use as a pregnancy test kit or fertile period test kit for use in the home or clinic. The user merely needs to apply a urine sample to the exposed porous member and then (after optionally replacing the cap) can observe the test result through aperture [0067] 508 within a matter of a few minutes.
    [0068] Although described with particular reference to pregnancy tests and fertile period tests, it will be appreciated that the device, as just described, can be used to determine the presence of a very wide variety of analytes if appropriate reagents are incorporated in the test strip. It will be further appreciated that aperture [0068] 509 is redundant and may be omitted if the test strip does not contain any control means. Further, the general shape of the housing and cap, both in terms of their length. cross-section and other physical features, can be the subject of considerable variation without departing from the spirit of the invention.
    [0069] A further option is the omission of the labelled reagent from the test strip, this reagent being added to the sample prior to application of the sample to the test device. Alternatively, the labelled reagent can be contained in the protruding porous member [0069] 506.
    [0070] FIG. 10 of the accompanying drawings shows an enlarged view of the porous receiving member and test strip in the device illustrated in FIGS. 8 and 9. [0070]
    [0071] The porous receiving member [0071] 506 is linked to the porous test strip 510, backed by the transparent plastics sheet 511, such that liquid can flow in the direction shown by the arrows through the porous receiving member and into the porous strip. Test zone 517 incorporates the immobilised specific binding reagent, and control zone 518 contains a reagent to indicate that the sample has permeated a sufficient distance along the test strip. A portion of the test strip surface opposite the backing strip 511 and adjacent the porous receiving member 506, carries a glaze 519 on which is deposited a layer 520 of labelled specific binding reagent. The thickness of these two layers as depicted in FIG. 10 is grossly exaggerated purely for the purpose of illustration. It will be appreciated that, in practice, the glaze may not form a true surface layer and the glazing material will penetrate the thickness of the strip to some extent. Similarly, the subsequently applied labelled reagent may also penetrate the strip. Nevertheless, the essential objective of reducing any interaction between the labelled reagent and the carrier material forming the strip will be achieved. An aqueous sample deposited in receiving member 506 can flow therefrom along the length of strip 510 and in so doing, will dissolve glaze 519 and mobilise the labelled reagent, and carry the labelled reagent along the strip and through zone 517.
    [0072] Embodiment 4 [0072]
    [0073] FIGS. 11 and 12 illustrate another embodiment of the invention, which is seen in plan view in FIG. 11 and in cross-section in FIG. 11, the cross-section being an elevation on the line A seen in FIG. 11. [0073]
    [0074] Referring to FIG. 11, the test device comprises a flat rectangular casing [0074] 600 incorporating a centrally disposed rectangular aperture 601, adjacent the left hand end 602, and two further apertures 603 and 604 near the mid point of the device and arranged such that apertures 601, 603 and 604 lie on the central longitudinal axis of the device corresponding to line A. Although all three apertures are illustrated as being rectangular, their actual shape is not critical.
    [0075] Referring to the cross-section seen in FIG. 12, the device is hollow and incorporates within it a porous sample receiving member adjacent end [0075] 602 of casing 600 and lying directly beneath aperture 601. A test strip of similar construction to that described with reference to Embodiment 4, comprising a porous strip 606 backed by a transparent plastics sheet 607 is also contained within casing 600, and extends from the porous receiving member 602, with which the porous carrier is in liquid permeable contact, to the extreme other end of the casing. The transparent backing sheet 607 is in firm contact with the upper inner surface 608 of casing 600, and provides a seal against apertures 603 and 604 to prevent ingress of moisture or sample into the casing. Although not shown in the drawings, the porous test strip 606 will incorporate a labelled specific binding reagent, and a test zone and a control zone placed appropriately in relation to apertures 603 and 604, in a manner analagous to that described in Embodiment 3.
    [0076] In operation, an aqueous sample can be applied through aperture [0076] 601, e.g. by means of a syringe, to saturate porous receiving member 605. Thereafter, the aqueous sample can permeate the test strip and after an appropriate time the test result can be observed through apertures 603 and 604.
    [0077] Embodiment 5 [0077]
    [0078] A yet further embodiment of the invention is illustrated in FIGS. 13 and 14 of the accompanying drawings. FIG. 13 shows a device comprising a rectangular casing [0078] 700 having in its upper surface 701 a rectangular aperture 702. One end wall 703 of the device 703 incorporates an aperture 704 through which a porous test element communicates with the exterior of the device. Aperture 702 is situated in surface 701 at a point relatively remote from the end 703 containing the aperture 704.
    [0079] FIG. 14 shows a partially cut-away view of the device in FIG. 13. The hollow device incorporates a porous test strip [0079] 705, running almost the entire length of casing 700 from aperture 704. Test strip 705 incorporates a first zone 706 containing a labelled specific binding reagent and a further zone 707, remote from aperture 704, incorporating an immobilised specific reagent. Zone 706 lies directly beneath aperture 702 is therefore observable from outside casing. Beneath strip 705 and adjacent zone 707, is a crushable element 708 containing one or more substrates or reagents which can be used to produce a detectable signal when released into zone 707, if labelled reagent from 706 has become bound in zone 707 following use of the device. Release of the reagents from member 708 can be effected by applying pressure to the outside of the casing at that point in order to crush the member and express the reagent therefrom.
    [0080] In operation, the first test element can be exposed to an aqueous sample, e.g. by dipping end [0080] 703 of casing 700 into a vessel containing the sample. The liquid sample will then permeate the length of test strip 705, taking labelled reagent from zone 706 and passing through zone 707 where the labelled reagent can become bound e.g. through a sandwich reaction involving an analyte in the sample. When the sample has permeated the test strip, reagent can be released from the crushable member 708 and the result of the test observed through aperture 702.
    [0081] By way of example only, certain preferred test strip materials, reagents, and methods for their production will now be described. [0081]
    [0082] 1. Selection of Liquid Conductive Material [0082]
    [0083] Representative examples of liquid conductive materials include paper, nitrocellulose and nylon membranes. Essential features of the material are its ability to bind protein; speed of liquid conduction; and, if necessary after pre-treatment, its ability to allow the passage of labelled antibodies along the strip. It this is a direct label, it may be desirable for the material to allow flow of particles of size up to a few microns (usually less than 0.5μ). Examples of flow rates obtained with various materials are given below: [0083] Time to Flow Pore size 45 mm (minutes) Schleicher + Schuell nitrocellulose 3μ 3.40 (unbacked) 5μ 3.30 8μ 3.00 12μ  2.20 polyester-backed 8μ (nominal) 3.40 Whatman Nitrocellulose 5  19.20  Pall “Immunodyne” (nylon) 3  4.00 5  3.20
    [0084] The speed of a test procedure will be determined by the flow rate of the material employed and while any of the above materials can be used some will give faster tests than others. [0084]
    [0085] Nitrocellulose had the advantage of requiring no activation and will immobilise proteins strongly by absorbtion. “Immunodyne” is pre-activated and requires no chemical treatment. Papers, such as Whatman 3MM, require chemical activation with for example carbonyldiimidazole in order to successfully immobilise antibody. [0085]
    [0086] 2. Labels [0086]
    [0087] Preparation of Labels [0087]
    [0088] A selection of labels which may be used are described below. This list is not exhaustive. [0088]
    [0089] A) Gold Sol Preparation [0089]
    [0090] Gold sols may be prepared for use in immunoassay from commercially-available colloidal gold, and an antibody preparation such as anti-alpha human chorionic gonadotrophin. Metallic sol labels are described, for example, in European patent specification No. EP 7654. [0090]
    [0091] For example, colloidal gold G20 (20 nm particle size, supplied by Janssen Life Sciences Products) is adjusted to pH 7 with 0.22μ filtered 0.1M K[0091] 2CO3, and 20 mls is added to a clean glass beaker. 200 μl of anti-alpha hCG antibody, prepared in 2 mM borax buffer pH9 at 1 mg/ml, and 0.22μ filtered, is added to the gold sol, and the mixture stirred continuously for two minutes. 0.1M K2CO3 is used to adjust the pH of the antibody gold sol mixture to 9, and 2 mls of 10% (w/v) BSA is added.
    [0092] The antibody-gold is purified in a series of three centrifugation steps at 12000 g, 30 minutes, and 4° C., with only the loose part of the pellet being resuspended for further use. The final pellet is resuspended in 1% (w/v) BSA in 20 mM Tris, 150 mM NaCl pH 8.2. [0092]
    [0093] B) Dye Sol Preparation [0093]
    [0094] Dye sols (see, for example, European patent specification No. EP 32270) may be prepared from commercially-available hydrophobic dyestuffs such as Foron Blue SRP (Sandoz) and Resolin Blue BBLS (Bayer). For example, fifty grammes of dye is dispersed in 1 liter of distilled water by mixing on a magnetic stirrer for 2-3 minutes. Fractionation of the dye dispersion can be performed by an initial centrifugation step at 1500 g for 10 minutes at room temperature to remove larger sol particles as a solid pellet, with the supernatant suspension being retained for further centrifugation. [0094]
    [0095] The suspension is centrifuged at 3000 g for 10 minutes at room temperature, the supernatant being discarded and the pellet resuspended in 500 mls distilled water. This procedure is repeated a further three times, with the final pellet being resuspended in 100 mls distilled water. [0095]
    [0096] The spectra of dye sols prepared as described above can be measured, giving lambda-max values of approximately 657 nm for Foron Blue, and 690 nm for Resolin Blue. The absorbance at lambda-max, for 1 cm path length, is used as an arbitrary measure of the dye sol concentration. [0096]
    [0097] C) Coloured Particles [0097]
    [0098] Latex (polymer) particles for use in immunoassays are available commerically. These can be based on a range of synthetic polymers, such as polystyrene, polyvinyltoluene, polystyrene-acrylic acid and polyacrolein. The monomers used are normally water-insuluble, and are emulsified in aqueous surfactant so that monomer mycelles are formed, which are then induced to polymerise by the addition of initiator to the emulsion. Substantially sperical polymer particles are produced. [0098]
    [0099] Coloured latex particles can be produced either by incorporating a suitable dye, such as anthraquinone, in the emulsion before polymerisation, or by colouring the pre-formed particles. In the latter route, the dye should be dissolved an a water-immiscible solvent, such a chroroform, which is then added to an aqueous suspension of the latex particles. The particles take up the non-aqueous solvent and the dye, and can then be dried. [0099]
    [0100] Preferably such latex particles have a maximum dimension of less than about 0.5 micron. [0100]
    [0101] Coloured latex particles may be sensitised with protein, and in particular antibody, to provide reagents for use in immunoassays. For example, polystyrene beads of about 0.3 micron diameter, (supplied by Polymer Laboratories) may be sensitised with anti-alpha human chorionic gonadotrophin, in the process described below: [0101]
    [0102] 0.5 ml (12.5 mg solids) of suspension is diluted with 1 ml of 0.1M borate buffer pH 8.5 in an Eppendorf vial. These particles are washed four times in borate buffer, each wash consisting of centrifugation for 3 minutes at 13000 rpm in an MSE microcentrifuge at room temperature. The final pellet is resuspended in 1 ml borate buffer, mixed with 300 μg of anti-alpha hCG antibody, and the suspension is rotated end-over-end for 16-20 hours at room temperature. The antibody-latex suspension is centrifuged for 5 minutes at 13000 rpm, the supernatant is discarded and the pellet resuspended in 1.5 mls borate buffer containing 0.5 milligrammes bovine serum albumin. Following rotation end-over-end for 30 minutes at room temperature, the suspension is washed three times in 5 mg/ml BSA in phosphate buffered saline pH7.2, by centrifugation at 13000 rpm for 5 minutes. The pellet is resuspended in 5 mg/ml BSA/5% (w/v) glycerol in phosphate buffered saline pH 7.2 and stored at 4° C. until used. [0102]
    [0103] (A) Anti-hCG—Dye Sol Preparation [0103]
    [0104] Protein may be coupled to dye sol in a process involving passive adsorption. The protein may, for example, be an antibody preparation such as anti-alpha human chorionic gonadotrophin prepared in phosphate buffered saline pH 7.4 at 2 milligram/ml. A reaction mixture is prepared which contains 100 μl antibody solution, 2 mls dye sol, 2 mls 0.1M phosphate buffer pH 5.8 and 15.9 mls distilled water. After gentle mixing of this solution, the preparation is left for fifteen minutes at room temperature. Excess binding sites may be blocked by the addition of, for example, bovine serum albumin: 4 mls of 150 mg/ml BSA in 5 mM NaCl pH 7.4 is added to the reaction mixture, and after 15 minutes incubation at room temperature, the solution is centrifuged at 3000 g for 10 minutes, and the pellet resuspended in 10 mls of 0.25% (w/v) dextran/0.5% (w/v) lactose in 0.04M phosphate buffer. This antibody-dye sol conjugate is best stored in a freeze dried form. [0104]
    [0105] (B) LH—Dye Sol Preparation [0105]
    [0106] Due to the structural homology between the alpha subunits of hCG and LH, alpha hCG antibody can be used to detect LH in a cross-reactive immunoassay. Thus, a labelled antibody may be prepared for use in an LH assay in an identical manner to that described in Example 1, using anti-alpha hCG antibody. [0106]
    [0107] 3. Preparation of Reagent Strip [0107]
    [0108] Zonal Impregnation of Liquid-conductive Materials [0108]
    [0109] Liquid-conducting material with a restricted zone of immobilised protein, particularly antibody, can be prepared for example as follows: [0109]
    [0110] A rectangular sheet of Schleicher and Schuell backed 8μ nitrocellulose measuring 25 cm in length and 20 cm in width may have a reaction zone formed upon it by applying a line of material about 1 m wide at 5 cm intervals along its length and extending throughout its 20 cm width. The material can, for example, be a suitably selected antibody preparation such as anti-beta (human chorionic gonadotropin) of affinity Ka at 10[0110] 9, prepared in phosphate buffered saline pH 7.4 at 2 milligram/ml, suitable for immunoassay of human chorionic gonadotrophin using a second (labelled) anti-hCG antibody in a sandwich format. This solution can be deposited by means of a microprocessor-controlled microsyringe, which delivers precise volumes of reagent through a nozzle, preferably 2 mm diameter. When the applied material has been allowed to dry for 1 hour at room temperature, excess binding sites on the nitrocellulose are blocked with an inert compound such as polyvinyl alcohol (1% w/v in 20 mM Tris pH 7.4) for 30 minutes at room temperature, and sheets are thoroughly rinsed with distilled water prior to drying for 30 minutes at 30° C.
    [0111] In one embodiment, the liquid conductive material can then be cut up into numerous strips 5 cm in length and 1 cm in width, each strip carrying a limited zone of the immobilised antibody to function as an immunosorbent part way (e.g. about half way) along its length. In this example the test strip is used with a liquid label which is mixed with sample. In use, this limited zone then becomes a test reaction zone in which the immunoassay reactions take place. [0111]
    [0112] In another embodiment, the label may be dispensed/deposited into/on a restricted zone before cutting up the liquid-conductive material into strips. By way of example, this reagent may be dye sol or dye polymer-conjugated anti-hCG antibody prepared as described under dye sol preparation, said reagent being retained in the zone when the material is in the dry state but which is free to migrate through the carrier material when the material is moistened, for example, by the application of liquid sample containing the analyte to be determined. This mobile reagent zone is applied, for example, as follows: [0112]
    [0113] A sheet of Schleicher and Schuell backed 8μ nitrocellulose, 25 cm in length and 20 cm in width with zones of immobilised antibody at 5 cm intervals along its length, is prepared as described previously. Prior to the deposition of dye labelled antibody, a sublayer of, for example, 60% w/v of sucrose in distilled water is applied by airbrush on the microprocessor controlled system at 6 cm intervals along the length of the sheet. Then several passes (e.g. three) of dye labelled. antibody prepared in 1% methacel KAM (Trademark for methylcellulose from Dow Chemical Company) and 0.6% (w/v) polyvinylalcohol are applied by airbrush or by microsyringe directly on top of the sublayer. Sheets are then allowed to dry, and cut into strips 5 cm in length and 1 cm in width, to be used in the completed device. [0113]
    [0114] Gold sols, or coloured polystyrene particles can be deposited by a similar process. [0114]
    [0115] In addition to the test zone various control zone options can be operated. For example a zone of anti-species IgG may be deposited after the test zone. [0115]
    [0116] 4. Sandwich Assays Using Strip Format [0116]
    [0117] A sandwich-type reaction may be performed for the detection of human chorionic gonadotrophin (hCG) in a liquid sample. Preferably the label used is a direct label which is readily visible to the naked eye. Dye sols, gold sols or coloured latex particles may be linked to anti hCG antibody, as described above. [0117]
    [0118] With direct labels, assays may be performed in which fresh urine samples are applied directly from the urine stream, or by delivering an appropriate volume (e.g. 100 μl) from a container using a pipette to the absorbent wick of the test device. Each sample is allowed to run for five minutes in the device, and the colour generated at the reactive zone read either by eye, or using a light reflectometer. [0118]
    [0119] Indirect labels such as enzymes e.g. alkaline phosphatase may also be used, but require the addition of substrate to generate a coloured endpoint. [0119]
    [0120] Enzyme assays may be performed in which the anti-hCG antibody is conjugated to alkaline phosphatase, using conventional techniques, and diluted {fraction (1/100)}in 0.01M phosphate buffered saline pH 7 containing 3% polyethylene glycol 6000, 1% (w/v) bovine serum albumin and 0.02% Triton X305 (Trademark—obtainable from Rohm and Haas) before application to the sheet. Fresh urine samples are then applied, either directly from the urine stream, or by delivering an appropriate volume (e.g. 100 μl) from a container using a pipette, to the absorbent wick of the test device. Each sample is allowed to run for five minutes before a pad of liquid-swellable material soaked in BCIP substrate (at 1 mg/ml in 1M Tris/HCl pH 9.8) is placed in contact with the immobile antibody zone. After a further five minutes, the pad is removed, and colour generated read either by eye, or by using a light reflectometer. [0120]
    [0121] A similar embodiment can be prepared using lutenising hormone (LH) instead of hCG. [0121]
    [0122] 5. Competitive Assays [0122]
    [0123] A competitive type assay may be performed as exemplified by estrone-3-glucuronide, a urinary metabolite of estrone. Conjugates of estrone-3-glucuronide and bovine serum albumin are prepared as follows: [0123]
    [0124] Preparation of BSA—Estrone-3-glucuronide [0124]
    [0125] The conjugation of E-3-G and BSA may be achieved through the use of a mixed anhydride. All of the glassware, solvents and reagents employed in the preparation of the activated species must be thoroughly dried using an oven, dessicator or molecular sieves, as appropriate, for at least 24 hours. [0125]
    [0126] Solutions of E-3-G (2 nM) in dry dimethylformamide (DMF) and tri-n-butylamine (TnB) (10 nM) in dry DMF were equilibrated separately at 4° C. Using pre-cooled glassware E-3-G in DMF (1.25 ml) and TnB in DMF (0.25 ml) were added to a pre-cooled 5 ml Reactivial containing a magnetic stirrer. A solution of isobutyl chloroformate in dry DMF (10 nM) was prepared and an aliquot (0.25 ml) was cooled to 4° C. and added to the Reactivial. The contents of the Reactivial were stirred for 20 minutes at 4° C. and a solution of BSA (1 mg/ml) in bicarbonate buffer (0.5%) was prepared. When the mixed anhydride incubation was complete, the contents of the Reactivial were added to the BSA solution (2.5 ml) and stirred on a magnetic stirrer for 4 hours at 4° C. The conjugate preparation was purified by passage through a Tris buffer equilibrated Pharmacia PD-[0126] 10 Sephadex G-25 column, transferred to an amber glass storage bottle and stored at 4° C.
    [0127] Preparation of BSA—E-3-G dye Sol [0127]
    [0128] A dispersion of dye (5% w/v) in distilled water was prepared with thorough mixing and aliquots were centrifuged at 3850 rpm (1500 g) for 10 minutes in a bench top centrifuge. The pellet was discarded and the supernatant was retained and centrifuged in aliquots at 4850 rpm (3000 g) for 10 minutes in a bench top centrifuge. The supernatant was discarded and the pellet was resuspended in half of its original volume in distilled water. This step was repeated four times to wash the pellet. The pellet was finally resuspended in distilled water and the absorbance at lambda max was determined. [0128]
    [0129] Solutions of dye sol in distilled water and E-3-G/BSA conjugate diluted in phosphate buffer were mixed to give final concentrations of 10 μg/ml conjugate (based on BSA content) and an extrapolated dye sol optical density of 20 at the absorbance maximum. The reaction mixture was incubated for 15 minutes at room temperature and blocked for 15 minutes at room temperature with BSA in a NaCl solution (5 mM, pH7.4) to yield a final BSA concentration of 25 mg/ml. The reaction mixture was centrifuged at 4850 rpm (3000 g) for 10 minutes in a benchtop centrifuge, the supernatant was discarded and the pellet was resuspended in half of its original volume in Dextran (0.25% w/v)/Lactose (0.5% w/v) phosphate (0.04M pH5.8) buffer. [0129]
    [0130] Preparation of E-3-G Test Strips [0130]
    [0131] Antibodies to E-3-G were deposited as described in example 3. BSA—E-3-G dye sol was deposited on the strips as described in 3. [0131]
    [0132] Determination of E-3-G [0132]
    [0133] Using reagents described above, a standard curve can be generated by running strips with samples with known concentrations of E-3-G. The colour at the immobile zone can be read, for example using a Minolta chromameter, and the concentration of E-3-G calculated by extrapolating from the reflectance value. [0133]
    [0134] The invention described herein extends to all such modifications and variations as will be apparent to the reader skilled in the art, and also extends to all combinations and subcombinations of the features of this description and the accompanying drawings. [0134]
    权利要求:
    Claims (38)
    [1" id="US-20010008774-A1-CLM-00001] 1. An analytical test device comprising a hollow casing constructed of moisture impervious solid material containing a dry porous carrier which communicates directly or indirectly with the exterior of the casing such that a liquid test sample can be applied to the porous carrier, the device also containing a labelled specific binding reagent for an analyte or which can participate in a competition reaction in the presence of an analyte, which labelled specific binding reagent is freely mobile within the porous carrier when in the moist state, and unlabelled specific binding reagent for the same analyte which unlabelled reagent is permanently immobilised in a detection zone on the carrier material and is therefore not mobile in the moist state, the relative positioning of the labelled reagent and detection zone being such that liquid sample applied to the device can pick up labelled reagent and thereafter permeate into the detection zone, and the device incorporating means enabling the extent (if any) to which the labelled reagent becomes bound in the detection zone to be observed.
    [2" id="US-20010008774-A1-CLM-00002] 2. An analytical test device comprising a hollow casing constructed of moisture- impervious solid material containing a dry porous carrier which communicates directly or indirectly with the exterior of the casing such that a liquid test sample can be applied to the porous carrier, the carrier containing in a first zone a labelled specific binding reagent for an analyte or which can participate in a competition reaction in the presence of an analyte, which labelled specific binding reagent is freely mobile within the porous carrier when in the moist state, and in a second zone spatially distinct from the first zone unlabelled specific binding reagent for the same analyte which unlabelled reagent is permanently immobilised on the carrier material and is therefore not mobile in the moist state, the two zones being arranged such that liquid sample applied to the porous carrier can permeate via the first zone into the second zone, and the device incorporating means enabling the extent (if any) to which the labelled reagent becomes bound in the second zone to be observed.
    [3" id="US-20010008774-A1-CLM-00003] 3. A test device according to
    claim 1 or
    claim 2 , wherein the label on the first specific binding reagent is a direct label.
    [4" id="US-20010008774-A1-CLM-00004] 4. A test device according to any one of
    claims 1 to
    3 , wherein the casing is constructed of opaque or translucent material, and is provided with at least one aperture through which the analytical result may be observed.
    [5" id="US-20010008774-A1-CLM-00005] 5. A test device according to any one of the preceding claims, within the porous carrier communicates with the exterior of the device via a bibulous sample receiving member which protrudes from the casing and which can act as a reservoir to receive the liquid sample and release it into the porous carrier.
    [6" id="US-20010008774-A1-CLM-00006] 6. A test device according to
    claim 5 , it incorporates a removable and replaceable moisture-impervious cover for the protruding bibulous sample receiving member.
    [7" id="US-20010008774-A1-CLM-00007] 7. A test device according to any one of the preceding claims, within the casing, and cover if present, is moulded from plastics material.
    [8" id="US-20010008774-A1-CLM-00008] 8. A test device according to any one of the preceding claims, wherein the porous carrier comprises a strip or sheet of porous material backed with a layer of transparent moisture-impervious material, the transparent layer being in contact with the inside of the casing adjacent the aperture(s) to inhibit ingress of moisture or sample.
    [9" id="US-20010008774-A1-CLM-00009] 9. A test device according to
    claim 7 , wherein the porous carrier material is nitrocellulose.
    [10" id="US-20010008774-A1-CLM-00010] 10. A test device according to
    claim 8 , wherein the nitrocellulose has a pore size of greater than about 1 micron.
    [11" id="US-20010008774-A1-CLM-00011] 11. A test device according to any one of the preceding claims, wherein the label comprises coloured latex particles having a maximum dimension of not greater than about 0.5 micron.
    [12" id="US-20010008774-A1-CLM-00012] 12. A test device according to any one of the preceding claims, incorporating a control zone downstream from the second zone in the porous carrier to indicate that the liquid sample has permeated beyond the second zone, the control zone also being observable from outside the casing.
    [13" id="US-20010008774-A1-CLM-00013] 13. A test device according to any one of the preceding claims, wherein the analyte is hCG.
    [14" id="US-20010008774-A1-CLM-00014] 14. A test device according to any one of
    claims 1 to
    12 , wherein the analyte is LH.
    [15" id="US-20010008774-A1-CLM-00015] 15. A pregnancy testing device comprising a hollow elongated casing containing a dry porous nitrocellulose carrier which communicates indirectly with the exterior of the casing via a bibulous urine receiving member which protrudes from the casing and which can act as a reservoir from which urine is released into the porous carrier, the carrier containing in a first zone a highly-specific anti-hCG antibody bearing a coloured “direct” label, the labelled antibody being freely mobile within the porous carrier when in the moist state, and in a second zone spatially distinct from the first zone an highly-specific unlabelled anti-hCG antibody which is permanently immobilised on the carrier material and is therefore not mobile in the moist state, the labelled and unlabelled antibodies having specificities for different hCG epitopes, the two zones being arranged such that a urine sample applied to the porous carrier can permeate via the first zone into the second zone, and the casing being constructed of opaque or translucent material incorporating at least one aperture through which the analytical result may be observed, together with a removable and replaceable cover for the protruding bibulous urine receiving member.
    [16" id="US-20010008774-A1-CLM-00016] 16. A fertile period prediction device, as claimed in
    claim 15 except that the analyte is LH.
    [17" id="US-20010008774-A1-CLM-00017] 17. A dry porous carrier useful in a device as claimed in
    claim 1 , comprising a strip or sheet of nitrocellulose.
    [18" id="US-20010008774-A1-CLM-00018] 18. A carrier according to
    claim 17 , wherein the nitrocellulose has a pore size of at least about 1 micron.
    [19" id="US-20010008774-A1-CLM-00019] 19. A carrier according to
    claim 18 , wherein the pore size is greater than about 5 microns.
    [20" id="US-20010008774-A1-CLM-00020] 20. A carrier according to
    claim 19 , wherein the pore size is about 8-12 microns.
    [21" id="US-20010008774-A1-CLM-00021] 21. A carrier according to any one of
    claims 17 to
    20 which is backed by a layer of solid water-impervious material.
    [22" id="US-20010008774-A1-CLM-00022] 22. A carrier according to
    claim 21 , wherein the backing material is transparent plastics material.
    [23" id="US-20010008774-A1-CLM-00023] 23. A carrier according to any one of claims 17-22, carrying in a zone thereof an immobilised specific binding reagent for an analyte.
    [24" id="US-20010008774-A1-CLM-00024] 24. A carrier according to
    claim 23 , carrying in another zone thereof a labelled specific binding reagent for the same analyte, which labelled specific binding reagent is freely mobile within the carrier material when in the moist state.
    [25" id="US-20010008774-A1-CLM-00025] 25. A carrier according to
    claim 24 , wherein the label is a direct label.
    [26" id="US-20010008774-A1-CLM-00026] 26. A carrier according to
    claim 25 , wherein the direct label is a coloured latex particle having a maximum dimension of not greater than about 0.5 micron.
    [27" id="US-20010008774-A1-CLM-00027] 27. A carrier according to
    claim 25 or
    26 , wherein the zone carrying the labelled reagent has been pre-treated with a glazing material prior to the application of the labelled reagent thereto.
    [28" id="US-20010008774-A1-CLM-00028] 28. A carrier according to
    claim 27 wherein the glazing material is a sugar.
    [29" id="US-20010008774-A1-CLM-00029] 29. A specific binding assay involving the use of a labelled reagent which is free to migrate through a porous carrier material moistened by the application thereto a an aqueous sample suspected of containing an analyte, wherein the label is a direct label.
    [30" id="US-20010008774-A1-CLM-00030] 30. A specific binding assay according to
    claim 29 , wherein the direct label is a coloured latex particle.
    [31" id="US-20010008774-A1-CLM-00031] 31. A pregnancy test kit suitable for home use, comprising a plurality of devices as claimed in
    claim 15 individually wrapped in moisture-impervious wrapping and packaged together with appropriate instructions to the user.
    [32" id="US-20010008774-A1-CLM-00032] 32. A fertile period prediction kit suitable for home use, comprising a plurality of devices according to
    claim 16 individually wrapped in moisture-impervious wrapping and packaged together with appropriate instructions to the user.
    [33" id="US-20010008774-A1-CLM-00033] 33. An analytical test device substantially as hereinbefore described with reference to FIGS. 3 to 5.
    [34" id="US-20010008774-A1-CLM-00034] 34. An analytical test device substantially as hereinbefore described with reference to FIGS. 6 and 7.
    [35" id="US-20010008774-A1-CLM-00035] 35. An analytical test device substantially as hereinbefore described with reference to FIGS. 8 and 9.
    [36" id="US-20010008774-A1-CLM-00036] 36. An analytical test device incorporating a test strip substantially as hereinbefore described with reference to FIG. 10.
    [37" id="US-20010008774-A1-CLM-00037] 37. An analytical test device substantially as hereinbefore described with reference to FIGS. 11 and 12.
    [38" id="US-20010008774-A1-CLM-00038] 38. An analytical test device substantially as hereinbefore described with reference to FIGS. 13 and 14.
    类似技术:
    公开号 | 公开日 | 专利标题
    US7109042B2|2006-09-19|Assays
    US5656503A|1997-08-12|Test device for detecting analytes in biological samples
    US7384796B2|2008-06-10|Assays
    EP0383619B1|1997-04-23|Solid-phase analytical device
    AU656967B2|1995-02-23|Analytical devices and assays
    AU3533800A|2000-07-27|Assays
    IE19980110A1|2000-02-23|Solid phase analytical device
    同族专利:
    公开号 | 公开日
    FR2614423A3|1988-10-28|
    WO1988008534A1|1988-11-03|
    AT225509T|2002-10-15|
    US6228660B1|2001-05-08|
    EP0560411A2|1993-09-15|
    HK140995A|1995-09-15|
    AU682071B2|1997-09-18|
    ES2050704T3|1994-06-01|
    DE291194T1|1992-03-19|
    EP0291194B1|1994-02-16|
    US5602040A|1997-02-11|
    EP0560411B1|2000-07-26|
    DE8805565U1|1988-08-18|
    EP0560410A3|1993-10-06|
    AU8049094A|1995-03-09|
    AU679279B2|1997-06-26|
    DE1248112T1|2003-03-20|
    GB2204398A|1988-11-09|
    JP2705768B2|1998-01-28|
    EP0291194B2|2003-07-23|
    DE3887771T2|1994-05-26|
    US6818455B2|2004-11-16|
    US6187598B1|2001-02-13|
    DE3887771T3|2004-03-25|
    DE560410T1|2001-12-20|
    JP2919392B2|1999-07-12|
    EP1248112A3|2004-08-25|
    IT8853100V0|1988-04-27|
    JPH09178748A|1997-07-11|
    GB2204398B|1991-08-28|
    FR2614423B3|1989-07-07|
    US7109042B2|2006-09-19|
    EP0560410B1|2002-10-02|
    JPH06160388A|1994-06-07|
    DE3856421D1|2000-08-31|
    AU4438697A|1998-03-19|
    IT214285Z2|1990-04-24|
    EP1555529A2|2005-07-20|
    ES2050704T5|2004-04-16|
    US20050244986A1|2005-11-03|
    EP0291194B8|2003-10-22|
    EP0560411A3|1993-10-06|
    AT195022T|2000-08-15|
    AU1622888A|1988-12-02|
    JPH01503174A|1989-10-26|
    JPH06180320A|1994-06-28|
    JP2705767B2|1998-01-28|
    ES2184734T3|2003-04-16|
    JPH0746107B2|1995-05-17|
    DE3856542T2|2003-10-30|
    ES2150428T3|2000-12-01|
    EP1248112A2|2002-10-09|
    EP1555529A3|2008-06-04|
    EP0560410A2|1993-09-15|
    GB8809867D0|1988-06-02|
    AU8048994A|1995-03-09|
    DE3856542D1|2002-11-07|
    DE3887771C5|2009-06-04|
    US20010041368A1|2001-11-15|
    AU626207B2|1992-07-23|
    DE3887771D1|1994-03-24|
    EP0291194A1|1988-11-17|
    DE3856421T2|2000-12-14|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4978503A|1984-06-13|1990-12-18|Ares-Serono Research & Development Limited Partnership|Devices for use in chemical test procedures|
    US5514602A|1986-06-09|1996-05-07|Ortho Diagnostic Systems, Inc.|Method of producing a metal sol reagent containing colloidal metal particles|
    US5571726A|1986-06-09|1996-11-05|Ortho Diagnostic Systems, Inc.|Kit containing glutaraldehyde coated colloidal metal particles of a preselected size|
    US6485982B1|1988-06-27|2002-11-26|Armkel, Llc|Test device and method for colored particle immunoassay|US20040248322A1|2003-06-06|2004-12-09|David Charlton|Diagnostic test for analytes in a sample|
    US20040253142A1|2002-01-09|2004-12-16|Brewster Barry Sinclair|Liquid sample assay device|
    US20040266024A1|2003-06-30|2004-12-30|Sysmex Corporation|Device for immunochromatography|
    US20040265800A1|2003-06-30|2004-12-30|Sysmex Corporation|Sample pretreatment solution for immunological test and method for using the same|
    US20050130322A1|2002-01-09|2005-06-16|Beesley Natalie E.|Assay device|
    US20060029924A1|2002-06-27|2006-02-09|Inverness Medical Switzerland Gmbh|Assay device for liquid sample|
    US20060160064A1|2004-06-09|2006-07-20| Pathogen Removal And Diagnostic Technologies Inc.|Devices and methods for removing target agents from a sample|
    US20060205090A1|2005-03-14|2006-09-14|Newton Michael W|Water-soluble conjugates for electrochemical detection|
    US20060263907A1|2005-04-29|2006-11-23|Zweig Stephen E|Fluorescence lateral flow immunoassay|
    US20090117665A1|2003-11-14|2009-05-07|Inverness Medical Switzerland Gmbh|Rapid sample collection and analysis device and methods of use|
    US20090208975A1|2007-12-13|2009-08-20|Beckman Coulter, Inc.|Device and methods for detecting a target cell|
    US20090226883A1|2005-11-30|2009-09-10|Yuzhang Wu|Devices and methods for detecting analytes in fluid samples|
    US20090232702A1|2006-07-26|2009-09-17|Inverness Medical Switzerland Gmbh|Test device for detecting an analyte in a liquid sample|
    US20090305231A1|2008-04-09|2009-12-10|Becton, Dickinson And Company|Sensitive Immunoassays Using Coated Nanoparticles|
    WO2010077722A1|2008-12-30|2010-07-08|Centocor Ortho Biotech Inc.|Serum markers predicting clinical response to anti-tnf antibodies in patients with ankylosing spondylitis|
    US8394626B2|2003-01-04|2013-03-12|Alere Switzerland Gmbh|Specimen collection and assay container|
    WO2014134033A1|2013-02-26|2014-09-04|Astute Medical, Inc.|Lateral flow assay with test strip retainer|
    US9140700B2|2012-03-19|2015-09-22|Milovan Stankov|Device for determining at least one analyte capable of being contained in a liquid sample|
    WO2016140862A1|2015-03-02|2016-09-09|Chembio Diagnostic Systems, Inc.|Integrated buffer dual-path immunoassay device|
    WO2016164365A1|2015-04-06|2016-10-13|Bludiagnostics, Inc.|A test device for detecting an analyte in a saliva sample and method of use|
    WO2017017676A1|2015-07-26|2017-02-02|Puddleby Tech Ltd|Device for non-intrusive and automated animal urine tests|
    WO2017156038A3|2016-03-07|2017-10-05|Alere San Diego, Inc.|Immunoassay controls and the use thereof|
    US10101326B2|2010-02-23|2018-10-16|B.R.A.H.M.S Gmbh|Method for determining a marker in small volume of a sample of a bodily fluid|
    US10359421B2|2014-11-25|2019-07-23|Fujifilm Corporation|Inspection kit|
    US10598625B2|2015-04-08|2020-03-24|Board of Regents, The University System of Texas|Methods and systems for the detection of analytes|NL286850A†|1961-12-18|1900-01-01|||
    US3410839A|1964-04-16|1968-11-12|Rand Dev Corp|Immunochromatographic partition of soluble antigens|
    US3420205A|1966-03-23|1969-01-07|Miles Lab|Indicating device|
    US3437449A|1966-06-08|1969-04-08|Manley J Luckey|Breath alcohol determination|
    GB979193A|1966-10-19|1965-01-01|Konstantin Sergeevich Evstropi|Optical glasses|
    US3720760B1|1968-09-06|1984-02-07|Pharmacia Ab||
    US3811840A|1969-04-01|1974-05-21|Miles Lab|Test device for detecting low concentrations of substances in fluids|
    USRE29169E|1971-02-10|1977-04-05|Akzona Incorporated|Process for the demonstration and determination of reaction components having specific binding affinity for each other|
    US3666421A|1971-04-05|1972-05-30|Organon|Diagnostic test slide|
    US3723064A|1971-07-26|1973-03-27|L Liotta|Method and device for determining the concentration of a material in a liquid|
    US4191533A|1971-09-29|1980-03-04|Behringwerke Aktiengesellschaft|Pregnancy-specific β1 -glycoprotein and process for isolating it|
    US3954564A|1971-10-29|1976-05-04|Mennen Frederick C|Instrument for the detection of neisseria gonorrhoeae and the like|
    BE792465A|1971-12-09|1973-03-30|Atomic Energy Commission|PERFECTED ROTOR FOR ROTARY PHOTOMETRIC ANALYZER, ESPECIALLY SUITABLE IN WEIGHTNESS CONDITIONS|
    US3798004A|1972-04-18|1974-03-19|Ames Yissum Ltd|Test device|
    FI49086C|1973-01-25|1975-03-10|Matti Antero Reunanen|Radioimmunoassay.|
    US3850578A|1973-03-12|1974-11-26|H Mcconnell|Process for assaying for biologically active molecules|
    US4166102A|1975-04-07|1979-08-28|Becton, Dickinson And Company|Immobilized immunoadsorbent|
    US4180383A|1975-04-07|1979-12-25|Becton, Dickinson And Company|Chamber holder for immobilized immunoadsorbent|
    US4022876A|1973-06-21|1977-05-10|Stanford Research Institute|Mass spectrometric immunoassay|
    US4166105A|1973-07-30|1979-08-28|Block Engineering, Inc.|Dye tagged reagent|
    US4169138A|1974-05-29|1979-09-25|Pharmacia Diagnostics Ab|Method for the detection of antibodies|
    US3876504A|1974-06-10|1975-04-08|Early Warning Co|Procedure for determination of antigens and antibodies and articles for use therewith|
    US3915647A|1974-08-16|1975-10-28|Polaroid Corp|Device for determining the concentration of a substance in a fluid|
    US4018662A|1975-01-03|1977-04-19|Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V.|Method and apparatus for simultaneous quantitative analysis of several constituents in a sample|
    SE388694B|1975-01-27|1976-10-11|Kabi Ab|WAY TO PROVIDE AN ANTIGEN EXV IN SAMPLES OF BODY WHEATS, USING POROST BERAR MATERIAL BONDED OR ADSORBING ANTIBODIES|
    US3992631A|1975-02-27|1976-11-16|International Diagnostic Technology, Inc.|Fluorometric system, method and test article|
    US4380580A|1978-04-10|1983-04-19|Miles Laboratories, Inc.|Heterogenous chemiluminescent specific binding assay|
    US4042335A†|1975-07-23|1977-08-16|Eastman Kodak Company|Integral element for analysis of liquids|
    US4016043A|1975-09-04|1977-04-05|Akzona Incorporated|Enzymatic immunological method for the determination of antigens and antibodies|
    US4474878B1|1975-09-29|1990-04-17|Diamedix Corp||
    US4087326A|1976-05-03|1978-05-02|Ethicon, Inc.|Microbiological scaled sterility test strips and method|
    US4087332A|1976-05-07|1978-05-02|Kai Aage Hansen|Indicator for use in selection of bactericidal and bacteristatic drugs and method for producing same|
    US4123173A|1976-06-09|1978-10-31|Electro-Nucleonics, Inc.|Rotatable flexible cuvette arrays|
    IL52322A|1976-06-18|1980-10-26|Alfa Laval Ab|Method of making reagent test device and device made accorording to this method|
    US4094647A|1976-07-02|1978-06-13|Thyroid Diagnostics, Inc.|Test device|
    US4120945A|1976-07-06|1978-10-17|Becton, Dickinson & Company|Substrate coated with receptor and labeled ligand for assays|
    US4032536A|1976-07-22|1977-06-28|Janssen Pharmaceutica N.V.|carbamates|
    US4326008A|1976-08-27|1982-04-20|California Institute Of Technology|Protein specific fluorescent microspheres for labelling a protein|
    US4145186A|1976-10-04|1979-03-20|H. W. Andersen Products Inc.|Sterilization detection device and method|
    GB1572220A|1976-10-07|1980-07-30|Mochida Pharm Co Ltd|Immunochemical process of measuring physiologically active substances|
    US4116638A|1977-03-03|1978-09-26|Warner-Lambert Company|Immunoassay device|
    IT1097442B|1977-08-18|1985-08-31|Guigan Jean|CONDITIONING DEVICE OF A LIQUID SAMPLE IN PREPARATION OF ITS ANALYSIS|
    GB1603406A|1977-08-31|1981-11-25|Nat Res Dev|Assay of immune complexes|
    US4122030A|1977-09-19|1978-10-24|Xerox Corporation|Formation of colloidal dispersions of selenium by the locus control method|
    US4411518A|1977-09-23|1983-10-25|Gamma Biologicals, Inc.|Apparatus for use in qualitative determination of immunological reactions|
    FR2409514B1|1977-11-17|1981-11-06|Bretaudiere Jean Pierre||
    US4298345A|1977-11-21|1981-11-03|Damon Corporation|Method and apparatus for chemical spot test analysis|
    US4256725A|1978-02-21|1981-03-17|Becton, Dickinson And Company|Preparation of solid substrate containing receptor and labeled form of ligand for assays|
    US4256724A|1978-02-21|1981-03-17|Becton, Dickinson And Company|Method for non-covalent coating of antibodies on solid substrates|
    GB2016687B|1978-03-20|1982-09-08|Abbott Lab|Sugar coated reagents for solid phase immunoassay|
    NZ190452A|1978-05-19|1981-04-24|Becton Dickinson Co|Solid phase assay receptor contacted with analyte and then with labeled analyte|
    NL7807532A|1978-07-13|1980-01-15|Akzo Nv|METAL IMMUNO TEST.|
    US4230683A|1978-08-09|1980-10-28|Abbott Laboratories|Hapten conjugated antibody for antibody or antigen detection|
    US4302536A|1978-08-15|1981-11-24|Longenecker Robert W|Colorimetric immunoassay process|
    DE2836046A1|1978-08-17|1980-02-28|Behringwerke Ag|IMMUNOLOGICAL DETERMINATION PROCEDURE|
    US4244940A|1978-09-05|1981-01-13|Bio-Rad Laboratories, Inc.|Single-incubation two-site immunoassay|
    US4219335A|1978-09-18|1980-08-26|E. I. Du Pont De Nemours And Company|Immunochemical testing using tagged reagents|
    US4225558A|1978-09-19|1980-09-30|Honeywell Inc.|Fluid sample test apparatus and fluid sample cell for use therein|
    US4278651A|1978-09-27|1981-07-14|Becton Dickinson & Company|Supported receptor and use thereof in an assay|
    US4233029A|1978-10-25|1980-11-11|Eastman Kodak Company|Liquid transport device and method|
    US4237234A|1978-10-30|1980-12-02|Meunier Henry E|Device for use in the study of biochemical or enzymatic reactions produced by living organisms|
    US4246339A|1978-11-01|1981-01-20|Millipore Corporation|Test device|
    US4374925A|1978-11-24|1983-02-22|Syva Company|Macromolecular environment control in specific receptor assays|
    US4493793A|1978-12-26|1985-01-15|E-Y Laboratories|Soluble immunoassay reagent comprising lectin covalently bonded to reactive component|
    US4258001A|1978-12-27|1981-03-24|Eastman Kodak Company|Element, structure and method for the analysis or transport of liquids|
    IL56342A|1978-12-29|1982-05-31|Zer Tamar|Method and means for determining human chorionic gonadotropin in urine|
    US4235601A|1979-01-12|1980-11-25|Thyroid Diagnostics, Inc.|Test device and method for its use|
    US4274832A|1979-02-12|1981-06-23|Eastman Kodak Company|Analytical element and method for analysis of multiple analytes|
    US4267270A|1979-05-21|1981-05-12|Enzyme Technology, Inc.|Method for the determination of antigens and antibodies using site-deactivating media|
    US4301139A|1979-06-21|1981-11-17|Ames-Yissum Ltd.|Multilayer column chromatography specific binding assay method, test device and test kit|
    US4270921A|1979-09-24|1981-06-02|Graas Joseph E|Microchromatographic device and method for rapid determination of a desired substance|
    US4338094A|1979-10-25|1982-07-06|Nasik Elahi|Macroencapsulated immunosorbent assay technique|
    NL8000173A|1980-01-11|1981-08-03|Akzo Nv|USE OF WATER-DISPERSIBLE HYDROPHOBIC DYES AS LABELS IN IMMUNOCHEMICAL TESTS.|
    US4483921A|1981-01-12|1984-11-20|Collaborative Research, Inc.|Immunoassay with antigen or antibody labeled liposomes sequestering enzyme|
    US4323536A|1980-02-06|1982-04-06|Eastman Kodak Company|Multi-analyte test device|
    DE3050311C2|1980-03-18|1987-06-04|Ciba Geigy Ag|Process for the preparation of solid supports for proteins for analytical purposes|
    US4452901A|1980-03-20|1984-06-05|Ciba-Geigy Corporation|Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays|
    US4347312A|1980-03-20|1982-08-31|Research Triangle Institute|Detection of antibiotics in milk|
    DE3172879D1|1980-05-22|1985-12-19|Pasteur Institut|Coupled product between a lectin and a specific ligand, obtention and use in the biological field|
    EP0146654A3|1980-06-20|1986-08-20|Unilever Plc|Processes and apparatus for carrying out specific binding assays|
    JPS6223826B2|1980-07-09|1987-05-25|Fuji Photo Film Co Ltd||
    JPS5719660A|1980-07-09|1982-02-01|Fuji Photo Film Co Ltd|Microcapsule for immune reaction|
    US4486530A|1980-08-04|1984-12-04|Hybritech Incorporated|Immunometric assays using monoclonal antibodies|
    US4366241B1|1980-08-07|1988-10-18|||
    DE3043608A1|1980-11-19|1982-06-24|Behringwerke Ag, 3550 Marburg|ANALYTICAL AGENT|
    DE3044385A1|1980-11-25|1982-06-24|Boehringer Mannheim Gmbh, 6800 Mannheim|METHOD FOR CARRYING OUT ANALYTICAL PROVISIONS AND ROTOR INSERT ELEMENT SUITABLE FOR THIS|
    US4517288A|1981-01-23|1985-05-14|American Hospital Supply Corp.|Solid phase system for ligand assay|
    US4425438A|1981-03-13|1984-01-10|Bauman David S|Assay method and device|
    US4373812A|1981-03-25|1983-02-15|Instrumentation Laboratory Inc.|Cuvette assembly|
    US4442204A|1981-04-10|1984-04-10|Miles Laboratories, Inc.|Homogeneous specific binding assay device and preformed complex method|
    US4447526A|1981-04-20|1984-05-08|Miles Laboratories, Inc.|Homogeneous specific binding assay with carrier matrix incorporating specific binding partner|
    DE3269567D1|1981-04-29|1986-04-10|Ciba Geigy Ag|New devices and kits for immunological analysis|
    JPS57200862A|1981-06-05|1982-12-09|Fuji Photo Film Co Ltd|Mutilayer analysis element utilizing unique binding reaction|
    US4363874A|1981-08-07|1982-12-14|Miles Laboratories, Inc.|Multilayer analytical element having an impermeable radiation nondiffusing reflecting layer|
    JPH0449658B2|1981-09-07|1992-08-12|Fuji Photo Film Co Ltd||
    US4461829A|1981-09-14|1984-07-24|Miles Laboratories, Inc.|Homogeneous specific binding assay element and lyophilization production method|
    US4446232A|1981-10-13|1984-05-01|Liotta Lance A|Enzyme immunoassay with two-zoned device having bound antigens|
    US4713249A|1981-11-12|1987-12-15|Schroeder Ulf|Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof|
    US4938927A|1982-01-08|1990-07-03|Environmental Diagnostics, Inc.|Rotary fluid manipulator|
    US5141875A|1982-01-08|1992-08-25|Environmental Diagnostics, Inc.|Rotary fluid manipulator|
    US4444193A|1982-01-11|1984-04-24|Medtronic, Inc.|Fluid absorbent quantitative test device|
    US5073484A|1982-03-09|1991-12-17|Bio-Metric Systems, Inc.|Quantitative analysis apparatus and method|
    US4454226A|1982-03-17|1984-06-12|Majid Ali|Enzymatic immunoassay|
    US4483929A|1982-05-03|1984-11-20|Liposome Technology Incorporated|Liposomes with glycolipid-linked antibodies|
    US4469787A|1982-05-14|1984-09-04|Mallinckrodt Inc.|Immunoassay involving soluble complex of second antibody and labeled binding protein|
    US4427779A|1982-05-26|1984-01-24|Ortho Diagnostic Systems Inc.|Agglutination-inhibition test method for detecting immune complexes|
    US4435504A|1982-07-15|1984-03-06|Syva Company|Immunochromatographic assay with support having bound "MIP" and second enzyme|
    US4503143A|1982-08-20|1985-03-05|Btc Diagnostics Limited Partnership|Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen|
    US4668638A|1983-03-24|1987-05-26|The Liposome Company, Inc.|Liposome composition for lupus assay|
    US4457916A|1982-08-31|1984-07-03|Asahi Kasei Kogyo Kabushiki Kaisha|Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same|
    US4659678A|1982-09-29|1987-04-21|Serono Diagnostics Limited|Immunoassay of antigens|
    JPS59102388A|1982-12-03|1984-06-13|Fuji Photo Film Co Ltd|Biological reaction layer and its preparation|
    US4849337A|1983-01-31|1989-07-18|Minnesota Mining And Manufacturing Company|Assaying allergen specific IgE levels with fluorogenic enzyme labeled antibody|
    US5089394A|1983-03-07|1992-02-18|E-Y Laboratories, Inc.|Neisseria detection system|
    US4608246A|1983-03-10|1986-08-26|Immucor, Inc.|Testing for a blood group immunological reaction|
    US4666866A|1983-04-19|1987-05-19|Krauth Gary H|Immunoassay for antigens employing supported binder|
    US4851356A|1983-05-06|1989-07-25|The Trustees Of Columbia University In The City Of New York|Immunoassay for human chorionic gonadotropin|
    AU2706384A|1983-05-06|1984-11-08|Monoclonal Antibodies Inc.|Colorimetric immunoassay on solid surface|
    US4518565A|1983-06-06|1985-05-21|Miles Laboratories, Inc.|Reagent test device holder|
    US4757002A|1983-06-13|1988-07-12|Regents Of The University Of Minnesota|Method and kit for the estimation of serum immunoglobulin|
    US4554256A|1983-07-21|1985-11-19|The Idaho Research Foundation, Inc.|Antigen associated with early detection of mammalian pregnancy|
    JPS6031058A|1983-07-29|1985-02-16|Fuji Seiyaku Kogyo Kk|Pregnancy diagnostic reagent|
    US4552839A†|1983-08-01|1985-11-12|Syntex Inc.|Determination of analytes in particle-containing medium|
    JPH0541946B2|1983-08-05|1993-06-25|Wako Pure Chem Ind Ltd||
    US4594327A|1983-11-02|1986-06-10|Syntex Inc.|Assay method for whole blood samples|
    GB8331514D0|1983-11-25|1984-01-04|Janssen Pharmaceutica Nv|Visualization method|
    JPH0479418B2|1983-12-19|1992-12-15|Daiichi Kagaku Yakuhin Kk||
    DE3484505D1|1983-12-19|1991-05-29|Daiichi Pure Chemicals Co Ltd|IMMUNTEST.|
    US4555546A†|1983-12-29|1985-11-26|Monsanto Company|Compatibilized blends of acrylic ester|
    US4595656A|1984-01-06|1986-06-17|Becton Dickinson & Company|Coupling agents and products produced therefrom|
    US4670406A|1984-01-06|1987-06-02|Becton Dickinson And Company|Tracers for use in assays|
    US4703017C1|1984-02-14|2001-12-04|Becton Dickinson Co|Solid phase assay with visual readout|
    US4695554A|1984-02-14|1987-09-22|Becton Dickinson And Company|Sac or liposome containing dye for immunoassay|
    GB8406752D0|1984-03-15|1984-04-18|Unilever Plc|Chemical and clinical tests|
    US4743560A|1984-03-26|1988-05-10|Becton Dickinson And Company|Solid phase assay|
    US4568102A|1984-03-29|1986-02-04|Dauvergne Hector A|Motor vehicle dashboard and seat arrangement|
    GB8418828D0|1984-07-24|1984-08-30|Lab Ltd Ab Ag|Calf screening|
    EP0170746A1|1984-08-07|1986-02-12|Covalent Technology Corporation|Biologically active material test|
    US4656129A|1984-08-16|1987-04-07|Becton Dickinson And Company|Assay for a ligand by use of supported binder and sac lysing agent|
    US4999285A|1984-11-15|1991-03-12|Syntex Inc.|Chromatographic cassette|
    DE3445816C1|1984-12-15|1986-06-12|Behringwerke Ag, 3550 Marburg|Flat diagnostic agent|
    AU592971B2|1984-12-20|1990-02-01|Axis-Shield Poc As|Solid phase diffusion assay|
    DE3585780D1|1984-12-24|1992-05-07|Abbott Lab|ANALYTICAL DEVICE AND METHOD FOR USE THEREOF.|
    CA1262364A|1984-12-28|1989-10-17|Nancy M. Page|Method and catalyst for converting propane topropylene|
    IT1200382B|1985-02-08|1989-01-18|Boehringer Biochemia Srl|DETECTION AND / OR DOSAGE SYSTEM OF CLINICAL PARAMETERS BY IMMUNO ENZYMATIC ROUTE|
    US4740468A|1985-02-14|1988-04-26|Syntex Inc.|Concentrating immunochemical test device and method|
    DE3507848A1|1985-03-06|1986-11-13|Boehringer Mannheim Gmbh, 6800 Mannheim|METHOD AND REAGENT FOR DETERMINING THE LUTEINIZING HORMONE AND MONOCLONAL ANTIBODIES SUITABLE FOR THIS|
    US5026653A|1985-04-02|1991-06-25|Leeco Diagnostic, Inc.|Scavenger antibody mixture and its use for immunometric assay|
    US4678757A|1985-04-11|1987-07-07|Smithkline Diagnostics, Inc.|Device and method for whole blood separation and analysis|
    CA1262432A|1985-04-22|1989-10-24|M. Sultan Siddiqi|Sealed reagent matrix|
    US4803170A|1985-05-09|1989-02-07|Ultra Diagnostics Corporation|Competitive immunoassay method, device and test kit|
    US4693970A|1985-06-21|1987-09-15|Becton, Dickinson And Company|Immunoassay using complement|
    AT68524T|1985-07-09|1991-11-15|Quadrant Bioresources Ltd|PROTECTION OF PROTEINS AND SIMILAR.|
    IL78205D0|1985-07-22|1986-07-31|Miles Lab|Multizone test device for the specific binding assay determinations|
    US4806312A|1985-08-28|1989-02-21|Miles Inc.|Multizone analytical element having detectable signal concentrating zone|
    US4806311A|1985-08-28|1989-02-21|Miles Inc.|Multizone analytical element having labeled reagent concentration zone|
    US4900663A|1985-09-13|1990-02-13|Environmental Diagnostics, Inc.|Test kit for determining the presence of organic materials and method of utilizing same|
    US4868106A|1985-10-17|1989-09-19|Konishiroku Photo Industry Co., Ltd.|Analytical element and method for determining a component in a test sample|
    US4725406A|1985-10-21|1988-02-16|American Bionetics, Inc.|Apparatus and method for diagnostic analysis of biological fluids|
    GB8526741D0|1985-10-30|1985-12-04|Boots Celltech Diagnostics|Binding assay device|
    US4608248A|1985-11-08|1986-08-26|Warner-Lambert Company|Process for time-controlled release of active ingredients|
    US4868108A|1985-12-12|1989-09-19|Hygeia Sciences, Incorporated|Multiple-antibody detection of antigen|
    CA1291031C|1985-12-23|1991-10-22|Nikolaas C.J. De Jaeger|Method for the detection of specific binding agents and their correspondingbindable substances|
    US4916056A|1986-02-18|1990-04-10|Abbott Laboratories|Solid-phase analytical device and method for using same|
    US4874710A|1986-02-20|1989-10-17|Becton Dickinson And Company|Assay and product in which binder and liposomes are supported on a solid support|
    US4906439A|1986-03-25|1990-03-06|Pb Diagnostic Systems, Inc.|Biological diagnostic device and method of use|
    US4762857A|1986-05-30|1988-08-09|E. I. Du Pont De Nemours And Company|Trehalose as stabilizer and tableting excipient|
    US4837145A|1986-06-09|1989-06-06|Liotta Lance A|Layered immunoassay using antibodies bound to transport particles to determine the presence of an antigen|
    AU602694B2|1986-06-09|1990-10-25|Ortho Diagnostic Systems Inc.|Improved colloidal gold membrane assay|
    AU7385687A|1986-06-09|1987-12-10|Ortho Diagnostic Systems Inc.|Immunoglobulin immunoassay with internalized control assays|
    CA1282693C|1986-07-10|1991-04-09|Richard L. Columbus|Analytical element having water-soluble polymers and determinations using same|
    GB8618443D0|1986-07-29|1986-09-03|Univ London|Monoclonal antibodies|
    US4963468A|1986-09-05|1990-10-16|Syntex Inc.|Immunoseparating strip|
    US4959307A|1986-09-05|1990-09-25|Syntex Inc.|Immunoseparating strip|
    US4707450A|1986-09-25|1987-11-17|Nason Frederic L|Specimen collection and test unit|
    US4960691A|1986-09-29|1990-10-02|Abbott Laboratories|Chromatographic test strip for determining ligands or receptors|
    US5030558A|1986-11-07|1991-07-09|Syntex Inc.|Qualitative immunochromatographic method and device|
    US4775515A|1986-11-18|1988-10-04|Cottingham Hugh V|Agglutinographic slide|
    US5079142A|1987-01-23|1992-01-07|Synbiotics Corporation|Orthogonal flow immunoassays and devices|
    US4774192A|1987-01-28|1988-09-27|Technimed Corporation|A dry reagent delivery system with membrane having porosity gradient|
    AU592174B2|1987-02-17|1990-01-04|Genesis Labs, Inc.|Immunoassay test strip|
    US4920046A|1987-02-20|1990-04-24|Becton, Dickinson And Company|Process, test device, and test kit for a rapid assay having a visible readout|
    US4918025A|1987-03-03|1990-04-17|Pb Diagnostic Systems, Inc.|Self contained immunoassay element|
    CA1303983C|1987-03-27|1992-06-23|Robert W. Rosenstein|Solid phase assay|
    US4857453A|1987-04-07|1989-08-15|Syntex Inc.|Immunoassay device|
    US4956275A|1987-04-14|1990-09-11|Molecular Devices Corporation|Migratory detection immunoassay|
    DE3856542T2|1987-04-27|2003-10-30|Inverness Medical Switzerland|Test device for carrying out specific binding tests|
    US5622871A|1987-04-27|1997-04-22|Unilever Patent Holdings B.V.|Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents|
    US4855240A|1987-05-13|1989-08-08|Becton Dickinson And Company|Solid phase assay employing capillary flow|
    US4904583A|1987-05-26|1990-02-27|Becton, Dickinson And Company|Cascade immunoassay by multiple binding reactions|
    US4810470A|1987-06-19|1989-03-07|Miles Inc.|Volume independent diagnostic device|
    US4954452A|1987-07-09|1990-09-04|Abbott Laboratories|Non-metal colloidal particle immunoassay|
    US5120643A|1987-07-13|1992-06-09|Abbott Laboratories|Process for immunochromatography with colloidal particles|
    US4981786A|1987-09-04|1991-01-01|Syntex Inc.|Multiple port assay device|
    US4956302A|1987-09-11|1990-09-11|Abbott Laboratories|Lateral flow chromatographic binding assay device|
    US4859612A|1987-10-07|1989-08-22|Hygeia Sciences, Inc.|Metal sol capture immunoassay procedure, kit for use therewith and captured metal containing composite|
    US5073340A|1987-10-08|1991-12-17|Becton, Dickinson And Company|Depositing a binder on a solid support|
    EP0323605B1|1987-12-21|1994-01-26|Abbott Laboratories|Chromatographic binding assay devices and methods|
    US6352862B1|1989-02-17|2002-03-05|Unilever Patent Holdings B.V.|Analytical test device for imuno assays and methods of using same|
    US5252496A|1989-12-18|1993-10-12|Princeton Biomeditech Corporation|Carbon black immunochemical label|
    US5141850A|1990-02-07|1992-08-25|Hygeia Sciences, Inc.|Porous strip form assay device method|US6472160B2|1919-09-08|2002-10-29|Fujirebio Inc.|Immunoassay device and immunoassay method using the same|
    DE3445816C1|1984-12-15|1986-06-12|Behringwerke Ag, 3550 Marburg|Flat diagnostic agent|
    US5763262A|1986-09-18|1998-06-09|Quidel Corporation|Immunodiagnostic device|
    CA1303983C|1987-03-27|1992-06-23|Robert W. Rosenstein|Solid phase assay|
    USRE38430E1|1987-03-27|2004-02-17|Becton, Dickinson And Company|Solid phase chromatographic immunoassay|
    DE3856542T2|1987-04-27|2003-10-30|Inverness Medical Switzerland|Test device for carrying out specific binding tests|
    US5120643A|1987-07-13|1992-06-09|Abbott Laboratories|Process for immunochromatography with colloidal particles|
    US4956302A|1987-09-11|1990-09-11|Abbott Laboratories|Lateral flow chromatographic binding assay device|
    EP0323605B1|1987-12-21|1994-01-26|Abbott Laboratories|Chromatographic binding assay devices and methods|
    AU2684488A|1988-06-27|1990-01-04|Carter-Wallace, Inc.|Test device and method for colored particle immunoassay|
    JPH0238972A|1988-07-29|1990-02-08|Nitto Denko Corp|Instrument and method for immunoassay|
    IT1227293B|1988-10-06|1991-04-05|Boehringer Biochemia Srl|DEVICE AND METHOD FOR PREGNANCY DIAGNOSIS|
    GB8903627D0|1989-02-17|1989-04-05|Unilever Plc|Assays|
    US6352862B1|1989-02-17|2002-03-05|Unilever Patent Holdings B.V.|Analytical test device for imuno assays and methods of using same|
    GB8909478D0|1989-04-26|1989-06-14|Bradwell Arthur R|Radial immunodiffusion and like techniques|
    US5411858A|1989-05-17|1995-05-02|Actimed Laboratories, Inc.|Manufacturing process for sample initiated assay device|
    GB8915654D0|1989-07-07|1989-08-23|Unilever Plc|Detectable particles|
    US5075078A|1989-10-05|1991-12-24|Abbott Laboratories|Self-performing immunochromatographic device|
    DE3941150A1|1989-12-13|1991-06-20|Boehringer Mannheim Gmbh|METHOD FOR DETERMINING AN ANALYTE|
    US5252496A|1989-12-18|1993-10-12|Princeton Biomeditech Corporation|Carbon black immunochemical label|
    US5141850A|1990-02-07|1992-08-25|Hygeia Sciences, Inc.|Porous strip form assay device method|
    US5096837A|1990-02-08|1992-03-17|Pacific Biotech, Inc.|Immunochromatographic assay and method of using same|
    AU650874B2|1990-03-27|1994-07-07|Pacific Biotech, Inc.|Solid phase immunoassay device and method of making same|
    US5223220A|1990-03-27|1993-06-29|Pacific Biotech, Inc.|Solid phase immunoassay device and method of making same|
    CA2035595A1|1990-04-12|1991-10-13|Carol A. Miller|Immunoassay test device with thread control element|
    GB9014903D0|1990-07-05|1990-08-22|Unilever Plc|Assays|
    AT153138T|1990-09-26|1997-05-15|Akers Lab Inc|IMPROVED LIGAND DETERMINATION PROCEDURE|
    IE75720B1|1990-10-08|1997-09-24|Akzo Nv|Device for performing a rapid single manual assay|
    US5334538A|1990-11-26|1994-08-02|V-Tech, Inc.|Gold sol immunoassay system and device|
    US5380492A|1990-12-18|1995-01-10|Seymour; Eugene H.|Sampling device and sample adequacy system|
    WO1992012428A1|1991-01-11|1992-07-23|Quidel Corporation|A one-step lateral flow nonbibulous assay|
    US6168956B1|1991-05-29|2001-01-02|Beckman Coulter, Inc.|Multiple component chromatographic assay device|
    US5998220A|1991-05-29|1999-12-07|Beckman Coulter, Inc.|Opposable-element assay devices, kits, and methods employing them|
    US5869345A|1991-05-29|1999-02-09|Smithkline Diagnostics, Inc.|Opposable-element assay device employing conductive barrier|
    US5877028A|1991-05-29|1999-03-02|Smithkline Diagnostics, Inc.|Immunochromatographic assay device|
    US5607863A|1991-05-29|1997-03-04|Smithkline Diagnostics, Inc.|Barrier-controlled assay device|
    US5468648A|1991-05-29|1995-11-21|Smithkline Diagnostics, Inc.|Interrupted-flow assay device|
    US5686315A|1991-06-14|1997-11-11|Quidel Corporation|Assay device for one step detection of analyte|
    CA2074752A1|1991-07-29|1993-01-30|Tadakazu Yamauchi|Process and device for specific binding assay|
    US6007999A|1991-07-31|1999-12-28|Idexx Laboratories, Inc.|Reversible flow chromatographic binding assay|
    US5726010A|1991-07-31|1998-03-10|Idexx Laboratories, Inc.|Reversible flow chromatographic binding assay|
    GB2262986A|1992-01-03|1993-07-07|Pall Corp|Particle agglutination assay|
    AU3439693A|1992-01-22|1993-09-01|Abbott Laboratories|Calibration reagents for semi-quantitative binding assays and devices|
    DE4202850A1|1992-01-31|1993-08-05|Boehringer Mannheim Gmbh|ANALYSIS ELEMENT FOR IMMUNOASSAYS|
    EP0630475B1|1992-03-10|2000-09-06|Quidel Corporation|Red blood cell separation means for specific binding assays|
    US5637469A|1992-05-01|1997-06-10|Trustees Of The University Of Pennsylvania|Methods and apparatus for the detection of an analyte utilizing mesoscale flow systems|
    US5726026A|1992-05-01|1998-03-10|Trustees Of The University Of Pennsylvania|Mesoscale sample preparation device and systems for determination and processing of analytes|
    WO1994001775A1|1992-07-02|1994-01-20|Quidel Corporation|Immunoassay using dye complexed enzyme conjugates|
    GB9217865D0|1992-08-21|1992-10-07|Unilever Plc|Monitoring method|
    GB9217866D0|1992-08-21|1992-10-07|Unilever Plc|Monitoring method|
    GB9217864D0|1992-08-21|1992-10-07|Unilever Plc|Monitoring method|
    GB9217808D0|1992-08-21|1992-10-07|Unilever Plc|Advisory method|
    US5820826A|1992-09-03|1998-10-13|Boehringer Mannheim Company|Casing means for analytical test apparatus|
    DE4229591C1|1992-09-04|1994-03-24|Draegerwerk Ag|Immunoassay using test strip with immobilised antibody - based on displacement of tracer from antibody by analyte, esp. for determn. of pollutants|
    AU659754B2|1992-09-04|1995-05-25|Becton Dickinson & Company|Chromatographic antigen sandwich test for detection of specific antibody and device therefor|
    US5807752A|1992-09-11|1998-09-15|Boehringer Mannheim Corporation|Assay using an unblocked solid phase with immobilized analyte binding partner|
    US5736410A|1992-09-14|1998-04-07|Sri International|Up-converting reporters for biological and other assays using laser excitation techniques|
    US6399397B1|1992-09-14|2002-06-04|Sri International|Up-converting reporters for biological and other assays using laser excitation techniques|
    US5384264A|1992-11-05|1995-01-24|Syntron Bioresearch, Inc.|Method and apparatus for single step assays of ligand-containing fluids|
    FI92882C|1992-12-29|1995-01-10|Medix Biochemica Ab Oy|Disposable test strip and process for its manufacture|
    WO1994018891A1|1993-02-23|1994-09-01|Trinity Research Limited|Apparatus for the collection and recovery of saliva for use in diagnostic assays|
    US5424193A|1993-02-25|1995-06-13|Quidel Corporation|Assays employing dyed microorganism labels|
    WO1994022011A1|1993-03-17|1994-09-29|Akzo Nobel N.V.|Apparatus for the detection of a specifically reacting substance|
    WO1994023299A1|1993-03-31|1994-10-13|Quidel Corporation|Multiple assay device|
    US5500375A|1993-04-13|1996-03-19|Serex, Inc.|Integrated packaging-holder device for immunochromatographic assays in flow-through or dipstick formats|
    JP3479100B2|1993-06-02|2003-12-15|帝国臓器製薬株式会社|Simple semi-quantitative immunochemical method and apparatus|
    WO1994029696A1|1993-06-09|1994-12-22|Quidel Corporation|Antigen-specific one-step assays|
    JP2907553B2|1993-07-02|1999-06-21|ユニパス・リミテツド|Methods, devices and test kits for monitoring ovulation|
    GB9314584D0|1993-07-14|1993-08-25|Cortecs Ltd|Test device|
    US5415994A|1993-08-02|1995-05-16|Quidel Corporation|Lateral flow medical diagnostic assay device with sample extraction means|
    US5756362A|1993-10-12|1998-05-26|Cornell Research Foundation, Inc.|Liposome-enhanced immunoaggregation assay and test device|
    US5789154A|1993-10-12|1998-08-04|Cornell Research Foundation, Inc.|Liposome-enhanced immunoassay and test device|
    US7141212B2|1993-11-12|2006-11-28|Inverness Medical Switzerland Gmbh|Reading devices and assay devices for use therewith|
    AT191087T|1993-11-12|2000-04-15|Unilever Plc|ANALYSIS DEVICE AND THEIR APPLICATION|
    SG72684A1|1993-11-12|2000-05-23|Unipath Ltd|Reading devices and assay devices for use therewith|
    US6451619B1|1994-06-29|2002-09-17|Inverness Medical Switzerland Gmbh|Monitoring methods and devices for use therein|
    EP0728309B1|1993-11-12|1997-08-20|Unipath Limited|Assay devices and the manufacture thereof|
    FR2714475A1|1993-12-23|1995-06-30|Toledano Jacques|Immunological test device for detection of e.g. cholesterol|
    US5547833A|1994-01-04|1996-08-20|Intracel Corporation|Radial flow assay, delivering member, test kit, and methods|
    US5563040A|1994-03-21|1996-10-08|The United States Of America As Represented By The Secretary Of Agriculture|Method and apparatus for immunological diagnosis of fungal decay in wood|
    US6037127A|1994-03-31|2000-03-14|E. I. Du Pont De Nemours And Company|Method for detection of non-denatured nucleic acid fragments|
    US5597700A|1994-04-28|1997-01-28|California Research, Llc|Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method|
    US5658747A|1994-05-10|1997-08-19|Biocontrol System, Inc.|Compositions and methods for control of reactivity between diagnostic reagents and microorganisms|
    WO1995032414A1|1994-05-20|1995-11-30|Chemtrak, Inc.|Qualitative surface immunoassay using consecutive reagent application|
    FR2721112B1|1994-06-13|1996-08-14|Gks Technologies|Device for rapid diagnosis of any glycated molecule and method of implementation.|
    US6653066B1|1994-06-17|2003-11-25|Trinity Biotech|Device and method for detecting polyvalent substances|
    AU756931B2|1994-09-23|2003-01-30|Inverness Medical Switzerland Gmbh|Assay devices with non-woven sample collection zone|
    DK0703454T3|1994-09-23|2002-04-02|Unilever Nv|Methods of monitoring and devices for use therewith|
    GB9419267D0|1994-09-23|1994-11-09|Unilever Plc|Assay devices|
    JP3010699U|1994-10-29|1995-05-02|株式会社ニッポンジーン|Chromatographic inspection device capable of direct urine collection|
    EP0724909A1|1994-11-28|1996-08-07|Akzo Nobel N.V.|Sample collection device|
    DE4443386C2|1994-12-06|1996-09-19|Seratec Ges Fuer Biotechnologi|Device for carrying out a pregnancy test|
    US5707818A|1994-12-13|1998-01-13|Bsi Corporation|Device and method for simultaneously performing multiple competitive immunoassays|
    US5569608A|1995-01-30|1996-10-29|Bayer Corporation|Quantitative detection of analytes on immunochromatographic strips|
    CA2167362A1|1995-02-10|1996-08-11|Alexei Dmitri Klimov|Apparatus and method for conducting a binding assay on an absorbent carrier material|
    AU4996796A|1995-02-28|1996-09-18|Joel R.L. Ehrenkranz|Rapid, self-performing tsh immunoassay|
    GB9505425D0|1995-03-17|1995-05-03|Unilever Plc|Assay devices|
    AU2147295A|1995-04-03|1996-10-23|Syncor Intellectual Properties Limited|Rapid assays for the detection of glutathione s-transferases|
    US6194079B1|1995-04-19|2001-02-27|Capitol Specialty Plastics, Inc.|Monolithic polymer composition having an absorbing material|
    US6460271B2|1995-04-19|2002-10-08|Csp Technologies, Inc.|Insert having interconnecting channel morphology for aldehyde absorption|
    US6177183B1|1995-04-19|2001-01-23|Capitol Specialty Plastics, Inc.|Monolithic composition having an activation material|
    US6316520B1|1995-04-19|2001-11-13|Capitol Specialty Plastics, Inc.|Monolithic polymer composition having a releasing material|
    US6221446B1|1995-04-19|2001-04-24|Capitol Specialty Plastics, Inc|Modified polymers having controlled transmission rates|
    US6174952B1|1995-04-19|2001-01-16|Capitol Specialty Plastics, Inc.|Monolithic polymer composition having a water absorption material|
    US6214255B1|1995-04-19|2001-04-10|Capitol Specialty Plastics, Inc.|Desiccant entrained polymer|
    US6465532B1|1997-03-05|2002-10-15|Csp Tecnologies, Inc.|Co-continuous interconnecting channel morphology polymer having controlled gas transmission rate through the polymer|
    US6124006A|1995-04-19|2000-09-26|Capitol Specialty Plastics, Inc.|Modified polymers having controlled transmission rates|
    USRE40941E1|1995-04-19|2009-10-20|Csp Technologies, Inc.|Monolithic polymer composition having a releasing material|
    US6080350A|1995-04-19|2000-06-27|Capitol Specialty Plastics, Inc.|Dessicant entrained polymer|
    US6319676B1|1995-05-02|2001-11-20|Carter Wallace, Inc.|Diagnostic detection device and method|
    EP0823877B1|1995-05-02|2001-11-07|Carter Wallace, Inc.|Process of preparing a laminated substrate|
    US5739041A|1995-05-02|1998-04-14|Carter Wallace, Inc.|Diagnostic detection device|
    DE19516179C1|1995-05-03|1996-11-21|Karl Prof Dr Cammann|Chemical-analytical sampling device with integrated dosimeter and function display|
    US5712172A|1995-05-18|1998-01-27|Wyntek Diagnostics, Inc.|One step immunochromatographic device and method of use|
    US5656502A|1995-06-07|1997-08-12|Diagnostic Chemicals Limited|Test strip holder and method of use|
    AU6720096A|1995-08-09|1997-03-05|Quidel Corporation|Test strip and method for one step lateral flow assay|
    US7635597B2|1995-08-09|2009-12-22|Bayer Healthcare Llc|Dry reagent particle assay and device having multiple test zones and method therefor|
    AUPN527995A0|1995-09-07|1995-09-28|Agen Biomedical Limited|Method and apparatus for semiquantification of an analyte|
    EP0763738A1|1995-09-14|1997-03-19|Unipath Limited|Assays for Chlamydia in diluted urine samples|
    US5628890A|1995-09-27|1997-05-13|Medisense, Inc.|Electrochemical sensor|
    DE19540541A1|1995-10-31|1997-05-07|Human Ges Fuer Biochemica Und|Test device and test procedure|
    JP3300583B2|1995-11-10|2002-07-08|幹男 中山|Antigen or antibody detection sheet, detection kit and detection method|
    JPH09145713A|1995-11-21|1997-06-06|Asahi Optical Co Ltd|Method for evaluating antigen or antibody inspection material|
    US5833924A|1995-12-22|1998-11-10|Universal Healthwatch, Inc.|Sampling-assay device and interface system|
    US5833923A|1995-12-22|1998-11-10|Universal Healthwatch, Inc.|Sampling-assay interface system|
    US5851777A|1996-02-05|1998-12-22|Dade Behring Inc.|Homogeneous sol-sol assay|
    AU2191297A|1996-03-01|1997-09-16|Majesco Biologicals, Inc.|Blood testing kit|
    US20020031845A1|1996-03-11|2002-03-14|American Bio Medica Corporation|Device for the collection, testing and shipment of body fluid samples|
    DE19609838A1|1996-03-13|1997-09-18|Boehringer Mannheim Gmbh|Methods and test strips for the determination of an analyte|
    US5753517A|1996-03-29|1998-05-19|University Of British Columbia|Quantitative immunochromatographic assays|
    CA2250684A1|1996-03-29|1997-10-09|Donald Elliott Brooks|Platelet count assay using platelet granule proteins|
    US5900379A|1996-04-11|1999-05-04|Mizuho Usa, Inc.|Analytical device|
    JP3026549B2|1996-05-02|2000-03-27|ダイナボット株式会社|Manufacturing method of chromatography immunoanalyzer|
    US6054277A|1996-05-08|2000-04-25|Regents Of The University Of Minnesota|Integrated microchip genetic testing system|
    US5968839A|1996-05-13|1999-10-19|Metrika, Inc.|Method and device producing a predetermined distribution of detectable change in assays|
    JP2000503773A|1996-05-23|2000-03-28|ユニリーバー・ナームローゼ・ベンノートシヤープ|Improved specific binding assays|
    US5876944A|1996-06-10|1999-03-02|Bayer Corporation|Method for amplification of the response signal in a sandwich immunoassay|
    US5945345A|1996-08-27|1999-08-31|Metrika, Inc.|Device for preventing assay interference using silver or lead to remove the interferant|
    US6001658A|1996-09-13|1999-12-14|Diagnostic Chemicals Limited|Test strip apparatus and method for determining presence of analyte in a fluid sample|
    US5958791A|1996-09-27|1999-09-28|Innovative Biotechnologies, Inc.|Interdigitated electrode arrays for liposome-enhanced immunoassay and test device|
    AT231971T|1996-09-27|2003-02-15|Inverness Medical Switzerland|TEST KIT AND DEVICES|
    EP0832713A1|1996-09-27|1998-04-01|Unilever Plc|Improvements in or relating to assembly of components|
    US6358752B1|1996-09-27|2002-03-19|Cornell Research Foundation, Inc.|Liposome-enhanced test device and method|
    EP0833158B1|1996-09-27|2001-11-28|Unilever Plc|Manufacture of test strips|
    ES2187622T3|1996-09-27|2003-06-16|Inverness Medical Switzerland|REAGENTS AND TEST DEVICES.|
    US5935864A|1996-10-07|1999-08-10|Saliva Diagnostic Systems Inc.|Method and kit for collecting samples of liquid specimens for analytical testing|
    US6165798A|1996-10-10|2000-12-26|University Of British Columbia|Optical quantification of analytes in membranes|
    EP0937257B1|1996-10-25|2004-12-29|Idexx Laboratories, Inc.|Immunoassay device employing housing which can be separated in two parts|
    AU8461998A|1997-10-21|1999-05-10|Sekisui Chemical Co., Ltd.|Colored latex|
    US6194221B1|1996-11-19|2001-02-27|Wyntek Diagnostics, Inc.|Hybrid one-step immunochromatographic device and method of use|
    US5879951A|1997-01-29|1999-03-09|Smithkline Diagnostics, Inc.|Opposable-element assay device employing unidirectional flow|
    US20050101032A1|1997-02-10|2005-05-12|Metrika, Inc.|Assay device, composition, and method of optimizing assay sensitivity|
    GB2322192B|1997-02-14|2001-01-31|Unilever Plc|Assay devices|
    US5969102A|1997-03-03|1999-10-19|St. Jude Children's Research Hospital|Lymphocyte surface receptor that binds CAML, nucleic acids encoding the same and methods of use thereof|
    US6924153B1|1997-03-06|2005-08-02|Quidel Corporation|Quantitative lateral flow assays and devices|
    WO1998044158A1|1997-03-28|1998-10-08|Epitope, Inc.|Simultaneous collection of dna and non-nucleic analytes from oral fluids|
    WO1998048280A1|1997-04-24|1998-10-29|Selfcare, Inc.|Device for detection of a substance in a liquid sample|
    US6103536A|1997-05-02|2000-08-15|Silver Lake Research Corporation|Internally referenced competitive assays|
    US5939252A|1997-05-09|1999-08-17|Lennon; Donald J.|Detachable-element assay device|
    ES2284210T3|1997-07-16|2007-11-01|Charm Sciences Inc.|A TEST DEVICE AND A METHOD FOR DETECTING THE PRESENCE OF A RESIDUAL ANALYTE IN A SAMPLE.|
    US6979576B1|1997-07-25|2005-12-27|Shu-Ching Cheng|Methods of use of one step immunochromatographic device for Streptococcus A antigen|
    JP3655990B2|1997-07-28|2005-06-02|アボットジャパン株式会社|Immune analyzer|
    US6426230B1|1997-08-01|2002-07-30|Qualigen, Inc.|Disposable diagnostic device and method|
    KR100292182B1|1997-09-18|2001-11-26|모리시타 요이찌|Immunochromatography Devices|
    US6368601B1|1997-10-03|2002-04-09|Merial|Porcine circovirus vaccine and diagnostics reagents|
    US6046057A|1997-10-24|2000-04-04|Carter-Wallace, Inc.|Analyte assaying device|
    US7232576B2|1997-10-31|2007-06-19|New Horizons Diagnostics Corp|Throat lozenge for the treatment of Streptococcus Group A|
    US6406692B1|1997-10-31|2002-06-18|New Horizons Diagnostics Corp|Composition for treatment of an ocular bacterial infection|
    US20020136712A1|1997-10-31|2002-09-26|Fischetti Vincent|Bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of colonization and infections caused by streptococcus pneumoniae|
    US20030129146A1|1997-10-31|2003-07-10|Vincent Fischetti|The use of bacterial phage associated lysing proteins for treating bacterial dental caries|
    US7063837B2|1999-09-14|2006-06-20|New Horizons Diagnostics Corp|Syrup composition containing phage associated lytic enzymes|
    US20030082110A1|1997-10-31|2003-05-01|Vincent Fischetti|Use of bacterial phage associated lysing proteins for treating bacterial dental caries|
    US6428784B1|1997-10-31|2002-08-06|New Horizons Diagnostics Corp|Vaginal suppository for treating group B Streptococcus infection|
    US20020127215A1|1999-09-14|2002-09-12|Lawrence Loomis|Parenteral use of bacterial phage associated lysing enzymes for the therapeutic treatment of bacterial infections|
    US20030129147A1|1997-10-31|2003-07-10|Vincent Fischetti|Use of bacterial phage associated lysing proteins for treating bacterial dental caries|
    US6432444B1|1997-10-31|2002-08-13|New Horizons Diagnostics Corp|Use of bacterial phage associated lysing enzymes for treating dermatological infections|
    US6423299B1|1997-10-31|2002-07-23|Vincent Fischetti|Composition for treatment of a bacterial infection of an upper respiratory tract|
    US6277399B1|1997-10-31|2001-08-21|New Horizon Diagnostics Corporation|Composition incorporating bacterial phage associated lysing enzymes for treating dermatological infections|
    US6056954A|1997-10-31|2000-05-02|New Horizons Diagnostics Corp|Use of bacterial phage associated lysing enzymers for the prophylactic and therapeutic treatment of various illnesses|
    DE19750869A1|1997-11-17|1999-06-02|Ultimate Products Gmbh|Immunoassay device for the detection of nicotine or cotinine|
    US7297554B2|1998-11-18|2007-11-20|Microdiagnostics, Inc.|Immunoassay system|
    US6437563B1|1997-11-21|2002-08-20|Quantum Design, Inc.|Method and apparatus for making measurements of accumulations of magnetically susceptible particles combined with analytes|
    WO1999030131A1|1997-12-11|1999-06-17|Quidel Corporation|One-step fluorescent immunosensor test|
    DE19816550A1|1997-12-24|1999-06-24|Roche Diagnostics Gmbh|Universally applicable structure of an analysis element and its use for analyte determination|
    SE9704935D0|1997-12-30|1997-12-30|Pharmacia & Upjohn Diag Ab|Method of analysis with particles|
    SE9704933D0|1997-12-30|1997-12-30|Pharmacia & Upjohn Diag Ab|Method utilizing a new calibrator and test kit containing the calibrator|
    US5985675A|1997-12-31|1999-11-16|Charm Sciences, Inc.|Test device for detection of an analyte|
    US6194222B1|1998-01-05|2001-02-27|Biosite Diagnostics, Inc.|Methods for monitoring the status of assays and immunoassays|
    US7034120B2|1999-02-02|2006-04-25|Edp Biotech Corporation, Inc.|Method and apparatus for detecting conception in animals|
    CA2319417A1|1998-02-02|1999-08-05|Concepto Diagnostics, Inc.|Method and apparatus for detecting conception in animals|
    US6394952B1|1998-02-03|2002-05-28|Adeza Biomedical Corporation|Point of care diagnostic systems|
    US6267722B1|1998-02-03|2001-07-31|Adeza Biomedical Corporation|Point of care diagnostic systems|
    FR2775523B1|1998-03-02|2000-05-05|Int Microbio|MODULAR ELEMENT FOR PERFORMING CHROMATOGRAPHIC TESTS AND / OR ANALYZES|
    EP1064553A4|1998-03-16|2001-09-12|Quidel Corp|Immunoassay device and method|
    EP1062508A1|1998-03-20|2000-12-27|The Rockefeller University|Assays for screening compounds which interact with cation channel proteins, mutant prokaryotic cation channel proteins, and uses thereof|
    US8062908B2|1999-03-29|2011-11-22|Orasure Technologies, Inc.|Device for collection and assay of oral fluids|
    US6303081B1|1998-03-30|2001-10-16|Orasure Technologies, Inc.|Device for collection and assay of oral fluids|
    DK1696236T3|1998-03-30|2014-08-18|Orasure Technologies Inc|Collection device for analysis of oral fluids|
    US6368873B1|1998-04-09|2002-04-09|Applied Biotech, Inc.|Identification of human urine for drug testing|
    CN1163753C|1998-04-14|2004-08-25|大塚制药株式会社|Method for assaying antibody and device for assaying antibody|
    USD434153S|1998-04-20|2000-11-21|Adeza Biomedical Corporation|Point of care analyte detector system|
    USD432244S|1998-04-20|2000-10-17|Adeza Biomedical Corporation|Device for encasing an assay test strip|
    US7476548B2|1998-04-23|2009-01-13|Bayer Healthcare Llc|Dry reagent strip configuration, composition and method for multiple analyte determination|
    SE9801563D0|1998-04-30|1998-04-30|Pharmacia & Upjohn Diag Ab|Method of separation and kit to be used in the process|
    US6271044B1|1998-05-06|2001-08-07|University Of Pittsburgh Of The Commonwealth System Of Higher Education|Method and kit for detecting an analyte|
    US20060019404A1|1998-05-06|2006-01-26|Blatt Joel M|Quantitative assay with extended dynamic range|
    US6753189B1|1998-06-04|2004-06-22|Mizuho Medy Co., Ltd.|Detection apparatus and method for the same|
    WO1999064864A1|1998-06-12|1999-12-16|New Horizons Diagnostics Inc.|Optimizing sensitivity in colloidal colorimetric flow through and lateral flow tests|
    DE19906005C2|1998-06-19|2002-12-19|Biomar Diagnostic Systems Gmbh|tester|
    FR2780317B1|1998-06-30|2000-08-11|Vedalab|DEVICE FOR DETERMINING AN ANALYTE IN A LIQUID SAMPLE|
    DE19830405C2|1998-07-08|2000-09-21|Draeger Sicherheitstech Gmbh|Test strips for immunochemical substance detection|
    GB2339615B|1998-07-14|2001-02-07|Cozart Bioscience Ltd|Screening device and method of screening an immunoassay test|
    EP0973034A1|1998-07-16|2000-01-19|Microbe Scope AG|Immunoassays and devices therefor|
    US7347972B1|1998-07-22|2008-03-25|Jin Po Lee|Multiple analyte assay device|
    ES2222719T3|1998-07-30|2005-02-01|Oakville Trading Hong Kong Limited|PROCEDURE TO PREPARE WATER SOLUBLE RETICULATED CONJUGATES.|
    US20080081347A1|1998-08-25|2008-04-03|Binax, Inc.|EIA for Monitoring Legionella Pneumophila Presence in Water Samples|
    US20080096236A1|1998-08-25|2008-04-24|Binax, Inc.|Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof|
    US9134303B1|1998-08-25|2015-09-15|Alere Scarborough, Inc.|ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto|
    US6245577B1|1998-09-11|2001-06-12|Midland Bioproducts Corporation|IgG antibody testing method|
    US6248598B1|1998-09-17|2001-06-19|Stuart C. Bogema|Immunoassay that provides for both collection of saliva and assay of saliva for one or more analytes with visual readout|
    US6372514B1|1998-09-18|2002-04-16|Syntron Bioresearch, Inc.|Even fluid front for liquid sample on test strip device|
    US6140136A|1998-09-18|2000-10-31|Syntron Bioresearch, Inc.|Analytical test device and method of use|
    ES2242421T3|1998-09-18|2005-11-01|Binax, Inc.|PROCEDURES AND MATERIALS FOR THE RAPID DETECTION OF STREPTOCOCCUS PNEUMONIAE USING SPECIFIC PURIFIED ANTIBODIES OF AN ANTIGEN.|
    US6824997B1|1998-09-18|2004-11-30|Binax, Inc.|Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies|
    WO2000019199A1|1998-09-29|2000-04-06|Fertility Acoustics Inc.|A method of and device for determining ovulation in mammals|
    GB9821526D0|1998-10-02|1998-11-25|Genosis Inc|Capture assay|
    US6245539B1|1998-10-06|2001-06-12|Board Of Trustees Operating Michigan State University|Human asparaginyl-tRNA synthetase DNA|
    US6379620B1|1998-11-16|2002-04-30|Barry M. Tydings|Assaying device and method for in field urinalysis|
    JP3395673B2|1998-11-18|2003-04-14|株式会社豊田中央研究所|Specific binding pair measurement method using micro oxygen electrode|
    DE19859066C2|1998-12-22|2003-04-17|Engel Matthias Werner|Test device for immunoassays|
    US7450229B2|1999-01-25|2008-11-11|Amnis Corporation|Methods for analyzing inter-cellular phenomena|
    US8131053B2|1999-01-25|2012-03-06|Amnis Corporation|Detection of circulating tumor cells using imaging flow cytometry|
    US8406498B2|1999-01-25|2013-03-26|Amnis Corporation|Blood and cell analysis using an imaging flow cytometer|
    US8885913B2|1999-01-25|2014-11-11|Amnis Corporation|Detection of circulating tumor cells using imaging flow cytometry|
    US6297020B1|1999-03-01|2001-10-02|Bayer Corporation|Device for carrying out lateral-flow assays involving more than one analyte|
    WO2000051520A2|1999-03-02|2000-09-08|Kems Bio-Test Ltd.|Bovine pregnancy testing|
    US6808889B2|1999-03-16|2004-10-26|Serex, Inc.|Method and device for detection of Apo A, Apo B and the ratio thereof in saliva|
    US6180417B1|1999-04-22|2001-01-30|Bayer Corporation|Immunochromatographic assay|
    JP4233686B2|1999-06-11|2009-03-04|日水製薬株式会社|Immunochromatography equipment housing|
    DE19927783A1|1999-06-18|2000-12-21|Roche Diagnostics Gmbh|Element for determining an analyte in a liquid, corresponding determination method using the element and kit for determining an analyte|
    JP4402263B2|1999-06-21|2010-01-20|パナソニック株式会社|Chromatographic quantitative measurement device|
    DE60012932T2|1999-06-23|2005-08-18|Cornell Research Foundation, Inc.|Dewatering / rehydration of labeled liposomes on a TEST EQUIPMENT|
    US6514769B2|1999-07-29|2003-02-04|Jin Po Lee|Multiple analyte assay device with sample integrity monitoring system|
    AT236398T|1999-10-12|2003-04-15|Connex Ges Zur Optimierung Von|IMPROVED METHOD FOR DETECTING ACID-RESISTANT BACTERIES OF THE GENE HELICOBACTER IN CHAIR|
    US6576460B1|1999-10-28|2003-06-10|Cornell Research Foundation, Inc.|Filtration-detection device and method of use|
    EP1261870A1|1999-11-02|2002-12-04|Ted Titmas|Personal pregnancy testing kit|
    US6727073B1|1999-11-19|2004-04-27|Binax, Inc.|Method for detecting enteric disease|
    US6509196B1|2000-01-04|2003-01-21|Response Biomedical Corp.|Compensation for non-specific signals in quantitative immunoassays|
    US6316205B1|2000-01-28|2001-11-13|Genelabs Diagnostics Pte Ltd.|Assay devices and methods of analyte detection|
    DE10003734A1|2000-01-28|2001-08-02|Bosch Gmbh Robert|Detection method and device|
    US20020004246A1|2000-02-07|2002-01-10|Daniels Robert H.|Immunochromatographic methods for detecting an analyte in a sample which employ semiconductor nanocrystals as detectable labels|
    EP1281089A1|2000-02-23|2003-02-05|Besst-Test APS|METHOD FOR CORRELATING BLOOD COAGULATION ACTIVITY WITH MARKERS IN BODY FLUIDS, e.g. URINE|
    DE10009503A1|2000-02-29|2001-08-30|Roche Diagnostics Gmbh|Procedure for immobilizing conjugates in diagnostic tests|
    US6607922B2|2000-03-17|2003-08-19|Quantum Design, Inc.|Immunochromatographic assay method and apparatus|
    GB0008124D0|2000-04-03|2000-05-24|Genosis Ltd|Capture assay|
    US6391261B1|2000-04-14|2002-05-21|Lifepoint, Inc.|Device for detecting analytes related to sample pH|
    US6699722B2|2000-04-14|2004-03-02|A-Fem Medical Corporation|Positive detection lateral-flow apparatus and method for small and large analytes|
    US6627459B1|2000-04-19|2003-09-30|Applied Biotech, Inc.|Immunoassay controls|
    US6752988B1|2000-04-28|2004-06-22|New Horizons Diagnostic Corp|Method of treating upper resiratory illnesses|
    US7018847B2|2000-05-05|2006-03-28|Pharmacia Diagnostics Ab|Assay device with timer function|
    JP4562854B2|2000-05-08|2010-10-13|パナソニック株式会社|Chromatographic measurement method|
    US6534324B1|2000-05-12|2003-03-18|Mizuho Usa, Inc.|Rapid assay strip and method of rapid competitive assay|
    IL140994A|2000-05-15|2005-12-18|Bayer Ag|Urinary trypsin inhibitor assay containing a chelating agent|
    JP3680090B2|2000-05-25|2005-08-10|株式会社ニチレイ|Analysis equipment|
    CN100533147C|2000-05-26|2009-08-26|松下电器产业株式会社|Biosensor|
    US6706474B1|2000-06-27|2004-03-16|Board Of Trustees Of The University Of Illinois|Nucleic acid enzyme biosensors for ions|
    US6617123B1|2000-06-29|2003-09-09|Jack V. Smith|Method for detection of 4-hydroxybutyric acid and its precursor in fluids|
    US20060134713A1|2002-03-21|2006-06-22|Lifescan, Inc.|Biosensor apparatus and methods of use|
    RU2278612C2|2000-07-14|2006-06-27|Лайфскен, Инк.|Immune sensor|
    AU7326401A|2000-07-21|2002-02-05|Cuno Inc|Improved blocking chemistries for nylon membrane|
    GB2365526B|2000-07-31|2003-12-03|Cambridge Life Sciences|Assay apparatus for measuring the amount of an analyte in a biological or environmental sample|
    DE60138953D1|2000-08-10|2009-07-23|Biomerieux Bv|DIAGNOSTIC TEST BASED ON MOVING DROPS|
    KR100403871B1|2000-08-12|2003-11-01|휴마시스 주식회사|Diagnostic Device For Distinguishing Between Normal And Ectopic Pregnancy And Process For Preparing The Same|
    AU8645101A|2000-08-17|2002-02-25|Lifepoint Inc|Assay method and device for detecting the presence and concentration of analyteswhile simultaneously preventing analyte adsorption to solid materials used in t he assay|
    US6372516B1|2000-09-07|2002-04-16|Sun Biomedical Laboratories, Inc.|Lateral flow test device|
    CN1287140C|2000-09-25|2006-11-29|松下电器产业株式会社|Device for chromatographic quantitative measurement|
    CN2445326Y|2000-10-09|2001-08-29|刘永详|Immune analysis device for assaying saccharified protein|
    US6764825B1|2000-10-13|2004-07-20|Tang J. Wang|Methods and device for detecting prostate specific antigen |
    US6528325B1|2000-10-13|2003-03-04|Dexall Biomedical Labs, Inc.|Method for the visual detection of specific antibodies in human serum by the use of lateral flow assays|
    GB0025245D0|2000-10-14|2000-11-29|Lee Helen|Multiple target detection|
    JP2002202310A|2000-10-27|2002-07-19|Morinaga Milk Ind Co Ltd|Substance detecting reagent and substance detecting method|
    EP1333854A4|2000-11-02|2005-10-05|New Horizons Diagnostics Corp|The use of bacterial phage associated lytic enzymes to prevent food poisoning|
    US7713703B1|2000-11-13|2010-05-11|Biosite, Inc.|Methods for monitoring the status of assays and immunoassays|
    US20020090663A1|2000-11-21|2002-07-11|Hartmann James X.|Immunoassay for fish identification|
    US6600057B2|2000-12-29|2003-07-29|Kimberly-Clark Worldwide, Inc.|Matrix metalloproteinase inhibitors|
    US7041787B2|2000-12-29|2006-05-09|Kimberly-Clark Worldwide, Inc.|Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases|
    US6818181B2|2001-03-15|2004-11-16|Savyon Diagnostics Ltd.|Kit and method for detecting food allergies|
    US6596502B2|2001-03-15|2003-07-22|Lee Research Laboratory, Inc.|Kit and method for detecting fecal parasites|
    US6767710B2|2001-03-30|2004-07-27|Praxsys Biosystems, Llc|Prewetting stop flow test strip|
    US20020182748A1|2001-03-30|2002-12-05|Reardon Paul C.|Method and device for testing for Bence-Jones Protein|
    WO2002084291A1|2001-04-12|2002-10-24|Arkray, Inc.|Specimen analyzing implement|
    US6833111B2|2001-04-13|2004-12-21|Varian, Inc.|Multiple analyte assaying device with a multiple sample introduction system|
    US20050266499A1|2001-04-25|2005-12-01|Rockeby Biomed Corporation, Ltd.|Method and apparatus for testing for presence or absence of select biological substances|
    US6770487B2|2001-05-01|2004-08-03|Ischemia Technologies, Inc.|Bar code readable diagnostic strip test|
    US20040213765A1|2001-07-13|2004-10-28|Vincent Fischetti|Use of bacterial phage associated lytic enzymes to prevent food poisoning|
    US6740293B1|2001-07-17|2004-05-25|Biotech Atlantic, Inc.|Housing for test strip device and test strip therefor|
    US7605004B2|2001-07-18|2009-10-20|Relia Diagnostic Systems Llc|Test strip for a lateral flow assay for a sample containing whole cells|
    US6818456B2|2001-07-20|2004-11-16|Varian, Inc.|Color contrast system for lateral flow immunoassay tests|
    US7067264B2|2001-07-23|2006-06-27|Bagaria Padma S|Test device for detecting human blood and method of use|
    US7300633B2|2001-07-25|2007-11-27|Oakville Hong Kong Company Limited|Specimen collection container|
    US7270959B2|2001-07-25|2007-09-18|Oakville Hong Kong Company Limited|Specimen collection container|
    EP1416276B1|2001-08-09|2007-03-07|Matsushita Electric Industrial Co., Ltd.|Biosensors and measurement method|
    AT501069A1|2001-08-20|2006-06-15|Walter Ing Pils|DEVICE AND METHOD FOR DETECTING AN ANALYTE|
    US7456025B2|2001-08-28|2008-11-25|Porex Corporation|Sintered polymer membrane for analyte detection device|
    WO2003020702A2|2001-08-31|2003-03-13|The Rockefeller University|Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain|
    AU2002330102A1|2001-09-28|2003-04-14|Aspenbio, Inc.|Bovine pregnancy test|
    US7879293B2|2001-09-28|2011-02-01|Orasure Technologies, Inc.|Sample collector and test device|
    DE10153925B4|2001-11-02|2005-08-11|Unlimited Pharmaceutical Deutschland Gmbh|Test device for the detection of pharmacologically active compounds from saliva|
    US8481334B1|2001-11-06|2013-07-09|Charm Sciences, Inc.|Method of attaching a ligand to a solid support|
    US6723500B2|2001-12-05|2004-04-20|Lifescan, Inc.|Test strips having reaction zones and channels defined by a thermally transferred hydrophobic barrier|
    US20030119073A1|2001-12-21|2003-06-26|Stephen Quirk|Sensors and methods of detection for proteinase enzymes|
    US20030119203A1|2001-12-24|2003-06-26|Kimberly-Clark Worldwide, Inc.|Lateral flow assay devices and methods for conducting assays|
    JP2005515429A|2001-12-27|2005-05-26|インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング|System and method for fluorescence detection|
    US7049150B2|2001-12-28|2006-05-23|Varian, Inc.|Binding assay device with non-absorbent carrier material|
    IL162838D0|2002-01-04|2005-11-20|Univ Rockefeller|Compositions and methods for prevention and treatment peptide-of amyloid- related disorders|
    US6634243B1|2002-01-14|2003-10-21|Rapid Medical Diagnostics Corporation|Sample testing device|
    US6927068B2|2002-01-30|2005-08-09|The United States Of America As Represented By The Secretary Of The Navy|Rapid and non-invasive method to evaluate immunization status of a patient|
    US20030166027A1|2002-02-21|2003-09-04|George Sachs|Compositions, test kits and methods for detecting helicobacter pylori|
    US6703216B2|2002-03-14|2004-03-09|The Regents Of The University Of California|Methods, compositions and apparatuses for detection of gamma-hydroxybutyric acid |
    US20030180814A1|2002-03-21|2003-09-25|Alastair Hodges|Direct immunosensor assay|
    US7524462B2|2002-03-29|2009-04-28|Agilent Technologies, Inc.|Capillary flow for a heterogenous assay in a micro-channel environment|
    ES2252358T3|2002-04-09|2006-05-16|Cholestech Corporation|METHOD AND TEST DEVICE FOR THE QUANTIFICATION OF CHOLESTEROL ASSOCIATED WITH HIGH DENSITY LIPOPROTEINS.|
    WO2003087822A2|2002-04-10|2003-10-23|Response Biomedical Corporation|Sensitive immunochromatographic assay|
    US7175992B2|2002-04-10|2007-02-13|Response Biomedical Corporation|Sensitive immunochromatographic assay|
    US7611670B2|2002-04-23|2009-11-03|Home Access Health Corporation|Quantitative analysis of a biological sample of unknown quantity|
    US6837171B1|2002-04-29|2005-01-04|Palmer/Snyder Furniture Company|Lightweight table with unitized table top|
    EP1546716A4|2002-05-02|2007-04-11|Aspenbio Inc|Pregnancy detection|
    US6890719B2|2002-05-10|2005-05-10|The Board Of Trustess Of The University Of Illinois|Fluorescence based biosensor|
    US7534560B2|2002-05-10|2009-05-19|The Board Of Trustees Of The University Of Illinois|Simple catalytic DNA biosensors for ions based on color changes|
    US20040002063A1|2002-05-16|2004-01-01|Medmira Inc.|Rapid vaccinia antibody detection device, method and test kit|
    AT478337T|2002-05-31|2010-09-15|Cornell Res Foundation Inc|METHODS OF DETECTION ANALYTES IN SAMPLES|
    EP1369473B1|2002-06-07|2009-01-21|Cholestech Corporation|Automated cassete module for an apparatus for conducting immunoassays and use thereof|
    US7238519B2|2002-06-07|2007-07-03|Cholestech Corporation|Automated immunoassay cassette, apparatus and method|
    US20040018576A1|2002-07-24|2004-01-29|Dematteo Todd M.|Bence Jones protein testing cassette|
    EP2204654B1|2002-08-13|2012-12-12|N-Dia, Inc.|Use of devices and methods for detecting amniotic fluid in vaginal secretions|
    US7432105B2|2002-08-27|2008-10-07|Kimberly-Clark Worldwide, Inc.|Self-calibration system for a magnetic binding assay|
    US7285424B2|2002-08-27|2007-10-23|Kimberly-Clark Worldwide, Inc.|Membrane-based assay devices|
    US7090802B1|2002-09-05|2006-08-15|Phenogenomics Corporation|Sampling assembly for simultaneously testing a liquid biological sample for a plurality of hormones and method thereof|
    US20040092036A1|2002-09-11|2004-05-13|Lattec I/S|Device for analysing analyte compounds and use hereof|
    CN1497255A|2002-10-02|2004-05-19|松下电器产业株式会社|Sampling element for tested body, tested body processing device and its processing method|
    US7883899B2|2002-10-11|2011-02-08|Zbx Corporation|Diagnostic devices|
    DE10248555B4|2002-10-18|2004-12-02|Roche Diagnostics Gmbh|Method and analysis system for determining the concentration of an analyte in a sample, which consists of the analyte and the sample matrix, and test element therefor|
    TW580376B|2002-10-24|2004-03-21|Oncoprobe Biotech Inc|Test pen|
    US7256053B2|2002-10-24|2007-08-14|Nanogen, Inc.|Diagnostic device for analyte detection|
    AU2003287697A1|2002-11-08|2004-06-03|Barnes-Jewish Hospital|Uncoupled collagen synthesis and degradation assays|
    US7135329B2|2002-11-18|2006-11-14|Princeton Biomeditech Corporation|Immunoassay device for diagnosing congestive heart failure and predicting mortality in congestive heart failure patients|
    AU2003302132B2|2002-11-21|2008-02-21|Inverness Medical Switzerland Gmbh|Bodily fluid markers of tissue hypoxia|
    US20040121334A1|2002-12-19|2004-06-24|Kimberly-Clark Worldwide, Inc.|Self-calibrated flow-through assay devices|
    TWI340829B|2002-12-27|2011-04-21|Transpacific Systems Llc|Method for determining a response of each probe zone on a test strip|
    US7197169B2|2003-01-02|2007-03-27|Kuo-Jeng Wang|Method for detecting a response of each probe zone on a test strip|
    US20040133128A1|2003-01-04|2004-07-08|Zhumin Guan|Assay device with attachable seal for use with specimen collection and assay containers|
    GB0301225D0|2003-01-20|2003-02-19|Univ Sunderland|Surface layer immuno-chromatography|
    US7220597B2|2003-01-30|2007-05-22|Zin Benedict L|Assay test device and method of making same|
    US7459314B2|2003-02-13|2008-12-02|Inverness Medical Switzerland Gmbh|Lateral flow immunoassay controls|
    JP4566983B2|2003-02-24|2010-10-20|バイナックスインコーポレイティッド|Lateral flow in dry chemistry-reconstituted chromatographic enzyme-driven assay|
    US20040241779A1|2003-02-24|2004-12-02|Piasio Roger N.|Dry chemistry, lateral flow-reconstituted chromatographic enzyme-driven assays|
    US7612185B2|2003-03-07|2009-11-03|The Board Of Trustees Of The University Of Illinois|Nucleic acid biosensors|
    WO2004081529A2|2003-03-10|2004-09-23|Robinson Joseph R|Assay device and method|
    US8003765B2|2003-04-09|2011-08-23|Stony Brook Anaesthesiology, University Faculty Practice Corporation|Methods, antibodies and kits for detecting cerebrospinal fluid in a sample|
    US20070003992A1|2003-04-09|2007-01-04|Pentyala Srinivas N|Methods and kits for detecting cerebrospinal fluid in a sample|
    US20040203079A1|2003-04-09|2004-10-14|Research Foundation Of The State University Of New York|Methods and kits for detecting cerebrospinal fluid in a sample|
    US7300802B2|2003-04-25|2007-11-27|Biodigit Laboratories Corp.|Membrane strip biosensor system for point-of-care testing|
    WO2004097371A2|2003-04-25|2004-11-11|Board Of Regents, The University Of Texas System|System and method for the detection of analytes|
    CN104076143B|2003-05-02|2017-06-13|安克塞斯生物公司|Chromatographic assay system|
    US7932093B2|2003-05-07|2011-04-26|Coris Bioconcept Sprl|One step oligochromatographic device and method of use|
    US8101429B2|2003-06-03|2012-01-24|Siemens Healthcare Diagnostics Inc.|Native analyte as a reference in lateral flow assays|
    CA2468014C|2003-06-04|2016-03-22|Inverness Medical Switzerland Gmbh|Flow sensing for determination of assay results|
    US7317532B2|2003-06-04|2008-01-08|Inverness Medical Switzerland Gmbh|Flow sensing for determination of assay results|
    US7239394B2|2003-06-04|2007-07-03|Inverness Medical Switzerland Gmbh|Early determination of assay results|
    AT422241T|2003-06-04|2009-02-15|Inverness Medical Switzerland|OPTICAL ARRANGEMENT FOR AN ASSAY READER|
    US7315378B2|2003-06-04|2008-01-01|Inverness Medical Switzerland Gmbh|Optical arrangement for assay reading device|
    JP4567597B2|2003-06-24|2010-10-20|日本碍子株式会社|Analytical specimen and method for producing the same|
    DE10330981B4|2003-07-09|2010-04-01|Medion Diagnostics Ag|Apparatus and method for simultaneously performing blood grouping, serum cross-checking and antibody-screening|
    US7517495B2|2003-08-25|2009-04-14|Inverness Medical Switzerland Gmbh|Biological specimen collection and analysis system|
    US7582472B2|2003-08-26|2009-09-01|Smith Kenneth E|Apparatus and method for liquid sample testing|
    DE10341662B4|2003-09-08|2007-10-11|Seratec Gesellschaft für Biotechnologie mbH|Production process for an immunoassay|
    US7238538B2|2003-09-19|2007-07-03|Freitag Helmut E|Chromatographic assay device and methods|
    EP1664781B1|2003-09-22|2013-05-08|Quidel Corporation|Devices for the detection of multiple analytes in a sample|
    WO2005031356A1|2003-09-23|2005-04-07|Epinex Diagnostic, Inc.|Rapid test for glycated albumin|
    CA2544353A1|2003-10-29|2005-05-12|Mec Dynamics Corp.|Micro mechanical methods and systems for performing assays|
    US7781172B2|2003-11-21|2010-08-24|Kimberly-Clark Worldwide, Inc.|Method for extending the dynamic detection range of assay devices|
    US7713748B2|2003-11-21|2010-05-11|Kimberly-Clark Worldwide, Inc.|Method of reducing the sensitivity of assay devices|
    US7943395B2|2003-11-21|2011-05-17|Kimberly-Clark Worldwide, Inc.|Extension of the dynamic detection range of assay devices|
    US7244252B2|2003-11-25|2007-07-17|Scimed Life Systems, Inc.|Medical device with visual indicator and related methods of use|
    DE10355731A1|2003-11-28|2005-06-30|Roche Diagnostics Gmbh|Analytical sandwich test to determine NT-proBNP|
    US7410808B1|2003-12-08|2008-08-12|Charm Sciences, Inc.|Method and assay for detection of residues|
    JP4624364B2|2003-12-12|2011-02-02|アレル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング|Assay|
    US7485419B2|2004-01-13|2009-02-03|The Board Of Trustees Of The University Of Illinois|Biosensors based on directed assembly of particles|
    WO2005072398A2|2004-01-28|2005-08-11|Bamburgh Marrsh Llc|Specimen sample collection device and test system|
    US7723124B2|2004-02-09|2010-05-25|Rapid Pathogen Screening, Inc.|Method for the rapid diagnosis of targets in human body fluids|
    US8445293B2|2005-02-09|2013-05-21|Rapid Pathogen Screening, Inc.|Method to increase specificity and/or accuracy of lateral flow immunoassays|
    FI20040205A|2004-02-11|2005-08-12|Reagena Ltd Oy|Method and apparatus for producing a rapid test|
    US20050191704A1|2004-03-01|2005-09-01|Kimberly-Clark Worldwide, Inc.|Assay devices utilizing chemichromic dyes|
    AU2005218391B2|2004-03-05|2008-11-20|Prima Meat Packers, Ltd.|Method of detecting allergen|
    US7339673B2|2004-03-05|2008-03-04|Siemens Healthcare Diagnostics Inc.|Miniature optical readhead for optical diagnostic device|
    US20050227370A1|2004-03-08|2005-10-13|Ramel Urs A|Body fluid analyte meter & cartridge system for performing combined general chemical and specific binding assays|
    US8150136B2|2004-03-16|2012-04-03|Amnis Corporation|Image based quantitation of molecular translocation|
    US8953866B2|2004-03-16|2015-02-10|Amnis Corporation|Method for imaging and differential analysis of cells|
    JP2007530946A|2004-03-23|2007-11-01|クイデル コーポレイション|Hybrid phase lateral flow assay|
    CN100357738C|2004-03-26|2007-12-26|博奥生物有限公司|Method of detecting small molecule compound and its special biochip|
    CA2561343C|2004-03-30|2013-01-22|Whatman, Inc.|Lateral flow assay on a single hydrophilic monolithic matrix made of a network of fibres|
    US10753931B2|2005-04-22|2020-08-25|Alverix, Inc.|Assay test strips with multiple labels and reading same|
    US20050221504A1|2004-04-01|2005-10-06|Petruno Patrick T|Optoelectronic rapid diagnostic test system|
    JP4401845B2|2004-04-06|2010-01-20|株式会社札幌イムノ・ダイアグノスティック・ラボラトリー|Sample test container set and sample test kit|
    US7378054B2|2004-04-16|2008-05-27|Savvipharm Inc|Specimen collecting, processing and analytical assembly|
    US7319032B2|2004-04-22|2008-01-15|Medtox|Non-sugar sweeteners for use in test devices|
    US7772012B2|2004-04-30|2010-08-10|Quest Diagnostics Investments Incorporated|Device for detecting the presence of hemoglobin in a biological sample|
    DE102004023402A1|2004-05-12|2005-12-08|Roche Diagnostics Gmbh|Method for increasing the dynamic measuring range of, in particular immunological test elements based on specific binding reactions|
    EP1787121B1|2004-07-29|2010-08-25|Relia Diagnostic Systems, LLC|Lateral flow system and assay|
    CN101031798B|2004-07-29|2012-06-27|瑞莱诊断体系有限公司|Quantitative lateral flow system and assay|
    FI20040768A0|2004-06-04|2004-06-04|Teemu Korpimaeki|Method for stabilizing assay reagents, reagent tank containing stabilized assay reagents and its use|
    GB0412659D0|2004-06-07|2004-07-07|Inverness Medical Switzerland|Method|
    GB2404022B|2004-06-14|2005-08-10|Cozart Bioscience Ltd|Competitive assays for the detection of methamphetamine group drugs|
    FI20040825A0|2004-06-15|2004-06-15|Ani Biotech Oy|Filter device, its use, method and kit|
    GB2415504A|2004-06-23|2005-12-28|Animal Health Inst|Detection of microbial agents|
    EP1761774A1|2004-07-01|2007-03-14|The Central Science Laboratory, "CSL", Representing The Secretary of State for Environment, Food and Rural Affairs|Analyte detection system|
    GB2404023B|2004-07-02|2005-07-06|Cozart Bioscience Ltd|Delta-9-tetrahydrocannabinol detection method|
    US7763454B2|2004-07-09|2010-07-27|Church & Dwight Co., Inc.|Electronic analyte assaying device|
    US20060008920A1|2004-07-09|2006-01-12|Branan Medical Corporation|Combination assay for alcohol and drugs of abuse|
    FR2873208B1|2004-07-13|2007-12-07|Vedalab Sa|DEVICE WITH A SAMPLING MEMBER FOR DETECTION OF AN ANALYTE IN A LIQUID SAMPLE|
    US20060019406A1|2004-07-23|2006-01-26|Ning Wei|Lateral flow device for the detection of large pathogens|
    IL169884A|2004-07-29|2010-11-30|Savyon Diagnostics Ltd|Assay device|
    US20060040258A1|2004-08-23|2006-02-23|Huiyan Guo|Water-soluble conjugates and methods of preparation|
    US20060046310A1|2004-08-25|2006-03-02|Zong-Li Xia|Amplification method for solid phase immunoassays|
    US20090087859A1|2004-09-20|2009-04-02|Johnson Brandon T|Microfluidic device for detecting soluble molecules|
    US20060068500A1|2004-09-28|2006-03-30|Kimberly-Clark Worldwide, Inc.|Detecting yeast infections using a lateral flow assay|
    FR2875910B1|2004-09-28|2007-04-06|Vedalab Sa|IMMUNOCHROMATOGRAPHIC DIAGNOSTIC DEVICES FOR THE DETECTION OF AN ANALYTE IN A LIQUID SAMPLE COMPRISING A POSITIVE SAMPLE INDEPENDENT OF THE DETECTED ANALYTE|
    US7442557B1|2004-10-22|2008-10-28|Idexx Laboratories, Inc.|Bi-directional flow assay device with reagent bridge|
    US8475735B2|2004-11-01|2013-07-02|Uma Mahesh Babu|Disposable immunodiagnostic test system|
    US20060094026A1|2004-11-03|2006-05-04|Yi Lu|Nucleic acid enzyme light-up sensor utilizing invasive DNA|
    EP1657550A1|2004-11-10|2006-05-17|Coris Bioconcept SPRL|Double-sided device for multiplex dipstick immunodiagnostic|
    DK1824991T3|2004-11-24|2016-03-29|Techlab Inc|Device and method for the detection of analytes|
    EP1669758A1|2004-12-01|2006-06-14|The Jordanian Pharmaceutical Manufacturing Co.|Lateral-flow test device providing improved test result validity|
    US7925445B2|2004-12-03|2011-04-12|Alverix, Inc.|Read-write assay system|
    US7465587B2|2004-12-03|2008-12-16|Genzyme Corporation|Diagnostic assay device|
    US7629180B2|2004-12-04|2009-12-08|Freedom Health, Llc|Test kit for the rapid detection and localization of digestive tract bleeding in equines|
    CN101974619B|2004-12-08|2012-11-21|安万特药物公司|Method for measuring resistance or sensitivity to docetaxel|
    US7387890B2|2004-12-16|2008-06-17|Chembio Diagnostic Systems, Inc.|Immunoassay devices and use thereof|
    US20060166222A1|2005-01-21|2006-07-27|Yi Lu|Nucleic acid enzyme ligation sensor|
    GB0501741D0|2005-01-27|2005-03-02|Binding Site The Ltd|Antibody|
    EP1848999A4|2005-02-16|2012-05-30|Gao Ping Epitope Diagnostics|Fecal sample test device and methods of use|
    US8709792B2|2005-02-18|2014-04-29|Charm Sciences, Inc.|Lateral flow test kit and method for detecting an analyte|
    WO2006089027A2|2005-02-18|2006-08-24|Charm Sciences, Inc.|Lateral flow test kit and method for detecting an analyte|
    US7704753B2|2005-03-03|2010-04-27|Inverness Medical Switzerland Gmbh|Devices and methods for analyte assays with built-in result reporting using recognizable symbols|
    WO2006098804A2|2005-03-11|2006-09-21|Chembio Diagnostic Systems, Inc.|Dual path immunoassay device|
    US7189522B2|2005-03-11|2007-03-13|Chembio Diagnostic Systems, Inc.|Dual path immunoassay device|
    US7939342B2|2005-03-30|2011-05-10|Kimberly-Clark Worldwide, Inc.|Diagnostic test kits employing an internal calibration system|
    WO2006110425A2|2005-04-07|2006-10-19|Rapid Medical Diagnostics, Inc.|Device and methods for detecting an analyte in a sample|
    US8128871B2|2005-04-22|2012-03-06|Alverix, Inc.|Lateral flow assay systems and methods|
    US20060246574A1|2005-04-29|2006-11-02|Sarah Rosenstein|Dispenser for making a lateral flow device|
    US8506934B2|2005-04-29|2013-08-13|Robert I. Henkin|Methods for detection of biological substances|
    US7439079B2|2005-04-29|2008-10-21|Kimberly-Clark Worldwide, Inc.|Assay devices having detection capabilities within the hook effect region|
    US7858384B2|2005-04-29|2010-12-28|Kimberly-Clark Worldwide, Inc.|Flow control technique for assay devices|
    US20060246599A1|2005-04-29|2006-11-02|Sarah Rosenstein|Lateral flow device|
    US7803319B2|2005-04-29|2010-09-28|Kimberly-Clark Worldwide, Inc.|Metering technique for lateral flow assay devices|
    US20070042427A1|2005-05-03|2007-02-22|Micronics, Inc.|Microfluidic laminar flow detection strip|
    EP1891447B1|2005-05-23|2011-07-06|Phadia AB|Two step lateral flow assay methods and devices|
    DE102005026674A1|2005-05-31|2006-12-07|M + W Zander Facility Engineering Gmbh|Method for separating gaseous constituents in gaseous media and filters for carrying out the method|
    GB2427271A|2005-06-16|2006-12-20|Porvair Filtration Group Ltd|Diagnostic device|
    US8148057B2|2005-06-21|2012-04-03|The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention|Methods, immunoassays and devices for detection of anti-lipoidal antibodies|
    CN101243321A|2005-06-21|2008-08-13|美国政府健康及人类服务部，疾病控制和预防中心|Methods, immunoassays and devices for detection of anti-lipoidal antibodies|
    US7785865B2|2005-06-28|2010-08-31|Zbx Corporation|Membrane array and analytical device|
    JP4689379B2|2005-07-12|2011-05-25|旭化成株式会社|Biochemical analyzer|
    DE202005011777U1|2005-07-21|2006-11-30|Engel, Matthias W.|Sample analyte concentration sensor for drug testing has housing with removable fluid impermeable barrier between detachable sample collector and chromatographic carrier|
    US7892734B2|2005-08-11|2011-02-22|The Board Of Trustees Of The University Of Illinois|Aptamer based colorimetric sensor systems|
    FR2890173B1|2005-08-23|2008-02-22|Vedalab Sa|DEVICE FOR DETERMINING AN ANALYTE IN A LIQUID SAMPLE BY A SANDWICH TEST AND A COMPETITION TEST|
    CA2620079A1|2005-08-23|2007-03-01|Paul C. Harris|Multi-directional immunochromatographic assays|
    US7829347B2|2005-08-31|2010-11-09|Kimberly-Clark Worldwide, Inc.|Diagnostic test kits with improved detection accuracy|
    US7504235B2|2005-08-31|2009-03-17|Kimberly-Clark Worldwide, Inc.|Enzyme detection technique|
    US8003399B2|2005-08-31|2011-08-23|Kimberly-Clark Worldwide, Inc.|Nitrite detection technique|
    US7833481B2|2005-10-05|2010-11-16|Redxdefense, Llc|Fully integrated portable screening system|
    US7910381B2|2005-10-13|2011-03-22|BioAssay Works|Immuno gold lateral flow assay|
    US7344893B2|2005-10-13|2008-03-18|Auric Enterprises, Llc|Immuno-gold lateral flow assay|
    US7858396B2|2005-10-31|2010-12-28|Orasure Technologies, Inc.|Lateral flow assay device with multiple equidistant capture zones|
    WO2007110702A2|2005-11-23|2007-10-04|Inverness Medical Switzerland Gmbh|Assays|
    WO2007061098A1|2005-11-25|2007-05-31|Japan Science And Technology Agency|Analyzer and analysis method|
    US9056291B2|2005-11-30|2015-06-16|Micronics, Inc.|Microfluidic reactor system|
    US7763453B2|2005-11-30|2010-07-27|Micronics, Inc.|Microfluidic mixing and analytic apparatus|
    EP1800751A1|2005-11-30|2007-06-27|The Jordanian Pharmaceutical Manufacturing Co.|Lateral-flow test device for liquid samples|
    CN101326441B|2005-12-08|2013-04-10|可瑞斯生物概念公司|Test device for rapid diagnostics|
    US7279136B2|2005-12-13|2007-10-09|Takeuchi James M|Metering technique for lateral flow assay devices|
    US7618810B2|2005-12-14|2009-11-17|Kimberly-Clark Worldwide, Inc.|Metering strip and method for lateral flow assay devices|
    US7727206B2|2005-12-27|2010-06-01|Gorres Geoffrey H|Device for monitoring a patient for a urinary tract infection|
    DE502007000483D1|2006-01-14|2009-04-23|Roche Diagnostics Gmbh|Immunological test element with improved control zone|
    US7871568B2|2006-01-23|2011-01-18|Quidel Corporation|Rapid test apparatus|
    US7794656B2|2006-01-23|2010-09-14|Quidel Corporation|Device for handling and analysis of a biological sample|
    US20070202561A1|2006-02-10|2007-08-30|Becton Dickinson And Company|Electronic Detection Immunoassays that Utilize a Binder Support Medium|
    US8497135B2|2006-02-13|2013-07-30|U.S. Environmental Protection Agency|Diagnostic kits to detect SP22 and SP22 antibodies|
    CA2659773A1|2006-02-21|2007-08-30|Nanogen, Inc.|Methods and compositions for analyte detection|
    GB2435511A|2006-02-23|2007-08-29|Mologic Ltd|Protease detection|
    DE102006009516B4|2006-02-28|2007-12-06|Analyticon Biotechnologies Ag|Test device, manufacturing method therefor and test method|
    EP2007905B1|2006-03-15|2012-08-22|Micronics, Inc.|Integrated nucleic acid assays|
    US7799554B2|2006-03-16|2010-09-21|The Board Of Trustees Of The University Of Illinois|Lateral flow devices|
    JP2009530639A|2006-03-20|2009-08-27|インバーネス・メデイカル・スウイツツアーランド・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング|Water-soluble conjugates for electrochemical detection|
    WO2007117155A1|2006-04-07|2007-10-18|Agresearch Limited|Solid phase immuno-assay|
    US7527765B2|2006-04-11|2009-05-05|Harrogate Holdings|Consumer food testing device|
    US7547557B2|2006-06-13|2009-06-16|Quantum Design, Inc.|Directed-flow assay device|
    US20070292969A1|2006-06-15|2007-12-20|Armando Canseco|Pregnancy test device|
    WO2008002462A2|2006-06-23|2008-01-03|Micronics, Inc.|Methods and devices for microfluidic point-of-care immunoassays|
    US20080014657A1|2006-07-12|2008-01-17|Beckton Dickinson And Company|Use of Albumin, Bovine, P-Aminophenyl N-Acetyl B-D Glucosaminide as a Control Line for an Immunoassay Device|
    EP2463656A1|2006-07-25|2012-06-13|Augurix S.A.|An immunochromatography device for the diagnosis of diseases in a sample|
    US9839909B2|2006-07-28|2017-12-12|Diagnostics For The Real World, Ltd.|Device, system and method for processing a sample|
    EP2053961A4|2006-08-09|2013-05-01|Biogen Idec Inc|Method for distribution of a drug|
    GB0617035D0|2006-08-30|2006-10-11|Inverness Medical Switzerland|Fluidic indicator device|
    US7569396B1|2006-09-08|2009-08-04|Purplecow Llc|Caffeine detection using internally referenced competitive assays|
    US7749775B2|2006-10-03|2010-07-06|Jonathan Scott Maher|Immunoassay test device and method of use|
    WO2008061130A2|2006-11-15|2008-05-22|Ucp Biosciences, Inc.|An improved collecting and testing device and method of use|
    US20080138842A1|2006-12-11|2008-06-12|Hans Boehringer|Indirect lateral flow sandwich assay|
    US8012761B2|2006-12-14|2011-09-06|Kimberly-Clark Worldwide, Inc.|Detection of formaldehyde in urine samples|
    US7935538B2|2006-12-15|2011-05-03|Kimberly-Clark Worldwide, Inc.|Indicator immobilization on assay devices|
    US7846383B2|2006-12-15|2010-12-07|Kimberly-Clark Worldwide, Inc.|Lateral flow assay device and absorbent article containing same|
    US8377379B2|2006-12-15|2013-02-19|Kimberly-Clark Worldwide, Inc.|Lateral flow assay device|
    GB0625309D0|2006-12-19|2007-01-24|Inverness Medical Switzerland|Device|
    US7919331B2|2006-12-21|2011-04-05|Silver Lake Research Corporation|Chromatographic test strips for one or more analytes|
    EP2126587B1|2007-01-09|2010-09-29|Cholestech Corporation|Device and method for measuring ldl-associated cholesterol|
    WO2008089248A2|2007-01-19|2008-07-24|The Board Of Trustees Of The University Of Illinois|Amphiphilic substances and triggered liberation from lipid vesicles|
    WO2008095136A2|2007-01-31|2008-08-07|Henkin Robert I|Methods for detection of biological substances|
    EA017403B1|2007-02-02|2012-12-28|Байоджен Айдек Эмэй Инк.|Use of semaphorin 6a for promoting myelination and oligodendrocyte differentiation|
    WO2008106021A1|2007-02-26|2008-09-04|Response Biomedical Corporation|Comparative multiple analyte assay|
    CN101261270B|2007-03-09|2012-11-07|中国人民解放军军事医学科学院微生物流行病研究所|Immunity-chromatography multiple detection test paper disk and immunity-chromatography multiple detection method|
    US7989217B2|2007-03-29|2011-08-02|Ameritek Usa, Inc.|Method for determining hCG levels in fluid samples|
    JP2008249339A|2007-03-29|2008-10-16|Gc Corp|Immunochromatography test tool|
    GB0717043D0|2007-04-10|2007-10-10|Inverness Medical Switzerland|Assay device|
    GB0707870D0|2007-04-23|2007-05-30|Selected Antibodies Ltd|Assay Devices and Methods and Components for use Therein|
    US8058415B2|2007-04-24|2011-11-15|The Board Of Trustees Of The University Of Illinois|Aptamer- and nucleic acid enzyme-based systems for simultaneous detection of multiple analytes|
    US9086408B2|2007-04-30|2015-07-21|Nexus Dx, Inc.|Multianalyte assay|
    US8501495B2|2007-05-03|2013-08-06|Equal Access To Scientific Excellence|Sequential solid phase immunoassay including contact pad to limit conjugate flow during manufacture|
    US20080280310A1|2007-05-09|2008-11-13|Louis Panagopoulos|Testing for Blood Group Immunological Reaction Without the Use of Anti-Human Globulin|
    US7709215B2|2007-06-01|2010-05-04|Cytonics Corporation|Method for diagnosing and treating acute joint injury|
    EP2716656B1|2007-06-15|2016-10-12|Xiamen University|Monoclonal antibodies binding to avian influenza virus subtype H5 haemagglutinin and uses thereof|
    GB2450351B|2007-06-20|2012-01-18|Cozart Bioscience Ltd|Monitoring an Immunoassay|
    US8409800B2|2007-07-16|2013-04-02|The Board Of Trustees Of The University Of Illinois|Nucleic acid based fluorescent sensor for copper detection|
    US8568690B2|2007-07-31|2013-10-29|The Board Of Trustees Of The University Of Illinois|MRI contrast agents and high-throughput screening by MRI|
    WO2009045632A2|2007-08-10|2009-04-09|The Board Of Trustees Of The University Of Illinois|Nucleic acid based fluorescent sensor for mercury detection|
    US9707556B2|2007-08-17|2017-07-18|Diagnostics For The Real World, Ltd.|Device, system and method for processing a sample|
    AU2008207371B2|2007-09-01|2014-05-22|Abbott Rapid Diagnostics International Unlimited Company|Assay device with shared zones|
    WO2009072001A2|2007-09-12|2009-06-11|Aurelium Biopharma Inc.|Slc9a3r1 directed diagnostics for neoplastic disease|
    US20090111131A1|2007-09-13|2009-04-30|Seth Fishman|Method of detecting protein losing enteropathy in animals|
    WO2009034563A2|2007-09-14|2009-03-19|Nanocomms Patents Limited|An analysis system|
    GB2453356A|2007-10-03|2009-04-08|James Homrig|Assay device comprising control analytes to confirm assay completion|
    KR101539016B1|2007-10-23|2015-07-23|스카넥스 에이에스|Immunoassay analysis method|
    US7768645B2|2007-11-20|2010-08-03|Siemens Healthcare Diagnostics Inc.|Miniature optical readhead and colorimeter for analysis media|
    EP2072529A1|2007-12-21|2009-06-24|basisnote AG|MHC rapid assay used for the customization of odours|
    JP5239696B2|2008-01-18|2013-07-17|日立化成株式会社|Chromatographic analysis strip packaging mount|
    US8986253B2|2008-01-25|2015-03-24|Tandem Diabetes Care, Inc.|Two chamber pumps and related methods|
    US20090233295A1|2008-01-29|2009-09-17|Elias Georges|Trim59 directed diagnostics for neoplastic disease|
    FR2929407B1|2008-03-25|2013-01-04|Biosynex|BIOLOGICAL ANALYZING OR COMPARISON DEVICE, RELATED METHODS, METHOD OF MANUFACTURE AND USES|
    US8025851B2|2008-04-07|2011-09-27|Bamburgh Marrsh Llc|Specimen sample collection device and test system|
    US9198641B2|2009-04-07|2015-12-01|Oasis Diagnostics, Corporation|Specimen sample collection system|
    EP2277040A4|2008-04-21|2011-06-08|Univ Arkansas|Acetaminophen-protein adduct assay device and method|
    US9513300B2|2008-05-05|2016-12-06|Cornell University|Determination of serum anti-mullerian hormone as a diagnostic test for spay in companion animals|
    GB0809995D0|2008-05-31|2008-07-09|Spd Swiss Prec Diagnostics Gmb|Assay device|
    US20100105039A1|2008-06-03|2010-04-29|Yi Lu|Label-free colorimetric detection|
    GB2460660B|2008-06-04|2013-05-22|Alere Switzerland Gmbh|Assay reader device & method for measuring hCG|
    DE102008028908B3|2008-06-18|2009-12-31|IfP Privates Institut für Produktqualität GmbH|Detection of an analyte in an aqueous medium|
    US8476008B2|2008-07-23|2013-07-02|Diabetomics, Llc|Methods for detecting pre-diabetes and diabetes|
    US8580801B2|2008-07-23|2013-11-12|Robert I. Henkin|Phosphodiesterase inhibitor treatment|
    US8715590B2|2008-08-15|2014-05-06|Prognosys LLC|Multiplexed lateral flow assay arrays|
    US8408421B2|2008-09-16|2013-04-02|Tandem Diabetes Care, Inc.|Flow regulating stopcocks and related methods|
    US8650937B2|2008-09-19|2014-02-18|Tandem Diabetes Care, Inc.|Solute concentration measurement device and related methods|
    US8062893B2|2008-10-10|2011-11-22|The Board Of Trustees Of The University Of Illinois|Fluorescent sensor for mercury|
    EP2353012B1|2008-10-16|2017-04-05|Cytonics Corporation|Biomarkers and methods for detecting and treating spinal and joint pain|
    GB0820999D0|2008-11-17|2008-12-24|Menon Johansson Anatole S|Pregnancy testing|
    EP2194381B1|2008-12-03|2015-12-02|Roche Diagnostics GmbH|Testing element with combined control and calibration zone|
    US9234889B1|2008-12-18|2016-01-12|Charm Sciences, Inc.|Method and test strip for detecting residues|
    WO2010070521A1|2008-12-18|2010-06-24|Koninklijke Philips Electronics N.V.|Sensing device for sensing a fluid|
    US8455263B2|2008-12-30|2013-06-04|Jin Po Lee|Quantitative analyte assay device and method|
    CA3013992A1|2008-12-30|2010-07-08|Children's Medical Center Corporation|Method of predicting acute appendicitis|
    US8900881B2|2008-12-30|2014-12-02|Jin Po Lee|Quantitative analyte assay device and method|
    US8692873B2|2009-01-15|2014-04-08|Alverix, Inc.|Video-frame data receiver with low frame capture rate|
    US8422740B2|2009-01-15|2013-04-16|Scott Dylewski|Methods for determining a liquid front position on a test strip|
    WO2010090810A2|2009-02-05|2010-08-12|Hydradx, Inc.|Diagnostic device and method|
    DE102009010563A1|2009-02-16|2010-08-26|Matthias W. Engel|Device for the detection of analytes in body fluids|
    US8377643B2|2009-03-16|2013-02-19|Abaxis, Inc.|Split flow device for analyses of specific-binding partners|
    GB0905519D0|2009-03-31|2009-05-13|Biofortuna Ltd|Assay method and device|
    ES2582784T3|2009-04-09|2016-09-15|Hitachi Chemical Company, Ltd.|Detector and detection method|
    WO2010129302A1|2009-04-28|2010-11-11|Innovative Laboratory Technologies, Inc.|Lateral-flow immuno-chromatographic assay devices|
    DE202009006503U1|2009-04-29|2010-06-24|Dr. Fooke-Achterrath Laboratorien Gmbh|Assay devices for the determination of immunoglobulins E|
    WO2010132447A2|2009-05-11|2010-11-18|Diabetomics, Llc|Methods for detecting pre-diabetes and diabetes using differential protein glycosylation|
    US20100290948A1|2009-05-15|2010-11-18|Xuedong Song|Absorbent articles capable of indicating the presence of urinary tract infections|
    US8802427B2|2009-06-09|2014-08-12|Church & Dwight Co., Inc.|Female fertility test|
    WO2011014704A2|2009-07-30|2011-02-03|Tandem Diabetes Care, Inc.|Infusion pump system with disposable cartridge having pressure venting and pressure feedback|
    US8012770B2|2009-07-31|2011-09-06|Invisible Sentinel, Inc.|Device for detection of antigens and uses thereof|
    US9557330B2|2009-10-09|2017-01-31|Invisible Sentinel, Inc.|Device for detection of analytes and uses thereof|
    JP2013507618A|2009-10-11|2013-03-04|バイオジェン・アイデック・エムエイ・インコーポレイテッド|Anti-VLA-4 related assays|
    GB2474306A|2009-10-12|2011-04-13|Bioproducts Ltd|Methods and device for detecting an analyte|
    US8105843B2|2009-11-04|2012-01-31|Buchanan Thomas M|Methods and devices to enhance sensitivity and evaluate sample adequacy and reagent reactivity in rapid lateral flow immunoassays|
    KR20120107497A|2009-12-17|2012-10-02|아박시스, 인크.|Novel assays for detecting analytes in samples and kits and compositions related thereto|
    NO2524060T3|2010-01-11|2018-04-28|||
    KR101851117B1|2010-01-29|2018-04-23|마이크로닉스 인코포레이티드.|Sample-to-answer microfluidic cartridge|
    US8313956B2|2010-03-09|2012-11-20|Nokia Corporation|Apparatus and associated methods|
    CN102200536B|2010-03-25|2015-05-27|艾博生物医药有限公司|Device for detecting analyzed objects in test liquid samples|
    WO2011124991A2|2010-04-07|2011-10-13|Biosensia Patents Limited|Flow control device for assays|
    US10295472B2|2010-05-05|2019-05-21|Alverix, Inc.|Assay reader operable to scan a test strip|
    WO2011140476A1|2010-05-06|2011-11-10|Charm Sciences, Inc.|Device, system and method for transit testing of samples|
    JP2013528228A|2010-06-11|2013-07-08|ギリアードカリストガエルエルシー|Methods of treating blood system disorders in selected patients with quinazolinone compounds|
    US9816987B2|2010-06-17|2017-11-14|Abaxis, Inc.|Rotors for immunoassays|
    GB201012049D0|2010-07-19|2010-09-01|Binding Site Group The Ltd|Competition assay|
    US8815156B2|2010-07-19|2014-08-26|Andalyze, Inc.|Sensor housing and reagent chemistry|
    EP2596347B1|2010-07-22|2017-09-06|Hach Company|Alkalinity analysis using a lab-on-a-chip|
    DE102010032718A1|2010-07-23|2012-01-26|Christoph Gienapp|Device for determining presence or amount of human chorionic gonadotropin in e.g. blood, has line element on housing at region of window-like opening, and cooperating with window-like opening for displaying positive presence of analytes|
    US8956859B1|2010-08-13|2015-02-17|Aviex Technologies Llc|Compositions and methods for determining successful immunization by one or more vaccines|
    AT509727B1|2010-08-13|2011-11-15|Scheuringer Kim|KIT INCLUDING A TEST DEVICE|
    US8828329B2|2010-10-01|2014-09-09|Church & Dwight, Co., Inc.|Electronic analyte assaying device|
    US8927262B2|2010-10-04|2015-01-06|Church & Dwight Co., Inc.|Ovulation predictor test|
    ES2380664B2|2010-10-19|2012-09-13|Certest Biotec, S.L.|METHOD AND DEVICE FOR THE FAST DIAGNOSIS OF DISEASES IN FECAL SAMPLES.|
    WO2012070111A1|2010-11-22|2012-05-31|アークレイ株式会社|Measurement system, measurement method, program for executing aforementioned method, and recording medium of said program|
    CN203479805U|2010-11-24|2014-03-12|瑞士斯保德精密诊断有限公司|Analysis equipment for detecting analyte in fluid sample|
    JP6088434B2|2010-12-10|2017-03-01|ポルバイル フイルトラトイオン グループ リミテッド|Methods for performing chromatin immunoprecipitation assays|
    US8486717B2|2011-01-18|2013-07-16|Symbolics, Llc|Lateral flow assays using two dimensional features|
    AU2012211141B2|2011-01-27|2016-11-03|Invisible Sentinel, Inc.|Analyte detection devices, multiplex and tabletop devices for detection of analytes, and uses thereof|
    US8603835B2|2011-02-10|2013-12-10|Chembio Diagnostic Systems, Inc.|Reduced step dual path immunoassay device and method|
    EP2694967A4|2011-04-06|2014-10-29|Ortho Clinical Diagnostics Inc|Assay device having rhombus-shaped projections|
    JP5146565B2|2011-05-13|2013-02-20|パナソニック株式会社|Chromatographic quantitative measurement method|
    GB201111673D0|2011-07-08|2011-08-24|Imp Innovations Ltd|Method|
    IL214096A|2011-07-14|2016-02-29|Gideon Mor|System for detection of meconium in amniotic fluid|
    CN102323215A|2011-08-05|2012-01-18|广州万孚生物技术有限公司|Analyzing and reading device and method|
    GB2496104B|2011-10-25|2019-12-11|Alere Switzerland Gmbh|Improvements in or relating to reading of assays|
    DE102011054966B3|2011-10-31|2012-08-02|Nal Von Minden Gmbh|Drug test device for examination of chemical or biochemical compounds in sample e.g. mouth liquid, has containment assembly that is protruded from middle housing portion when protection device is in open operating point|
    US8211715B1|2011-11-15|2012-07-03|Harrogate Holdings, Ltd. Co.|Consumer food testing device providing remote monitoring|
    CN103115897B|2011-11-17|2017-04-12|艾博生物医药有限公司|Device for reading test results on test carrier|
    ES2407055B1|2011-12-07|2014-04-16|Universidad Pablo De Olavide|EMPLOYMENT OF ANTI-BETA-LACTOGLOBULIN ANTIBODIES IN THE DIAGNOSIS AND FOLLOW-UP OF CELIAC DISEASE|
    WO2013088429A1|2011-12-13|2013-06-20|Kieran Gerard Walshe|A homogeneous competitive lateral flow assay|
    US8999728B2|2011-12-21|2015-04-07|Church & Dwight Co., Inc.|Diagnostic detection device|
    WO2013096822A2|2011-12-23|2013-06-27|Abbott Point Of Care Inc|Integrated test device for optical and electrochemical assays|
    CN104081210B|2011-12-23|2018-11-30|雅培医护站股份有限公司|Optical detecting device with the actuating of pneumatic type sample|
    WO2013096801A1|2011-12-23|2013-06-27|Abbott Point Of Care Inc|Reader devices for optical and electrochemical test devices|
    WO2013096817A2|2011-12-23|2013-06-27|Abbott Point Of Care Inc|Integrated test device for optical detection of microarrays|
    US20130171619A1|2011-12-30|2013-07-04|General Electric Company|Porous membranes having a hydrophilic coating and methods for their preparation and use|
    CN102590517A|2012-01-19|2012-07-18|南京基蛋生物科技有限公司|Immunochromatography test paper and preparation method thereof|
    WO2013109821A1|2012-01-20|2013-07-25|Ortho-Clinical Diagnostics, Inc.|Assay device having multiplexing|
    CN103257225B|2012-01-20|2016-08-31|奥索临床诊断有限公司|Control the fluid through determinator to flow|
    BR102013001328A2|2012-01-20|2015-05-12|Ortho Clinical Diagnostics Inc|Teaching device having uniform flow near corners|
    BR102013001394A2|2012-01-20|2014-12-02|Ortho Clinical Diagnostics Inc|LOW TESTING DEVICE THAT HAS INCREASED SENSITIVITY|
    CA2802670C|2012-01-20|2020-09-01|Ortho-Clinical Diagnostics, Inc.|Assay device having multiple reagent cells|
    BR102013001324A2|2012-01-20|2015-07-28|Ortho Clinical Diagnostics Inc|Test device having controllable sample size and method for controlling sample size in a test device|
    WO2013112216A1|2012-01-24|2013-08-01|Cd Diagnostics, Llc|System for detecting infection in synovial fluid|
    WO2013112162A1|2012-01-26|2013-08-01|Salvo Lawrence A|Fast flow apparatus and method to evaluate analytes in liquid, solid and semi-solid samples|
    US10816492B2|2012-01-31|2020-10-27|Regents Of The University Of Minnesota|Lateral flow assays with thermal contrast readers|
    US10725033B2|2012-01-31|2020-07-28|Regents Of The University Of Minnesota|Lateral flow assays with thermal contrast readers|
    PL2810052T3|2012-01-31|2018-07-31|Regents Of The University Of Minnesota|Thermal contrast assay and reader|
    WO2013119763A1|2012-02-07|2013-08-15|Intuitive Biosciences, Inc.|Mycobacterium tuberculosis specific peptides for detection of infection or immunization in non-human primates|
    US9588113B2|2012-02-22|2017-03-07|Church & Dwight Co., Inc.|Methods for electronic analyte assaying|
    WO2013134503A2|2012-03-09|2013-09-12|Invisible Sentinel, Inc.|Methods And Compositions For Detecting Multiple Analytes With A Single Signal|
    US20130280696A1|2012-04-23|2013-10-24|Elliott Millenson|Devices and methods for detecting analyte in bodily fluid|
    CN104759373B|2012-04-25|2017-08-01|艾博生物医药有限公司|A kind of fluid distribution equipment|
    EP2841938A4|2012-04-25|2015-12-02|Compliance Software Inc|Capturing and processing instant drug test results using a mobile device|
    US9094493B2|2012-04-25|2015-07-28|Compliance Software, Inc.|Capturing and processing instant drug test results using a mobile device|
    USD701320S1|2012-04-25|2014-03-18|Compliance Software, Inc.|Adaptable housing for mobile device based drug testing|
    US9180242B2|2012-05-17|2015-11-10|Tandem Diabetes Care, Inc.|Methods and devices for multiple fluid transfer|
    MX2015016047A|2013-05-23|2016-07-26|Iphenotype Llc|Method and system for maintaining or improving wellness.|
    US9180449B2|2012-06-12|2015-11-10|Hach Company|Mobile water analysis|
    DE202012012084U1|2012-07-09|2013-04-15|Schebo Biotech Ag|Test kitfor the synchronous detection of biomarkers in stool for the detection of pathological changes in the gastrointestinal tract, especially in the intestine|
    DE102012013888A1|2012-07-09|2014-05-22|Schebo Biotech Ag|Test kitfor the synchronous detection of biomarkers in stool for the detection of pathological changes in the gastrointestinal tract, especially in the intestine|
    US9651549B2|2012-07-13|2017-05-16|Genisphere, Llc|Lateral flow assays using DNA dendrimers|
    ES2859522T3|2012-07-13|2021-10-04|Univ Pennsylvania|Control of toxicity for antitumor activity of CAR|
    US9874556B2|2012-07-18|2018-01-23|Symbolics, Llc|Lateral flow assays using two dimensional features|
    AU2013305887B2|2012-08-21|2018-02-22|Janssen Pharmaceutica Nv|Antibodies to risperidone and use thereof|
    WO2014031668A2|2012-08-21|2014-02-27|Ortho-Clinical Diagnostics, Inc|Antibodies to quetiapine and use thereof|
    EP2888284A4|2012-08-21|2016-03-30|Ortho Clinical Diagnostics Inc|Antibodies to risperidone haptens and use thereof|
    CN104736567B|2012-08-21|2019-09-03|詹森药业有限公司|The antibody and application thereof of Aripiprazole haptens|
    PL2888373T3|2012-08-21|2018-08-31|Janssen Pharmaceutica Nv|Antibodies to aripiprazole and use thereof|
    PL2888590T3|2012-08-21|2020-11-30|Janssen Pharmaceutica Nv|Antibodies to olanzapine and use thereof|
    EP3581195A1|2012-08-21|2019-12-18|Janssen Pharmaceutica NV|Antibodies to olanzapine haptens and use thereof|
    US20140057297A1|2012-08-21|2014-02-27|Janssen Pharmaceutica Nv|Antibodies to Paliperidone Haptens and Use Thereof|
    EP3663317A1|2012-08-21|2020-06-10|Janssen Pharmaceutica NV|Antibodies to quetiapine haptens and use thereof|
    PL3321254T3|2012-08-21|2021-01-11|Janssen Pharmaceutica Nv|Haptens of aripiprazole and their use in immunoassays|
    CN104736561B|2012-08-21|2018-06-12|詹森药业有限公司|Antibody of Paliperidone and application thereof|
    US20140072959A1|2012-09-12|2014-03-13|Force Diagnostics, Inc.|Rapid tests for insurance underwriting|
    JP2014071015A|2012-09-28|2014-04-21|Taiheiyo Material Kk|Measurement instrument and measurement method|
    CA2911090C|2013-05-02|2019-07-09|Echo Electricity Co., Ltd.|Liquid test device|
    RU2013150854A|2012-11-15|2015-05-20|Орто-Клиникал Дайэгностикс, Инк.|QUALITY CONTROL / OPERATION OF THE DEVICE FOR LATERAL FLOW-THROUGH ANALYSIS BASED ON THE FLOW MONITORING|
    BR112015011040A2|2012-11-15|2017-07-11|Ortho Clinical Diagnostics Inc|test calibration using reaction time|
    US20150299760A1|2012-11-21|2015-10-22|Oslo Universitetssykehus Hf|Systems and methods for monitoring biological fluids|
    USD768872S1|2012-12-12|2016-10-11|Hach Company|Cuvette for a water analysis instrument|
    CN107824233B|2012-12-21|2020-06-30|珀金埃尔默健康科学有限公司|Low elasticity membranes for microfluidic applications|
    EP2935908B1|2012-12-21|2019-08-14|PerkinElmer Health Sciences, Inc.|Fluidic circuits and related manufacturing methods|
    EP2935559B1|2012-12-21|2020-09-16|PerkinElmer Health Sciences, Inc.|Fluorescence detection system|
    JP6465812B2|2013-01-02|2019-02-06|キアゲン・サイエンシズ・エル・エル・シー|A method for predicting time to delivery in pregnant women|
    US8968677B2|2013-01-22|2015-03-03|Quantum Design International, Inc.|Frazil ice conjugate assay device and method|
    KR20140100843A|2013-02-07|2014-08-18|삼성전자주식회사|Support for capturing glycated protein in a sample and device and method for measuring the glycated protein using the same|
    CA2841692A1|2013-02-12|2014-08-12|Zhong Ding|Reagent zone deposition pattern|
    US9173998B2|2013-03-14|2015-11-03|Tandem Diabetes Care, Inc.|System and method for detecting occlusions in an infusion pump|
    US9052314B2|2013-03-14|2015-06-09|Silver Lake Research Corporation|Biomarkers for detecting the presence of bacteria|
    EP2777499B1|2013-03-15|2015-09-16|Ortho-Clinical Diagnostics Inc|Rotatable fluid sample collection device|
    US9151754B2|2013-03-15|2015-10-06|Church & Dwight Co., Inc.|Diagnostic test device with improved structure|
    EP2778679B1|2013-03-15|2017-09-27|Ortho-Clinical Diagnostics Inc|Rotable disk-shaped fluid sample collection device|
    US10190153B2|2013-05-07|2019-01-29|Micronics, Inc.|Methods for preparation of nucleic acid-containing samples using clay minerals and alkaline solutions|
    CA2911308C|2013-05-07|2021-10-19|Micronics, Inc.|Device for preparation and analysis of nucleic acids|
    WO2014182844A1|2013-05-07|2014-11-13|Micronics, Inc.|Microfluidic devices and methods for performing serum separation and blood cross-matching|
    EP3004334A4|2013-05-28|2016-12-21|Biogen Ma Inc|Method of assessing risk of pml|
    EP3004396B1|2013-06-06|2019-10-16|The General Hospital Corporation|Compositions for the treatment of cancer|
    GB201313121D0|2013-07-23|2013-09-04|Oxford Nanopore Tech Ltd|Array of volumes of polar medium|
    JP6273107B2|2013-08-02|2018-01-31|デンカ生研株式会社|Method for enhancing detection light using light reflector in immunochromatography|
    EP3044592B1|2013-09-13|2019-07-17|Symbolics, LLC|Lateral flow assays using two dimensional test and control signal readout patterns|
    GB201317458D0|2013-10-02|2013-11-13|Spd Swiss Prec Diagnostics Gmbh|Improved pregnancy test device and method|
    EP3502270B1|2013-10-21|2020-03-18|The General Hospital Corporation|Methods relating to circulating tumor cell clusters and the treatment of cancer|
    GB201321430D0|2013-12-04|2014-01-15|Spd Swiss Prec Diagnostics Gmbh|Assay device|
    JP6651448B2|2013-12-06|2020-02-19|オーソ−クリニカル・ダイアグノスティックス・インコーポレイテッドＯｒｔｈｏ−Ｃｌｉｎｉｃａｌ Ｄｉａｇｎｏｓｔｉｃｓ， Ｉｎｃ．|Assay device with wash port|
    CA2934344A1|2013-12-20|2015-06-25|David T. TING|Methods and assays relating to circulating tumor cells|
    US9352313B2|2013-12-31|2016-05-31|Hangzhou Ditu Technology Co., Ltd.|Device for collecting and testing analyte in a liquid sample|
    JP6496962B2|2014-02-14|2019-04-10|バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ|Acetaminophen-protein adduct and method of use thereof|
    US10598672B2|2014-02-18|2020-03-24|Cyrano Therapeutics, Inc.|Methods and compositions for diagnosing and treating loss and/or distortion of taste or smell|
    US10107780B2|2014-03-11|2018-10-23|Bio-Rad Laboratories, Inc.|Dip-stick western blot|
    CN111077309A|2014-04-02|2020-04-28|生化诊断系统公司|Immunoassays with capture conjugates|
    US9903858B2|2014-07-23|2018-02-27|Ortho-Clinical Diagnostics, Inc.|Multiplexing with single sample metering event to increase throughput|
    US10073091B2|2014-08-08|2018-09-11|Ortho-Clinical Diagnostics, Inc.|Lateral flow assay device|
    US11033896B2|2014-08-08|2021-06-15|Ortho-Clinical Diagnostics, Inc.|Lateral-flow assay device with filtration flow control|
    US10071373B2|2014-08-08|2018-09-11|Ortho-Clinical Diagnostics, Inc.|Lateral-flow assay device having flow constrictions|
    JP6159957B2|2014-08-20|2017-07-12|株式会社シン・コーポレイション|Inspection equipment|
    EP3183575A1|2014-08-22|2017-06-28|NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen|Testing device for examining a food for an analyte and test strips intended therefor|
    CN106796231A|2014-10-07|2017-05-31|3M创新有限公司|The method that thing is tested and analyzed using chromatographic isolation enrichment|
    KR20170057452A|2014-10-07|2017-05-24|쓰리엠 이노베이티브 프로퍼티즈 컴파니|Method of detecting a microorganism using chromatographic enrichment|
    US20160116466A1|2014-10-27|2016-04-28|Chembio Diagnostic Systems, Inc.|Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses|
    DE102014223430A1|2014-11-17|2016-05-19|Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.|Competitive immunoassay test system for detecting a pyrogen|
    AU2015358373B2|2014-12-03|2021-05-27|Arkansas Children's Research Institute|Anti-acetaminophen antibodies and acetaminophen protein adducts|
    WO2016172660A1|2015-04-23|2016-10-27|Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno|Fungal detection using mannan epitope|
    EP3298403A1|2015-05-19|2018-03-28|Ortho-Clinical Diagnostics Inc|Method of improving liquid sample flow in assay device|
    FR3038056B1|2015-06-25|2019-08-02|Commissariat A L'energie Atomique Et Aux Energies Alternatives|SIDE FLOW DEVICE WITH SAMPLING|
    EP3331572A4|2015-08-04|2019-05-01|CD Diagnostics, Inc.|Methods for detecting adverse local tissue reactionnecrosis|
    MX2018001353A|2015-08-06|2018-05-22|Lia Diagnostics Inc|Water dispersible assays.|
    KR20180088382A|2015-10-15|2018-08-03|인바이오스 인터네셔널, 인크.|Multi-lateral flow analysis system and method of using same|
    US9377457B1|2015-10-19|2016-06-28|Naishu Wang|Progressive compression driven flow cartridge for analyte detecting strip and method|
    US20180321202A1|2015-11-06|2018-11-08|Oslo Universitetssykehus Hf|Methods and devices for detecting methanol poisoning using formate oxidase|
    US20190120828A1|2016-10-27|2019-04-25|Angela Renee Crumitie|Pregnancy test and keepsake device and method of use thereof|
    US20180364243A1|2015-12-09|2018-12-20|Intuitive Biosciences, Inc.|Automated silver enhancement system|
    US10435478B2|2015-12-17|2019-10-08|Janssen Pharmaceutica Nv|Antibodies to quetiapine and use thereof|
    JP6949025B2|2015-12-17|2021-10-13|ヤンセン ファーマシューティカ エヌ．ベー．|Antibodies to risperidone and its use|
    US11119102B1|2016-02-16|2021-09-14|Charm Sciences, Inc.|Test device, method, and assembly|
    WO2017147186A1|2016-02-22|2017-08-31|Ursure, Inc.|System and method for detecting therapeutic agents to monitor adherence to a treatment regimen|
    ES2866880T3|2016-04-13|2021-10-20|Inst Nat Sante Rech Med|Methods and kits for the rapid detection of Escherichia Coli clone O25B-ST131|
    US20180011079A1|2016-07-08|2018-01-11|Healgen Scientific Limited|Apparatus for Detecting Analyte in a Liquid Sample and Method Thereof|
    US10877027B2|2016-08-01|2020-12-29|Webb Diagnostics Technologies, Inc.|Device and method for detecting a target analyte|
    EP3504551A1|2016-08-23|2019-07-03|Qoolabs, Inc.|Lateral flow assay for assessing recombinant protein expression or reporter gene expression|
    EP3335638A1|2016-12-13|2018-06-20|Colorimetrix GmbH|Method and device for estimation of ovulation date|
    US10656164B2|2016-12-22|2020-05-19|Qiagen Sciences, Llc|Screening asymptomatic pregnant woman for preterm birth|
    US10935555B2|2016-12-22|2021-03-02|Qiagen Sciences, Llc|Determining candidate for induction of labor|
    WO2018129261A1|2017-01-05|2018-07-12|Brown University|Methods and compositions relating to anti-chi3l1 antibody reagents|
    WO2018152496A1|2017-02-17|2018-08-23|The Usa, As Represented By The Secretary, Dept. Of Health And Human Services|Compositions and methods for the diagnosis and treatment of zika virus infection|
    US20200003772A1|2017-02-21|2020-01-02|Medicortex Finland Oy|Non-invasive brain injury diagnostic device|
    CN106932598A|2017-03-24|2017-07-07|南通伊仕生物技术股份有限公司|HCG cycle detection kits and preparation method thereof|
    US20200190168A1|2017-04-25|2020-06-18|The Usa, As Represented By The Secretary, Department Of Health And Human Services|Antibodies and methods for the diagnosis and treatment of epstein barr virus infection|
    JP2020518243A|2017-05-01|2020-06-25|ザ チルドレンズ メディカル センター コーポレーション|Methods and compositions relating to anti-PD1 antibody reagents|
    WO2018203145A1|2017-05-03|2018-11-08|Oslo Universitetssykehus Hf|Systems and methods for monitoring biological fluids|
    US20210380668A1|2017-07-19|2021-12-09|The Usa, As Represented By The Secretary, Dept, Of Health And Human Services|Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection|
    WO2019152657A1|2018-02-03|2019-08-08|Simple Healthkit, Inc.|Reliable, comprehensive, and rapid sexual health assessment|
    CN108519489A|2018-03-26|2018-09-11|南通伊仕生物技术股份有限公司|A kind of detection of electrons pen and early pregnancy pregnant week number detection method|
    WO2019213416A1|2018-05-02|2019-11-07|The Usa, As Represented By The Secretary, Dept. Of Health And Human Services|Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection|
    EP3791167A1|2018-05-07|2021-03-17|Immundiagnostik AG|System for analysing quantitative lateral flow chromatography|
    GB2574048B|2018-05-24|2021-06-16|Oxford Nanopore Tech Ltd|Nanopore sensor component with electrostatic discharge protection|
    CA3104142A1|2018-07-11|2020-01-16|Timothy Clyde GRANADE|Monoclonal antibody for the detection of the antiretroviral drug emtricitabine |
    GB2581988A|2019-03-06|2020-09-09|Sumitomo Chemical Co|Assay device|
    GB201905090D0|2019-04-10|2019-05-22|Spd Swiss Prec Diagnostics Gmbh|Assay device|
    WO2020245653A1|2019-06-04|2020-12-10|Alere Toxicology Plc|Fluid specimen testing|
    FR3100123A1|2019-09-03|2021-03-05|Toda Pharma|Device for testing biological fluid, especially saliva testing|
    GB201917832D0|2019-12-05|2020-01-22|Oxford Nanopore Tech Ltd|Microfluidic device for preparing and analysing a test liquid|
    EP3865874A1|2020-02-13|2021-08-18|Zhejiang Orient Gene Biotech Co., LTD|Device and method for distinguishing smoking e-cigarettes from smoking cigarettes|
    WO2021205228A1|2020-04-07|2021-10-14|Abbott Rapid Diagnostics International Unlimited Company|Assay device|
    GB202005103D0|2020-04-07|2020-05-20|Spd Swiss Prec Diagnostics Gmbh|Test device|
    WO2021211331A1|2020-04-13|2021-10-21|Abbott Point Of Care Inc.|METHODS, COMPLEXES AND KITS FOR DETECTING OR DETERMINING AN AMOUNT OF A ß-CORONAVIRUS ANTIBODY IN A SAMPLE|
    EP3896447A4|2020-04-16|2021-10-20|Hangzhou Biotest Biotech Co Ltd|A lateral flow detection device for detecting a coronavirus by immunoassay|
    WO2021219491A1|2020-04-27|2021-11-04|Zenares S.R.L.|Disposable self-test device with self-certification capability and kit containing the same|
    EP3904879A1|2020-04-27|2021-11-03|Abacuslabs Ltd.|A method for distinguishing healthy individuals from individuals having infectious or inflammatory conditions|
    EP3904877A1|2020-04-30|2021-11-03|Hangzhou Biotest Biotech Co., Ltd.|Lateral flow detection device for detecting a coronovirus by immunoassay|
    WO2021236050A1|2020-05-18|2021-11-25|Baseline Global, Inc.|Assay device, system, method, and kit|
    WO2021240152A1|2020-05-27|2021-12-02|University Of Warwick|Flow device for detection of glycans|
    GB202103200D0|2021-03-08|2021-04-21|Terasom S R O|Lung Cancer diagnosis|
    法律状态:
    2002-01-14| AS| Assignment|Owner name: INVERNESS MEDICAL SWITZERLAND GMBH, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UNILEVER U.K. HOLDINGS LIMITED;CONOPCO, INC.;REEL/FRAME:012312/0652 Effective date: 20011220 |
    2002-03-07| AS| Assignment|Owner name: INVERNESS MEDICAL SWITZERLAND GMBH, SWITZERLAND Free format text: CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNOR'S NAME PREVIOUSLY RECORDED ON REEL 012312, FRAME 0652;ASSIGNOR:UNILEVER PATENT HOLDINGS BV CONOPCO, INC.;REEL/FRAME:012607/0316 Effective date: 20011220 |
    2005-12-15| AS| Assignment|Owner name: GENERAL ELECTRIC CAPITAL CORPORATION, AS AGENT, MA Free format text: 2ND AMENDED AND RESTATED U.S. IP SECURITY AGR. -JUNE 30, 2005;ASSIGNORS:INVERNESS MEDICAL SWITZERLAND GMBH;ISCHEMIA TECHNOLOGIES, INC.;REEL/FRAME:017823/0219 Effective date: 20050630 |
    2007-10-16| RR| Request for reexamination filed|Effective date: 20070831 |
    2010-04-26| REMI| Maintenance fee reminder mailed|
    2010-09-19| LAPS| Lapse for failure to pay maintenance fees|
    2010-10-18| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2010-11-09| FP| Expired due to failure to pay maintenance fee|Effective date: 20100919 |
    2020-10-30| AS| Assignment|Owner name: ABBOTT RAPID DIAGNOSTICS INTERNATIONAL UNLIMITED COMPANY, IRELAND Free format text: CONFIRMATORY ASSIGNMENT;ASSIGNOR:ALERE SWITZERLAND GMBH;REEL/FRAME:054260/0479 Effective date: 20201029 |
    优先权:
    申请号 | 申请日 | 专利标题
    GB878709873A|GB8709873D0|1987-04-27|1987-04-27|Assays|
    GB8709873||1987-04-27||
    GB878725457A|GB8725457D0|1987-10-30|1987-10-30|Assays|
    PCT/GB1988/000322|WO1988008534A1|1987-04-27|1988-04-26|Immunoassays and devices therefor|
    US29414689A| true| 1989-02-27|1989-02-27||
    US79526691A| true| 1991-11-19|1991-11-19||
    US87644992A| true| 1992-04-30|1992-04-30||
    US08/102,313|US5622871A|1987-04-27|1993-07-15|Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents|
    US08/487,319|US6187598B1|1987-04-27|1995-06-07|Capillary immunoassay and device therefor comprising mobilizable particulate labelled reagents|
    US09/780,351|US7109042B2|1987-04-27|2001-02-12|Assays|US09/780,351| US7109042B2|1987-04-27|2001-02-12|Assays|
    [返回顶部]